Improving Outcomes in NF1 Spine Fusion by Bobyn, Justin Daniel
1 
 
Improving Outcomes  
in  
NF1 Spine Fusion 
 
 
 
 
 
Justin Daniel Bobyn 
MBBS BSc 
 
A thesis submitted in fulfilment of the requirements of the degree of  
Doctor of Philosophy 
 
Supervisor: Prof David G Little 
Associate Supervisor: Dr Aaron Schindeler 
2018 
 
 
 
 
 
 
 
The University of Sydney 
Sydney Medical School 
2 
 
Declaration of Contributions 
 
The work presented in this thesis was conducted during a combination of full time 
and part-time candidature to fulfil the requirements of Doctor of Philosophy through 
the Sydney Medical School, The University of Sydney. Unless otherwise stated, all 
experiments and analysis were conducted by myself at the Orthopaedic Research 
and Biotechnology Unit at the Children’s Hospital Westmead. Animal Ethics were 
approved by CMRI/CHW Animal Ethics Committee. All surgeries, unless otherwise 
stated, were performed by myself. Anaesthetics were performed by Kathy Mikulec-
Langton and Lauren Peacock. Confocal imaging methods were developed with Dr 
Laurence Cantrill, unless otherwise specified. Experimental conception, and 
manuscript and thesis editing were conducted in conjunction with my supervisors 
Prof David Little and A/Prof Aaron Schindeler.  
 
In Chapters 2 and 3, the surgical approach was developed with Dr Anton Rasch. Dr 
Rasch also assisted in performing the surgeries.  
 
In Chapter 4, culture of AdCre virus was prepared by Dr Nikita Deo.  
 
In Chapter 5, the ectopic bone experiments were conceived and analyzed by Dr Mille 
Kolind. These surgeries were performed by Kathy Mikulec-Langton and Lauren 
Peacock. Spine fusion surgeries were conducted at the Department of 
Reconstructive Sciences, School of Dental Medicine, UConn Health, Farmington, 
CT, USA under the supervision of Dr Ivo Kalajzic. Anaesthetics were provided by Dr 
Brya Matthews.  
3 
 
Statement of Originality 
 
 
This is to certify that to the best of my knowledge, the content of this thesis is my 
own work. This thesis has not been submitted for any degree or other purposes. 
I certify that the intellectual content of this thesis is the product of my own work and 
that all the assistance received in preparing this thesis and sources have been 
acknowledged. 
 
 
Justin D Bobyn 
 
 
 
The content of this thesis is the sole work of Dr Justin Bobyn, unless otherwise 
stated.  
 
   
Prof David Little                    A/Prof Aaron Schindeler 
 
4 
 
Acknowledgements 
 
I would like to thank everyone who contributed to this research and guided me along 
the way, especially those who dragged me kicking and screaming to the finish line. 
 
5 
 
Abstract 
 
NF1 (neurofibromatosis type 1) is a relatively common genetic disease which may be 
characterized by the presence of scoliosis and altered bone metabolism, amongst its 
many orthopaedic manifestations. Traditionally, spine fusion procedures have been 
used to correct and limit the progression of this deformity. NF1 bone healing at the 
tibia and spine feature impaired bone anabolism, excessive catabolism, and fibrosis. 
Fibrotic tissue in the tibia and between the vertebrae can lead to pseudarthrosis, 
which can require substantive clinical intervention. In particular, complications 
associated with the spine can represent a significant source of morbidity in this 
population, often presenting with persistent deformity, pain, and hardware failure. 
Revision procedures, themselves a source of morbidity, are often required when a 
primary procedure has failed. This thesis explores systematic approaches to 
modelling deficient NF1 spine healing and treatment to improve outcomes in this 
patient population.  
A murine model of posterolateral fusion using rhBMP-2 (bone morphogenetic 
protein-2) was developed to test a range of pharmacological interventions. This 
model was first applied to Nf1 heterozygous mice and was reproducible and reliable. 
Nf1+/- mice exhibited a mild orthopaedic phenotype with increased osteoclasts on 
histology. Treatment with the bisphosphonate Zoledronic acid (ZA) increased the 
bone volume of the fusion masses in both control and Nf1+/- mice, though the 
improvement was larger in controls.  
Several studies have shown that tibial pseudarthroses can be associated with a 
localized double inactivation of the Nf1 gene, and we speculated that this could 
underlie local lesions in the spine. To recapitulate this, we utilized a model where a 
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Cre-expressing adenovirus induced local double inactivation in Nf1flox/flox mice. This 
was then applied to the established spine fusion model. Consistent with the clinical 
presentation of spinal pseudarthrosis, a limited amount of rhBMP-2 bone was formed 
and substantive fibrous tissue was present. Targeted treatments with pharmaceutical 
agents were next trialled in this model. The MEK inhibitor PD0325901 increased 
bone volume in all groups while ZA increased bone density. In summary, this model 
represents a robust platform upon which to test targeted interventions to reduce the 
fibroproliferative phenotype of NF1.  
A second goal of this research project was to investigate the cellular contributors to 
spine fusion in general, which could be used to design new treatments both for NF1 
and non-NF1 spine fusion. To accomplish this, a murine genetic model of lineage 
tracking was employed. This featured Tie2-Cre:Ai9 and αSMA-creERT2:Col2.3-
GFP:Ai9 reporter mice. Spine fusion operations were performed in these mice, and 
the distribution of lineage-labelled cells were traced using fluorescence. Notably, 
Tie2 lineage cells co-labelled with TRAP positive cells, suggesting a primary 
contribution to the osteoclasts but not osteoblasts of the fusion mass. Conversely, 
αSMA lineage cells co-labelled with Col2.3-GFP expressing osteoblasts, suggesting 
new bone primarily arises from mesenchymal cells with negligible input from 
endothelial cells undergoing transdifferentiation.  
In conclusion, treatment of scoliosis remains a challenge in individuals with NF1. The 
development of a fibroproliferative model of spine fusion in an Nf1 deficient mouse 
represents a robust platform upon which to test targeted interventions to improve 
outcomes in NF1. Additionally, advancements in genetic modeling of human disease 
in animals may provide new models in which to investigate this process.   
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1. Literature Review 
 
1.1 Bone and Orthopaedic Biology 
The bony skeleton provides a scaffold upon which the tissues of the body are 
supported and protected. It serves as the rigid component of the musculoskeletal 
system that, coupled with the muscles, tendons and ligaments, allows for motion. 
Bone is also a biologically active tissue that serves as a storage unit for minerals 
(calcium in particular) and houses bone marrow, the production centre of the body’s 
blood cells. It therefore plays important roles in mineral homeostasis and 
haematopoiesis. [2-4]  
 
Figure 1. 1 Human skeleton with axial (pink) and appendicular (blue) divisions. 
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1.1.1 Skeletal anatomy 
The adult human skeleton (figure 1.1) comprises approximately 206 bones [5] and 
associated cartilage and can be organizationally divided into the axial skeleton and 
the appendicular skeleton. The axial skeleton, as the name implies, is the axis of the 
body and is formed by the skull, ribs and vertebral column. It functions to maintain 
posture and to protect vital organs from external injury. Attached to this are the 
bones of the limbs that form the appendicular skeleton, which is responsible for 
mobility. Bones can also be categorized based upon their morphology - that is 
whether they are long, short or irregular in shape. [2] 
 
1.1.2 Bone anatomy and histology  
The external surfaces of bones are enveloped in a complex and highly specialised 
connective tissue called the periosteum. The periosteum comprises two distinct 
layers: a thick outer, fibrous layer, which protects the bone and serves as an anchor 
point for tendons and ligaments and a thin inner layer which is rich in osteoprogenitor 
cells and plays an important role in bone growth and fracture repair. Beneath this 
cellular layer is compact cortical bone that provides most of the material stiffness and 
strength and constitutes about 80% of the weight of the skeleton. Running 
longitudinally through the cortical bone are a series of central or Haversian canals 
which are encircled concentrically by lamellae, or rings of bone. Bones gain 
additional strength from an internal sponge-like lattice of bone tissue called 
cancellous or trabecular bone. In long bones, cancellous bone is principally located 
in the metaphyses or end-regions. Cancellous bone comprises approximately 20% of 
bone weight and while less dense than cortical bone has a significantly greater 
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surface area. It is a highly vascular tissue and stores the bone marrow, where 
haematopoiesis occurs, within its bony lattice. [3] 
 
Cellular composition of bone 
Bone is a metabolically active organ. Its structure is maintained through continuous 
remodelling, which involves a balance between the ongoing processes of bone 
formation and resorption. Each of these activities is primarily mediated by a specific 
cell type. Osteoblasts regulate formation of new bone, while osteoclasts perform the 
opposing action, controlling bone resorption. Remodelling may be activated by 
mechanical force, microdamage to the bone, or by changes to plasma 
concentrations of calcium and phosphorus. The purpose of remodelling is to yield a 
structure of maximal strength and minimal mass, while in the process also effecting 
important repair to any microdamage that arises from everyday function. [3, 6-9] 
Osteoblasts or bone forming cells, are derived from osteoprogenitors - stem cells 
that have committed to the osteogenic lineage. Osteoprogenitors are present in 
many tissues, but are greatly enriched in the cellular inner layer of the periosteum. 
The primary function of osteoblasts is to produce and secrete osteoid, an 
extracellular collagen-based matrix, and then calcify that osteoid to produce 
mineralized bone tissue. As osteoblasts complete their cycle of differentiation and 
secretion of osteoid, they become buried in the lacunae of their matrix and become 
known as osteocytes. Osteocytes regulate bone metabolism by exchanging nutrients 
and waste with the vascular system via extensions of their plasma membrane and 
are critical to the maintenance of fluid flow through the bone. The flow of this fluid 
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may also be important to the process of remodelling by signalling mechanical 
stresses. [9] 
Osteoclasts, the bone resorbing cells, are derived from the differentiation of 
haematopoietic macrophages/monocytes precursors located near the surface of 
bone. Once activated, osteoclasts migrate and bond to the surface of mineralized 
bone. Osteoclasts then release HCl and lysosomal enzymes into the resorptive 
microenvironment, creating a low pH (4.5) and degrading the components of the 
bone matrix. The products of degradation are taken up by the osteoclast and 
released from its free surface [6, 8, 9]. 
 
1.1.3 Embryonic development of bone 
Ossification is the process by which new bone is formed. The embryonic formation of 
bone is an important point of discussion and its principles are revisited in a 
subsequent section on bone repair. Developmentally, bones can form by either 
endochondral or intramembranous processes. With some overlap, long and short 
bones are formed via the former, while flat bones and irregular bones are formed via 
the latter. Bones are formed from the embryonic connective tissue known as 
mesenchyme, from which all connective tissue of the body ultimately is formed. 
Initially, mesenchymal cells are arranged loosely in the shape of bones. These 
mesenchymal templates will either differentiate directly into bone, via the process of 
intramembranous ossification, or will do this via a cartilaginous intermediary template 
by the process of endochondral ossification. [3] 
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(i) Endochondral ossification 
Endochondral ossification (figure 1.2) is the process by which most bones of the 
body are formed. This process involves the formation of a cartilaginous bone 
template which is replaced with bone matrix by proliferating osteoblasts. It is best 
illustrated using the example of a long bone. In the embryo, mesenchymal cells 
aggregate into the shape of the bone and differentiate into cartilage producing 
chondroblasts which lay down a cartilage extracellular matrix. When surrounded by 
extracellular matrix, the chondroblasts are called chondrocytes. Chondrocytes 
undergo hypertrophy, degradation and mineralization, producing the primary 
ossification centre. The mineralized matrix is then removed by osteoclast-like 
cells.[10] Osteoprogenitor cells in the periphery of the bone are stimulated by the 
penetration of a nutrient artery to differentiate into osteoblasts. Osteoblasts migrate 
into the spaces of the mineralized ossification centre and the consequent trabeculae 
and secrete osteoid, which hardens over a period of several days as calcium and 
other mineral salts are deposited. As the primary ossification centre grows towards 
the ends of the bone, osteoclasts (bone destroying cells) break down some of the 
newly formed bone in the centre of the shaft, leaving a cavity which is later filled with 
bone marrow. [3, 11]  
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Figure 1. 2 Endochondral ossification. Hyaline cartilage model with bone collar (1) ; Cavitation within 
cartilage model (2) ; Internal cavity invaded by periosteal blood supply with cancellous bone formation 
(3) ; medullary cavity formation and appearance of secondary ossification site in epiphysis (4) ; 
ossification of epiphyses and remainder of cartilage at physeal plates and articular surfaces. 
 
(ii) Intramembranous ossification 
The flat bones of the body, including the skull and ribs, are formed by the process of 
intramembranous ossification (figure 1.3). Ossification occurs between sheets of 
mesenchymal cells at multiple ossification centres. Beginning at the ossification 
centre, a cluster of mesenchymal cells form and subsequently differentiate into 
osteoprogenitor cells, which in turn differentiates into osteoblasts. As in 
endochondral ossification, the osteoblasts in an ossification centre lay down osteoid 
which mineralizes, forming new bone. Continued bone formation allows the multiple 
ossification centres to coalesce and fuse. [3, 10] 
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Figure 1. 3 Intramembranous ossification. (1) Ossification centre appears within connective 
tissue membrane. (2) Osteoblasts secrete osteoid which mineralizes to form bone. Trapped 
osteoblasts become osteocytes (3) Random laying down of osteoid results in a poorly 
organized trabecular network of bone. Vascularized mesenchyme is laid down on the 
surface of the bone. (4) Dense mesenchyme becomes the periosteum and the bone deep to 
this thickens forming a cuff of mature lamellar bone. 
 
 
1.1.4 Bone repair 
Bone is repaired by a complex regenerative process involving the orchestration of 
multiple cell types which is stimulated as a response to injury. Unlike the healing of 
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other tissues which leaves a scar, bone repair implies the new formation of the 
original tissue. [12] The optimal result is repair with maximum strength and minimum 
weight with full restoration of skeletal function. During the repair process, the 
embryonic pathways of bone formation are repeated. All disrupted structures, 
including the periosteum, cortex, marrow and surrounding soft tissues contribute to 
bone regeneration. [13] Historically, fracture healing has been divided into primary 
and secondary fracture healing, though the former is rare and most fractures heal by 
the latter. [14] The process of bone repair may also be appreciated as a balance 
between anabolic (tissue forming), and catabolic (tissue remodelling), forces. [15] 
 
(i) Primary fracture healing 
When bone fragments are reduced and immobilized with rigid fixation, the process of 
primary fracture healing may occur. Primary fracture healing attempts to restore the 
continuity of the Haversian system of the cortex. This process is callus-free and 
involves periosteal recruitment of osteoprogenitor cells. [13] It is also likely that 
contributing osteoprogenitor cells can originate from the surrounding soft tissues. [16] 
 
(ii) Secondary fracture healing  
Secondary fracture healing (figure 1.4) involves a combination of intramembranous 
and endochondral bone formation, though the latter predominates. This process can 
be divided into 5 discrete stages, though there is considerable overlap between 
these chronologically. The process is initiated with the formation of a haematoma (1) 
and subsequent inflammation (2); this is followed by angiogenesis and the formation 
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of a soft cartilage callus (3). Hard callus formation (4) and bone remodelling (5) 
complete the process.  
The trauma associated with a fracture tends to additionally injure surrounding soft 
tissues. At the moment of fracture, the blood vessels crossing the fracture line are 
disrupted leading to the production of a haematoma. Platelets in the haematoma 
release the cytokines TGF-β and PDGF, initiating an inflammatory cascade which 
recruits osteoclasts and phagocytes to remove the newly dead tissue. Following this, 
fibroblasts and chondrocytes migrate to the fracture site from the periosteum and 
produce a collagen cuff around the fracture which is called the callus. The callus 
provides mechanical support to the fracture site as well as a scaffold for the 
formation of new bone. As an apparent recapitulation of embryonic processes, 
osteoblasts differentiate from osteoprogenitor cells and migrate into the collagen 
callus where they lay down osteoid. Once mineralized, the result is a hard callus 
uniting the bone fragments. The process of bone remodelling completes the process 
of fracture healing. Osteoclasts continue to remove dead bone and areas of callus 
that are not under mechanical load from the body, such as the periphery, are 
resorbed. Under normal healing conditions, the result is a perfect union of the 
fracture without any radiographic signs of previous fracture. [3, 13, 14, 16] 
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Figure 1. 4 Secondary fracture healing. (1) Normal bone. (2) Fracture with disruption of 
blood vessels and haematoma formation. (3) Cartilaginous callus. (4) Replacement of 
cartilaginous callus by bony callus. (5) Remodelled bone. 
 
1.1.5 Failure of the bone repair process 
As bone repair is a multifactorial process, success depends upon the orchestration 
of many factors. Disruption of the bone repair pathway may result in the 
development of a delayed union or non-union of the fracture ends. At the point of 
non-union, all reparative processes have ceased. [17] The incidence of impaired 
healing has been reported as being 5-10%, resulting in significant morbidity. [18] 
Non-union occurs in the context of a poor biological and mechanical environment, 
though the specific cause for a particular failure of healing is often never known. 
Grossly, the predominant factors that determine successful outcome are blood 
supply and stability of the fracture site. [12] 
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(i) Blood supply 
During the process of endochondral ossification, osteoblast differentiation is 
stimulated by the penetration of a nutrient artery. Blood supply is similarly important 
to the success of fracture healing. Immediately following fracture, the blood supply is 
disrupted leading to necrosis of the fracture ends. Angiogenesis is an important 
phase of the fracture healing cascade and is responsible for restoring local blood 
supply to the fracture site. [18, 19] There is evidence to suggest that angiogenesis is 
stimulated by the same factors that stimulate osteogenesis and that the fracture 
haematoma is itself directly angiogenic. [20] Furthermore, it has long been 
appreciated that adequate blood supply to a fracture site is required for the formation 
of a strong callus. [21] 
There is strong clinical evidence demonstrating a correlation between vascular 
impairment and unsuccessful bone healing. [18, 21, 22] The tibia offers an excellent 
example of how the rate of bone healing correlates with vascular supply. The upper 
metaphysis has a rich vascular supply. Fractures in this area tend to heal very well 
while fractures in the distal tibia, notorious for having one of the poorest vascular 
supplies in the body, have a tendency to develop non-unions and pseudoarthroses. 
[21, 23]  
Experimental evidence has supported clinical findings regarding bone healing and 
vascular supply. Angiogenesis has been disrupted in animal models via physical 
impairment [24, 25], irradiation [26-28], disease [29] and pharmacological 
intervention [29, 30]. Interruption of angiogenesis in these models results in 
significantly impaired fracture healing. 
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(ii) Mechanical stability 
Reduction of a fracture, with the apposition of fragment ends, is an important factor 
governing subsequent successful healing. The degree to which primary or secondary 
healing contributes to the repair of a given fracture is determined largely by the 
relative motion between the fragments. When a fracture is stabilised with rigid, 
compressive fixation, primary fracture healing dominates. Bone is thus repaired by 
direct cortical reconstruction without formation of stabilising callus. When less rigid 
stabilisation is employed, secondary fracture healing via a cartilaginous intermediate 
callus is observed. [31, 32] Secondary healing is accepted as being the quickest 
method of restoring strength and form to a bone. Multiple studies have shown that 
delayed fixation of a diaphyseal fracture results in quicker healing when compared 
with immediate fixation. .[33], [16, 34] Furthermore, numerous studies and clinical 
evidence support the finding that small amounts of relative movement between 
fragment ends promotes the formation of abundant callus, thereby enhancing the 
chance of union. [9, 32, 35, 36] These observations are likely the result of the 
secondary injury phenomenon which attributes these changes to the re-injury of the 
fracture site imposed by excessive motion without fixation. [12] However, excessive 
motion of unstable fragments impairs bone repair by not permitting soft tissue 
healing and periosteal revascularization, resulting in non-union. [37] The cellular 
mechanisms by which the mechanical micro-environment of a fracture dictates 
healing are largely unknown.  
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1.1.6 Cellular contributors to bone repair 
Bone repair depends upon the differentiation of osteoblasts from osteoprogenitor 
cells. Traditionally, these cells have been thought to be derived from the bone 
marrow and periosteum. [13, 14, 37-39] There exists clinical and experimental 
evidence however suggesting that extraosseous tissues contribute progenitor cells to 
the bone repair process.  
 
(i) Clinical evidence for extraosseous cell contribution to osteogenesis 
Heterotopic ossification (HO) is a phenomenon in which mature trabecular bone 
forms in extraosseous tissues. Bone may form in tissues adjacent to skeletal bone, 
as in the case of periarticular HO [40], or in more distant tissues of the skeletal 
muscle [41], skin [42], mesentery [43], or blood vessels [44, 45]. HO is significant to 
our understanding of osteogenesis because bone formation occurs at sites that are 
remote from the bone marrow and periosteum, the traditionally accepted location of 
osteogenic precursor cells. It has been proposed that HO is a reactive process that 
is stimulated in response to tissue injury, prompting the differentiation of osteoblasts 
and chondroblasts from non-committed mesenchymal stem cells located in injured 
tissue via protein signalling. [42] 
A breakthrough in the understanding of the protein signalling that underlies HO was 
made by Urist in 1965. It was demonstrated that demineralised and lyophilized bone 
implanted into rabbit muscle pouches induced ectopic bone formation. [46] He 
determined that this was due to the effect of a mixture of proteins located in the 
extracellular matrix of bone which he named the ‘bone morphogenetic proteins’. In 
recent decades, the proteins have been isolated from the decalcified matrix and the 
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BMP genes have been cloned. The resultant recombinant proteins (BMP-1, BMP-2) 
have been shown to be biologically effective at inducing the ectopic formation of new 
bone (Wozney, Rosen et al. 1988). As of 2002, the use of BMP in a collagen sponge 
vehicle has been approved for use in human patients in the forms of BMP-2 and 7. 
[47] 
 
(ii) Experimental evidence for extraosseous cell contribution to 
osteogenesis  
Urist demonstrated that BMP was capable of inducing osteogenesis in extraosseous 
soft tissue when introduced experimentally. These results have been reproduced in 
vivo via both the physical implantation of BMP-2 into muscle [48-52] as well as via 
retroviral delivery of BMP-2 to target cells [49, 53, 54]. The ability of a BMP solution 
and retroviral delivery of BMP to stimulate differentiation of muscle cells into an 
osteoblastic phenotype is also supported by in vitro data. [49, 53-55] In vitro studies 
used ALP activity and osteocalcin production as markers of osteoblastic 
differentiation.  
Wang et al [52] purified and characterized the osteogenic activity of rhBMP-2. 
Following implantation of the protein under the skin of rats in incremental doses 
between 0.46µg and 3µg, the implants were removed between day 5-21 and 
examined histologically. At day 5, immature and some hypertrophic cartilage cells 
were observed in the implants. At 7 days post implantation, chondrocytes were 
hypertrophic and the cartilage was mineralized. Osteoblasts surrounded by osteoid 
and vascular elements were also noted. By 14 days, removal of cartilage was nearly 
complete and bone was abundant. Osteoblasts and osteoclasts were widespread. 
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The implants were highly vascular and some haematopoietic cell maturation was 
identified. Implants removed at 21 days showed highly matured bone architecture. 
Doses of rhBMP-2 of 6µg and above were noted to yield consistent ectopic bone 
formation, though even at the lowest dose of 0.46µg ectopic bone was detected in 
half of implants removed at 21 days. They suggest that 0.6µg is the lowest dose that 
can reliably produce bone formation.  
 
(iii) A genetic basis for HO 
HO is not associated with any known metabolic disorders (ie: hypercalcaemia) but is 
manifested extensively in individuals with fibrodysplasia ossificans progressiva (FOP) 
and progressive osseous heterodysplasia (POH). FOP is an autosomal dominant 
disease, though it may arise by spontaneous mutation [42], that is characterized by 
progressive ossification of the tendons, ligaments, fasciae and skeletal muscle, 
resulting in significant morbidity and suffering. [56] An understanding of the genetics 
that underlie these disorders may provide greater insight into the pathogenesis of 
HO as well as skeletal osteogenesis.  
Patients with FOP have been shown to over-express BMP-4 [57]. The BMP-4 
transcription rate in the cells of affected has been demonstrated to be 4-7 times 
greater than in unaffected controls. [58] Several mutations have been identified in 
genes that are associated with this disease. [42] Feldman [59] found an association 
between the FOP phenotype and a mutation at 4Q27-41 in four families with familial 
FOP. At least one of these genes is proposed to be linked with the BMP-signalling 
pathway. Shore [60] found that the mutation was specific to the gene for ACVR1, a 
receptor for BMP-4. Constitutive activation of ACVR1 results in the induction of 
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alkaline phosphatase activity in C2C12 cells upregulating BMP-4 and downregulating 
BMP antagonists.  
 
(iv) BMP and vascular calcification 
The association between endogenous (as opposed to implanted) BMP and HO has 
also been demonstrated in patients who are not affected by a BMP related mutation. 
Vascular calcification is a common condition that is associated with significant 
morbidity and mortality in the population. Traditionally it has been believed that 
vascular calcification occurs via a passive crystallization process involving the 
precipitation of minerals from calcium and phosphate saturated extracellular fluid. [61] 
There is evidence that vascular calcification is not the result of a passive process, 
but rather an active biologic mechanism involving BMP-stimulated osteogenesis. 
Prompted by the observation that these calcifications frequently contained fully 
formed bone tissue (including bone marrow) Bostrom et al [62] found that calcific 
atherosclerotic plaques expressed BMP-2.  
 
1.1.7 Cellular tracking 
The de novo formation of bone in skeletal muscle and other extraosseous tissues 
implies that these tissues, and potentially circulating systemic cell populations, 
represent sources of non-committed precursor cells that are capable of contributing 
to osteogenesis. In order to prove that these cells feature in the repair process of 
bone, a cellular tracking system must be implemented that allows for the permanent 
and selective labelling of precursor cells, permitting identification regardless of final 
differentiated cell type.  
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Early techniques for tracking the lineage of a cell involved the intracellular injection of 
a dye and observing the progeny of the mother cell. This system was limited by 
issues of dilution of dye strength by cell division and by transfer between cells, 
resulting in a reduction in specificity of labelling. [63-65] Genetic cell marking using 
tissue specific promoters, such as with LacZ gene, [66] resolves many of the issues 
that impede dye labelling but ceases to work once a cell stops expressing a 
promoter. This is a significant limitation for lineage tracking. Transplantation of a 
labelled cell population from a donor animal to a recipient allows for lineage tracking, 
although the injection of single cell suspensions can be a limiting factor compared to 
transplanting tissue grafts. For this reason, transplantation of cell suspensions is 
often best suited to haematopoietic studies.  
Genetic recombination via the Cre-Lox/P system is a system that permits permanent 
labelling of a cell population under the control a tissue specific promoter. This proved 
to be the most suitable technique for our purposes.  
 
(i) The Cre-LoxP system 
The Cre-LoxP system allows the introduction of selective genome alterations in a 
reporter mouse. Cre-recombinase is a bacteriophage P1 derived 38 kDa protein that 
is capable of recognizing 34 bp sequences, called LoxP sites, along the genome. 
When Cre-recombinase is expressed, site-specific recombination between two LoxP 
sites is catalysed. [67] Depending on the orientation of the LoxP sites, Cre-mediated 
recombination may lead to deletion, translocation between chromosomes or 
inversion of the DNA segment. [68] This system can be used to label a population of 
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cells spatially (tissue specific) and temporally. This is illustrated especially well by the 
lab of Ivo Kalajzic using the aSMACreERT2/Ai9 transgenic mouse line.  
In order to achieve tissue-specific cell tracking, Cre-recombinase expression is under 
the regulation of tissue-specific promoters. For example, a population of cells 
expressing smooth muscle actinin (αSMA) has been identified that has osteogenic 
potential. Cells expressing this are known to reside in areas known to contain 
osteoprogenitor cells (perivascular niches, periosteum). Cre-recombinase may be 
‘knocked in’ to the genome in such a way that it is promoted only in cells expressing 
αSMA. [68] LoxP site recombination is therefore restricted to tissues in which αSMA 
is expressed.  
Temporal control of the Cre-mediated recombination of the LoxP site can also be 
achieved. In order to accomplish this, a ligand binding domain for human estrogen 
receptor (ERt) to the Cre enzyme. When tamoxifen (an ERt antagonist) is given 
systemically to the mouse, the Cre-ERt complex is able to penetrate the nucleus of 
the cell and induce mutation.  
When crossed with Ai9 reporter mice, this temporal and spatially specific Cre-
mediated recombination results in the red fluorescence of the target cells, due to the 
expression of the TdTomato gene. This fluorescent labelling permits a permanent 
way of tracking a target cell population, regardless of transdifferentiation and ultimate 
cell fate.  
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1.2 Scoliosis  
1.2.1 The anatomy of the spine 
The vertebral column, is a component of the axial skeleton. It consists of 33 
vertebrae can be divided into 5 regions based upon the morphology of their 
respective vertebrae: cervical (7 vertebrae), thoracic (12 vertebrae), lumbar (5 
vertebrae), sacral (5 vertebrae), and coccygeal (4 vertebrae) (figure 1.5). These 
regions of the spine are in turn associated with natural anterior-posterior curvatures. 
The spine exhibits what Hippocrates called “ithiscolios”, meaning that it is straight in 
the coronal plane and curved in the sagittal plane. Specifically, when viewed front-on 
the cervical and lumbar spines are associated with convex curvature while the 
thoracic and pelvic (sacral and coccygeal) spines demonstrate concave curvature. 
Prior to birth only the Thoracic and Pelvic curves (concave curvatures) are present. 
The cervical curvature develops as the infant begins to raises its head, causing a 
convexity in the spine. The lumbar curve develops as the child begins to stand 
upright.  
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Figure 1. 5 Anatomy of the spine and morphology of a typical lumbar vertebra. 
 
The morphology of vertebrae differs subtly between regions, reflecting their function. 
The body of the vertebrae constitutes the bulk of the volume of the bone and bears 
the majority of the weight of the spine. It is roughly cylindrical in shape with superior 
and inferior surfaces bearing a thin cartilaginous layer. Adjacent vertebral bodies are 
separated via an intervertebral disc forming a joint which allows for flexion and 
compression. The vertebral arch attaches to the body posteriorly and is formed by 
the fusion of twin pedicles and laminae. The space bounded by the vertebral arch 
and posterior vertebral body is the vertebral foramen, in which the spinal cord lies 
protected. The spinous process projects posteriorly from the vertebral arch and is 
formed by the fusion of the laminae. At the union of the laminae and pedicles rise a 
pair of transverse processes which project laterally, and two pairs of articular 
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processes (superior and inferior). The first two cervical vertebrae, named the atlas 
and the axis, are exceptions. In place of a vertebral body, the atlas (Cervical 
vertebrae 1) possesses an anterior arch in which lies the odontoid process, a strong 
bony post arising superiorly from the vertebral body of the axis (C2). This joint is 
responsible for 90% of the rotation of the head from left to right. Intervertebral discs 
allow motion in any direction. The articular processes of adjacent vertebrae form 
synovial joints, limiting the spines motion in certain planes. In the cervical and lumbar 
spines they are positioned in such a fashion that facilitates flexion and extension with 
limited rotation. In the thoracic spine they guide lateral bending and rotation. The 
spinous and transverse processes provide anchor points for the ligaments and 
tendons of the spinal musculature. [69] 
 
1.2.2 Scoliosis 
Scoliosis is a physical disorder of the spine that is characterized by lateral curvature, 
typically appearing during adolescence. [70] When combined with excessive 
kyphosis or lordosis, which are exaggerated curvatures of the thoracic and lumbar 
spine in the sagittal plane respectively often referred to as ‘hump back’ and ‘sway 
back’, the result is a complicated three dimensional deformity. Scoliosis is not a 
disease in itself, but is rather is the manifestation of one of a number disease 
processes which result in spinal asymmetry. It is a common disorder, with an 
incidence in the background population as high as 4.5%. [71]  
Scoliosis is a diagnosis that comprises one of several aetiologies (figure 1.6). 
Congenital deformities result from primary physical abnormality of the vertebrae 
which develop during the first 6 weeks of intrauterine growth and manifest as spinal 
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curvature from birth. [72] These deformities are referred to as ‘dystrophic’. The spinal 
curvature of neuromuscular scoliosis is progressive and arises secondary to the 
muscular weakness or spasticity of the trunk as is seen for example in patients with 
cerebral palsy, muscular dystrophy, or spinal cord injury. [73] The causes of the 
appropriately named idiopathic scoliosis (IS) are still not clear. Metabolic, hormonal, 
mechanical and genetic factors have been proposed. [74] Some speculate that it 
may in fact be a late onset subtype of neuromuscular scoliosis. [75]  
 
Figure 1. 6  A) Normal spine (i) compared with thoracic (ii) and lumbar (iii) scoliotic deformity. 
B) Congenital deformity of spine secondary to partial unilateral failure of formation (i) 
complete unilateral failure of formation (ii), unilateral failure of segmentation (iii), and bilateral 
failure of segmentation (iv). 
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Lateral curvature of the spine is also evident as a sign in some well described 
conditions including, Osteogenesis imperfecta (OI) [76], Duchenne Muscular 
Dystrophy [77], Marfan Syndrome [78], Charcot-Marie-Tooth disease [79], Prader-
Willi syndrome [80], Ehlers-Danlos disease, and [81] Filamin B (FLNB) associated 
disorders. Of particular note is the high prevalence of spine curvature requiring 
intervention in Neurofibromatosis type 1 (NF1).  
 
 
1.3  Spine Fusion  
1.3.1 Indications for spinal fusion 
Spinal fusion is a procedure that immobilizes segments of the spine via the formation 
of bone bridges between adjacent vertebrae. Early implementation of spinal fusion 
focused on preventing the increasing deformity associated with scoliosis, as well as 
infections and traumatic injuries. [82] Scoliosis is a deformity of the spine 
characterized by a lateral curvature. When combined with the natural kyphosis and 
lordosis of the spine, the result is a complicated three-dimensional deformity. The 
disease is typically progressive, worsening as the vertebrae grow. Bamfield 
observed that progression of the disease occurred during growth of the vertebral 
body and suggested that it is caused by the asymmetrical growth of one side of the 
body with a conjugate resorption of the other side secondary to increased pressure 
on the growth plate. [70] With the cessation of vertebral growth, so ends the 
progressive deformity of scoliosis. However, a worsening of scoliosis may be noted 
through adulthood which is due largely to degeneration of the intervertebral discs 
with age. [83]  
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Spine fusion surgery has since been implemented in the treatment of pain secondary 
to unstable motion or degenerative change of the spine. [82] 
 
1.3.4 Historical treatments for spinal deformity 
Scoliosis is amongst the oldest diseases known, and early treatments are referenced 
in literature dating back as far as 3500 BC. Hippocrates (460 -370 BC) was the first 
to document the anatomy of the disease.[84] Early interventions encompassed a 
range of combinations of traction, casting and bracing and therapy for spinal 
deformity had evolved little until the 20th century. [85] 
The development of x-rays by Röntgen as well as the emergence of modern surgery 
encouraged the surgical manipulation of spinal deformities. For the first time, 
surgeons were able to visualize and compare patients’ deformities and formulate 
evidence-based approaches to treatment. The first surgical approaches focused on 
instrumented correction of deformity. Richard von Volkmann (1830–1889) and Hadra 
[86] used silver wire to correct deformity in Pott’s disease (spinal manifestation of 
extrapulmonary tuberculosis) while in 1902 Fritz Lange splinted the spine with 
bilateral 4 mm steel rods secured at either end with silver wire (Lange 1910, 
suggesting that bracing systems should be placed under the skin.  
 
1.3.5 Early instrumentation for spinal correction 
(i) The pioneering work of Hibbs, Albee and DeQuervain 
Spine fusion surgery was pioneered in 1911 independently by Hibbs, Albee, and De 
Quervain. Hibbs observed that a tuberculosis infected spine that has been treated 
with casting and bracing displayed a tendency towards a natural bony ankylosis [87] . 
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He proposed that surgical acceleration of this process may assist the healing 
process. Later, he commented on its potential use in the treatment of the advancing 
deformity that results from scoliosis. By splitting the spinous processes and laminae 
and elevating them to come into contact with adjacent spinous processes and 
laminae he attempted to induce fusion. He assisted this bridging effect with bone 
graft harvested from spinous processes. In 1917, he applied spinal arthrodesis to the 
treatment of scoliosis and eventually to fracture dislocations and spondylolisthesis 
[87] .  Around the same time as Hibbs’ first surgeries, Albee created an internal splint 
by inserting a section of tibial graft between adjacent spinous processes for the 
purpose of treating Potts disease. He had noted that bony union of joints elsewhere 
in the body caused the tuberculous process to disappear rapidly. His poor 
experience with infection and failure of implanted screws and other foreign bodies 
led him to use autologous tissue as a means of securing fixation. [88] De Quervain 
used scapular spine for his graft. The use of arthrodesis as therapy for joint pain and 
deformity was well established at this time but had not yet been applied to the spine. 
 
(ii) Early instrumented spinal fusion procedures 
The practice of spine fusion evolved to incorporate the use of internal fixation 
devices (figure 1.7). As suggested by Lange, there were benefits to braces being put 
under the skin. Internal fixation yields a more stable construct than external bracing. 
In 1955, Allan built upon the work of Lange and began to use internal fixation 
devices to stabilise the fusion site with the intention to provide a quicker and more 
effective means of correcting spinal curvature. He devised a means of lengthening 
the concavity of a curvature via an expanding device. The device consisted of a jack 
formed my two Y-shaped pieces which are connected by a threaded sleeve. The 
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forked ends sat at a 30 degree angle from the shaft of the tool. The jack was placed 
between adjacent transverse processes along the concave side of the joint to be 
fused. As the sleeve rotated, the jack expanded and increased the distance between 
the transverse processes, lengthening the concavity of the deformity. Bone graft 
could then be positioned as for a standard fusion procedure. [89] Harrington 
subsequently developed a set of instrumentation (Harrington instrumentation) that 
consisted of a distraction bar and a compression rod with ratcheted hooks placed on 
either side of the curvature to incrementally achieve correction in the absence of 
vertebral fusion. [90]  
 
 
 
Figure 1. 7  Instrumented spine fusion permits correction of scoliotic deformity with fixation of 
bilateral rods via pedicle screws extending into vertebral body. 
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1.3.6 Anabolic approaches for spinal fusion 
The use of autogenous bone as a graft material was ubiquitous in early fusion 
surgeries and is still the gold standard grafting substrate. In the context of spine 
fusion, autologous bone graft possesses several qualities that make it a desirable 
grafting material. It provides immediate structural support allowing for the splinting of 
adjacent vertebrae, therefore limiting motion. Autologous bone also has osteogenic, 
osteoinductive, and osteoconductive properties. [91] When autologous bone is 
harvested and transferred to a graft site, it carries with it its native osteogenic cells 
which, in the correct environment, are capable of forming bone. Native bone also has 
osteoinductive proteins which stimulate the proliferation of undifferentiated 
mesenchymal cells and formation of osteoprogenitor cells. The structure of bone 
consists of an osteoconductive three dimensional matrix that provides a scaffold that 
can support the ingrowth of new bone as well as new capillaries and perivascular 
tissues. The osteoconductive property of bone is thought to result from its physical 
architecture, chemical structure and surface charge. [92].  
Autologous bone may be harvested from the iliac spine, as well as the ribs, fibula, 
and distal tibia. In addition to being limited in availability, its harvesting comes at the 
cost of significant morbidity. The frequency of major complications following 
autologous bone harvest has been reported to be 8.6%, with minor complications 
occurring in 20.6% of cases [93]. Numerous substitutes have been used that 
possess one or several of the qualities of autologous bone. The matrix of trabecular 
bone has been replicated using synthetic (such as calcium based porous ceramics) 
and biologic alternatives. Bone in the form of allograft (from a non-genetically 
identical individual of the same species) and xenograft (from a member of a different 
species) are examples of biologic substitutes. These materials provide immediate 
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structural support for surrounding tissue but in the process of cleaning and sterilising 
to prevent disease transmission and rejection, lose their osteogenic potential and do 
not function as well as native bone. [94] Their structural lattice remains intact, 
however, and they are effective osteoconductive substitutes for autograft.  
BMPs are amongst the more popular anabolic bone graft substitutes. When 
compared against iliac crest autograft in posterolateral intertransverse lumbar spine 
fusion, BMP treated individuals yielded significantly higher fusion rates while 
reducing donor site morbidity [95].  
 
1.3.7 BMP delivery systems  
BMP must be introduced into the body by way of a carrier material. The role of the 
carrier is to deliver and localise the drug to the target site, where it can exert its 
biological activity, and to provide a substrate for the bone forming cells. The quality 
of the BMP induced bone mass is largely dependent upon the quality of the carrier. 
Under optimal conditions, the bone mass will closely mimic the carrier in size and 
shape [4]. Kwon et al have proposed a series of criteria to define the ideal carrier 
material. A carrier must be biocompatible to limit inflammatory response and should 
localize the drug to the target site while maximizing its osteoinductive and osteogenic 
properties. These properties can be amplified if the carrier material provides an 
osteoinductive scaffold with a porosity mimicking native bone, promoting the 
ingrowth of bone forming cells and vasculature. Additionally, the structure of the 
carrier should limit the local effects of space occupying delivery systems and not 
compete with or limit bone formation. Finally, an ideal carrier will be biodegradable 
allowing timely removal from the body. 
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It is likely that the previously discussed adverse events associated with BMP use 
may be mitigated by the use of an improved carrier system. In current practice 
rhBMP-2 (marketed under the INFUSE® brand by Medtronic©) is distributed as a 
powder which is reconstituted into aqueous form at the time of surgery and 
impregnated into an absorbable collagen sponge. It has been suggested that 
adverse events are contributed to by the tendency of aqueous BMP to diffuse rapidly 
from the collagen sponge resulting in migration of the drug to sites remote from the 
fusion bed [96, 97]. In this way, BMP exerts its osteogenic and proinflammatory 
properties on extraosseous tissues, resulting in ectopic bone formation and soft 
tissue swelling respectively. Ectopic bone formation is a predictable result of the user 
of BMP and examples include foraminal and spinal canal bone deposition [98, 99] 
which may result in neurological impairment. The proinflammatory properties of BMP 
are responsible for the perivertebral soft tissue swelling. Cervical tissue swelling has 
been associated with dysphagia and airway oedema [100, 101], which has resulted 
in patient intubation and occasional mortality [102]. Inflammatory response disrupting 
the superior hypogastric plexus following anterior interbody lumbar fusion has been 
associated with in increased incidence of retrograde ejaculation in male patients [50]. 
Immobilization of BMP at the site of fusion is critical in achieving adequate local drug 
concentrations and preventing diffusion associated adverse events [97]. In order to 
better control BMP delivery at the target site, alternative delivery mechanisms have 
been investigated. Compression resistant carriers such as collagen/calcium 
phosphate composites [103-105], calcium sulphate biomaterials [75] and 
biodegradable polymers [72, 73, 106] are of particular note as they promote localised 
delivery of BMP as well as maintain a potential space for bone growth by preventing 
soft tissue compression.  
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1.3.8 Adverse effects associated with BMP induced spine fusion 
Due to its efficacy in forming new bone and the eliminated donor site morbidity 
associated with harvesting iliac crest bone graft, BMP is increasingly used to 
augment spine fusion procedures. It is currently only approved for use in anterior 
interbody lumbar cage fusions (AILF). In this procedure, the intervertebral disk is 
removed completely and is replaced with a metal cage which maintains intervertebral 
space and vertebral alignment. The cage, which has historically been iliac crest bone 
graft, may be filled with a BMP-impregnated carrier which promotes fusion of the 
adjacent vertebral bodies. Increasingly, BMP has been used off-label in alternate 
spine fusion techniques, including cervical fusion and lumbar posterolateral 
intertransverse fusion (PLF).  
The initial peer reviewed, industry sponsored safety reviews of BMP in spine fusion 
suggested that its recommended use was not associated with any adverse effects or 
that any adverse effects noted were unrelated to its use. In these initial studies, 780 
patients received BMP augmented spine fusion (including AILF and PLF techniques), 
without adverse effects reported. Due in large part to the promising findings of these 
trials, the use of BMP jumped dramatically from use in 0.7% of all fusions in 2002, to 
25% in 2006. With the rising use of BMP in spine fusion there have been many 
reports of serious complications arising secondary to the use of BMP in the spine. 
Most complications arose between day 2 and 14 post-op. Early events were 
associated with what appeared to be a pro-inflammatory activity of BMP. When used 
in the context of cervical spine fusion, patients were reported to develop a swelling of 
the neck soft which could progress to airway obstruction requiring emergency 
intervention. Patients were also known to report difficulty in breathing and speaking 
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as well as pain while swallowing. Smucker et al noted a 27.5% incident of clinically 
significant swelling. Other significant events observed were related to overgrowth 
and uncontrolled bone formation, and to the negative effect of BMP on exposed 
nerves and dura which may result in nerve symptoms including pain, loss of function 
and retrograde ejaculation. [71]  
 
1.3.9 Failure of Spine Fusion Surgery 
Since the first pioneering operations for spinal fusion performed by Hibbs and Albee 
100 years ago, the procedure has been plagued by high failure rates.[88, 107] 
Pseudoarthrosis is the name given to the ‘false joint’ created by non-union of two 
bones at a site of desired fusion. The rate of pseudarthrosis has been estimated to 
be between 5% and 35% [108]. Successful fusion is dependent upon a multifactorial 
process. The process of osteogenesis involved in the fusion of adjacent vertebrae 
involves the same mechanisms discussed in bone repair. As with bone repair, 
vascularity and mobility are important factors which determine the success of the 
fusion procedure.  
 
(i) Influence of vascularity on spinal fusion success 
 Blood supply and the fusion bed 
The importance of vascularity to the bone repair process has been described. 
Cytokines released immediately following vascular injury associated with bone 
trauma promote an influx of osteogenic cells, while intact vessels provide a conduit 
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for their migration. In the case of spinal fusion surgery, bone trauma is induced by 
the surgeon during decortication of the fusion bed.  
Decortication of the graft site establishes the contact surface area available for the 
growth of the bony bridge between adjacent bones. A greater decorticated surface 
area will encourage the growth of a larger fusion mass [109] , by exposing a greater 
amount of osteogenic cells which will be available for subsequent bone formation. 
The decorticated fusion bed must expose and traumatise viable and vascular bone 
to be effective. Use of power burrs may induce thermal necrosis of the bone, limiting 
the effective surface area available to participate in bone healing. (Boden 1998) The 
transverse processes are difficult to decorticate and have a smaller available surface 
area compared to the body of the vertebrae, resulting in a smaller fusion bed. 
Posterolateral fusion beds, therefore, represent a comparatively poor bone 
environment for bone growth. [110]   
 
Osteoporosis is a condition associated with poor vascular supply 
and poor surgical outcome 
Osteoporosis is the most common metabolic bone disease. It is characterized by 
bone that has a lower density and decrease turnover rate, resulting in decreased 
healing capacity when compared with healthy tissue. There is a strong association 
between osteoporosis and vascular disease. [111] Men and women with known 
peripheral arterial disease have been shown to have lower bone mineral densities 
and present with more fractures than matched controls. [112, 113] Cancellous bone 
is affected more than cortical bone by the decreased turnover and its effects are 
more pronounced in the vertebrae, which have a relatively high ratio of cancellous to 
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cortical bone. Additionally, the trabeculation in affected bone are sparser and 
significantly more brittle than non-affected bone resulting in a poor anchor site for 
instrumentation used to secure vertebrae. [114, 115]  
 
Factors influencing bone vascularity 
Circulating drugs, nicotine and irradiation are amongst the most prominently 
investigated factors which threaten bone vascularity. The rate of their investigation is 
surely associated with their incidence in the population and strong association with 
impaired bone healing.  
Non-Steroidal Anti-inflammatory agents (NSAIDS) are commonly used in the 
perioperative period for pain relief. Several studies have shown an association 
between high dose NSAIDs, specifically Ketorolac and non-union in spinal 
arthrodesis. [116] [117-119] There is strong evidence suggesting that NSAIDs inhibit 
angiogenesis [120, 121] and interfere with the inflammatory cascade which is critical 
for initiating the early stages of bone healing. Furthermore, it has been proposed that 
these agents may have a direct inhibitory effect osteoblast and osteoclast function. 
[122-124] 
Similar effects on bone vasculature have been shown secondary to circulating 
nicotine.[125] The correlation between cigarette smoking and non-union after 
attempted spinal arthrodesis is well established.[125-128]  Nicotine is thought to 
inhibit the revascularization of bone graft. [30]  A non-union rate of 26.5% in smokers 
has been compared with 14.2% in non-smokers. [129] Patients who ceased smoking 
for 6 months showed non-union rates comparable to their non-smoking counterparts.  
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 Irradiation during the peri-operative period has long been appreciated to have 
deleterious effects on bone. Post-operative radiotherapy has greatly decreased the 
incidence and recurrence of soft tissue sarcomas [27] but has been shown to have 
an adverse effect on bone healing. Arnold et al [26] demonstrated an inversely 
proportional relationship between preoperative irradiation and the healing of rat 
femoral fractures. Similar relationships have been established by Emery and 
Bouchard using canine and rabbit models, respectively [130]. They found that 
irradiation administered in the immediate postoperative period was detrimental to 
successful bone growth. They proposed that this was due to the adverse effect of 
irradiation on bone vascularity resulting in a graft bed of diminished viability. They 
also suggested that irradiation was directly deleterious to dividing mesenchymal 
stem cells and immature osteoblasts.  
 
(ii) Mechanical stability 
Immobilization is critical in the establishment of union between the bony fragments of 
a fracture [16]. The fusion of adjacent bones united by a bony bridge is analogous to 
the fracture scenario with respect to the need for immobilization. In non-instrumented 
spine fusion, splinting of adjacent vertebrae is accomplished solely by the 
mechanical properties of the graft material. There is consequently a greater 
propensity for relative motion between the vertebrae that are intended to be fused.  
It has been observed that when interlocking cortical or cortico-cancellous grafts are 
used in lumbosacral sheep spine, union always occurs at the interlumbar joints and 
never occurs at lumbosacral joints. Nagel et al concluded that this was the result of 
increased relative motion at the lumbosacral joints relative to interlumbar joints. Their 
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study showed that a strain of approximately 10% at the joint site will be tolerated and 
result in successful fusion. A strain of approximately 36% or greater, which is 
observed at the lumbosacral joint, will result in the development of a pseudoarthrosis 
[131]. Similar observations have also been made in dogs [132, 133]  where it was 
noted in a segmental spine fusion model that more cranial interlumbar fusion 
segments yielded stiffer fusion masses compared to their caudal counterparts. 
Excessive motion in the rabbit spine yielded similar inhibition of fusion [134] This 
effect is evidenced in human patients in the extreme case of spinal fusion in patients 
with Muscular –Dystrophy. These patients exhibit a higher rate of union which is 
likely due to their decreased voluntary movement relative to non-affected patients. 
Evidence suggests that the effects of motion may be mitigated by the use of 
immobilising instrumentation. Using a canine model, Gurr and McAfee demonstrated 
that 6 months postoperatively, fusion was more probable if spinal instrumentation 
were used [135, 136]. The fusion mass was also shown to be more rigid compared 
with the non-instrumented fusion mass. It was noted, however, that the use of 
instrumentation resulted in a degree of device-related osteoporosis. Fuller [137] 
demonstrated in a study of canine anterior spine fusion that ceramic implants 
showed a significantly increased degree of revascularization and new bone growth 
when used with instrumentation, compared with no vascularisation or growth when 
used without, suggesting the importance of fixation when using non-biologic graft 
substitutes.  
The stress and mechanical load at the fusion site have an effect on the resultant 
union. In the spine, compressive forces are transmitted from vertebrae to vertebrae 
by way of the intervertebral disc. Consequently, nearly 80% of the mechanical load 
of a segment is sustained by the intervertebral disc. Interbody fusion, therefore, is 
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subject to higher mechanical load and responds with a high degree of bone 
formation. It is proposed that the increased compressive forces stimulate 
vascularisation and mesenchymal cell proliferation into the graft. [138] Additionally, 
these forces act to stabilise the graft between adjacent vertebrae, thereby 
decreasing relative motion that may impede new bone formation. Posteriorly placed 
grafts along a transverse process fusion bed are subject to primarily tensile force 
and little compressive force and thus demonstrate poor bone formation.[139] Bone 
formation at these sites are primarily dependent upon the biological (osteogenic, 
osteoinductive) activity of the graft. [138]  
With respect to pseudoarthrosis, DePalma suggested that the “…condition is 
iatrogenic; its responsibility lies entirely in the hands of the surgeon.” [108] Technical 
choices made by the surgeon, including location of fusion site, degree of 
immobilization, and quality of bone bed, will affect the result of a fusion procedure. 
Anterior interbody fusions, for example, show a lower probability of developing non-
union than do posterior fusions.  
 
1.4 Neurofibromatosis type 1 (NF1)  
1.4.1 NF1 is characterized by scoliosis  
Neurofibromatosis type 1 (NF1) is a common genetic disease with an incidence of 1 
in 3000-3,500 which results from mutations in the NF1 tumour suppressor gene [140]. 
The Nf1 gene encodes the protein neurofibromin which is expressed in all tissues of 
the body. Although NF1 exhibits high penetrance, its expression is variable resulting 
in a wide spectrum of tissue manifestations, including bone.  
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Though the pattern of inheritance and nature of the genes involved has only been 
described recently, its relatively high incidence has meant that it has been observed 
and discussed extensively as far back at the thirteenth century. [141] 
Early descriptions of NF1 made note of its cutaneous manifestations, in particular the 
neurofibromas that are characteristic of the disease. These present as cutaneous 
nodules, are often present in infancy, and may cover the body extensively in a 
disfiguring fashion. These early descriptions compared patients to amphibians, 
reptiles and monsters. Early accounts are sufficiently vague that it is not known for 
certain that they pertain to NF1, and retrospective diagnosis employs a degree of 
conjecture (figure 1.8). 
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Figure 8.  
 
 
Figure 1. 8  Illustration from Aldovandri’s ‘Monstrorum Historia’ depicting of an individual 
with what is now been thought to be NF1. [1] 
55 
 
The 1700s saw descriptions of NF1, become more scientific with a focus on the 
experience of the patient. In this fashion, Akenside observed that the skin wens 
(presumably neurofibromas), were at times associated with neurological symptoms 
[142] . Smith correlated these symptoms of numbness with pathology described on 
autopsy of patients suffering from NF1 [143]. He concluded that the lesions were 
subcutaneous and originated in the nerve, though he suggested incorrectly that they 
developed in response to a cancer of the surrounding connective tissue. Virchow 
further refined these observations and suggested that these lesions were fibromas of 
the connective tissue that contained nerves and noted that the disease was inherited 
by familial transmission[144] . However, it was von Recklinghausen who the disease 
came to be named for. Von Recklinghausen, a student of Virchow, performed a 
meticulous dissection of the cadaver of a patient with Nf1 and described in great 
detail the location, morphology and contents of the neurofibromas. He also was the 
first to note the pigmented café-au-lait spots and axillary and inguinal freckling that 
are utilised diagnostically today. [145] 
It has since been documented that in addition to the cutaneous signs and associated 
neurological symptoms, patients with NF1 exhibit a host of other complications 
including cognitive impairment [146] and musculoskeletal problems.  
The most common musculoskeletal manifestations include tibial bowing or 
pseudarthrosis, sphenoid wing dysplasia and dystrophic scoliosis [147]. With respect 
to the spine, as many as 25% of patients with NF1 will demonstrate a degree of 
scoliotic deformity. This deformity may be divided into either non-dystrophic or 
dystropic types. [148] Non-dystrophic deformities present in a fashion similar to 
idiopathic scoliosis - that is to say without significant morphologic change to the 
vertebrae or surrounding soft tissues. This is contrasted with the dystrophic type in 
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which vertebrae may show failure of formation or segmentation, and surrounding soft 
tissues may contain large tumour masses. The deformity associated with dystrophic 
scoliosis is more severe and challenging to treat than its non-dystrophic counterpart. 
Approximately a quarter of these individuals will require spine fusion surgery to 
correct the curvature and prevent deformity [149].  
 
1.4.2 NF1 is a RASopathy that is plagued by poor bone healing 
Pseudarthrosis in the spine may develop in as many as 13% of patients with NF1 in 
whom fusion is attempted, with solid fusion seen in as few as 7% of patients [93]. 
This is likely associated with primary defects in bone metabolism that is seen in NF1. 
It has been shown in multiple studies that patients with NF1 demonstrate a reduced 
bone mineral density (BMD) [71, 150-153]. Impaired bone anabolism via reduced 
osteoblastogenesis, and augmented bone catabolism via increased 
osteoclastogenesis have been proposed as contributing factors [154]. When the Nf1 
gene is intact, it acts to downregulate the Ras family of proteins. Ras proteins are 
critically involved in cell survival, proliferation, differentiation and apoptosis. When 
the Nf1 gene is faulty or missing, Ras activity is uninhibited [155]. It has been 
proposed that the upregulation of osteoclasts function in NF1 occur secondary to 
uninhibited Ras activity, as occurs in NF1 [147, 155-157]. Yang et al. observed a 
gain in function by osteoclasts in Nf1+/- mice, including increased survival, 
proliferation, migration, adhesion, and lytic activity [158]. Similar processes are likely 
to contribute to the poor bone healing that is characteristic of the fractures in patients 
with NF1. NF1 patients requiring spine fusion for the correction of scoliotic curvature 
and the prevention of future deformity demonstrate a high rate of complication 
including the formation of spinal pseudarthrosis. In these cases adjacent vertebrae 
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are united by fibrous tissue rather than with a bone bridge. The Ras-ERK pathway 
has been implicated in uncontrolled cell proliferation and fibrosis [159] .  
Historically, bone graft (crushed up bone harvested from the patient or cadavers) has 
been used as an osteoinductive agent to induce the formation of new bone to unite 
adjacent vertebrae. In recent years recombinant human bone morphogenetic 
proteins (rhBMPs) such as rhBMP-2 and rhBMP-7 (OP-1) are now clinically 
approved for use in anterior interbody fusions when paired with a tapered spinal 
fusion cage. Increasingly, these agents are being used off-label in posterior 
interbody, posterolateral intertransverse, and anterior cervical fusions. Bone graft 
and rhBMPs have been used separately or in combination to achieve successful 
fusion in some NF1 patients. 
 
1.5 Animal Models of Scoliosis  
1.5.1 Biomechanical forces in scoliosis modelling 
Multiple animal species have been used to model the pathogenesis of idiopathic-type 
scoliosis. Historically, IS has only been observed in humans though there is limited 
evidence that it may also occur in the chicken. [15] Spinal deformities seen in other 
animals are typically classified as congenital, suggesting that IS may be exclusive to 
bipeds. [16] Consequently, it has traditionally been accepted that the mechanisms 
implicated in IS act in concert with axial loading along the spine to produce deformity. 
Weakening of the vertebral bone, of the surrounding supporting tissues or positional 
asymmetry is exploited by the force of gravity acting upon the vertebral column of a 
biped. The force of gravity is resolved in the spine as dorsal shear forces causing the 
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natural column to fail, resulting in lateral curvature. [16, 17] Burwell et al describe this 
as The Nottingham Concept. [17]  
 
1.5.2 Quadrupedal Models of Scoliosis 
Mechanical models 
Quadrupedal animals are not subject to the same axial loading and dorsal shear 
stress as bipeds. Despite this, cost and efficiency have favoured their use in 
experimental research. They are, without question, the most utilised systems for the 
purpose of modelling scoliosis.  
The majority of scoliosis models have been developed around techniques designed 
to create a mechanical asymmetry in the spine. This has been accomplished via 
several techniques. In 1961 Langenskiold et al [18] described a series of mechanical 
methods with which to induce scoliosis in a quadruped. He proposed that the primary 
techniques for inducing scoliosis in quadrupedal animals include (i) the excision or 
denervation of local musculature, (ii) the resection of ribs, or (iii) the fixation of 
vertebrae or ribs to each other. Each of these approaches serves to create an 
asymmetry in the natural column of the spine or supporting tissues without altering 
the structure of the vertebral bodies themselves. The development of spine curvature 
in these animal models is consistent with clinical evidence showing that humans in 
prolonged recumbence can develop scoliotic deformity, suggesting that gravity is not 
in fact a prerequisite. To date, the majority of experimentation to produce models of 
scoliosis in animals has followed these techniques, although with varied success.  
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Langenskiold, in a landmark paper in which he performed 15 surgical interventions 
on rabbits (figure 1.9), found that deformity could not be induced by sectioning of the 
phrenic nerves or the lower intercostals muscles. Unilateral resection of the erector 
spinae muscles, sectioning of the lower intercostals nerves (6-11) with or without 
sectioning of the associated ribs, and unilateral tethering of the transverse processes 
of T6-11 only seldom produced a curvature which was generally quite slight. He 
found that only by resecting the posterior end of ribs 6-11, including the 
costovertebral joints, was he able to create significant spinal deformity in all subjects. 
However, Langenskiold acknowledged that despite achieving scoliosis consistently 
in these subjects, little was known about the deforming forces that were released by 
the operation. It was understood that an asymmetry of forces on the spine resulted in 
a deformity, but the nature of these forces was not clear. Michelsson [19] has since 
proposed that the dorsal rib acts as a lever. When the costovertebral joint is 
disrupted, the lever mechanism of the rib fails and an asymmetry of forces upon the 
spine results.  
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Figure 1. 9  Mechanical asymmetry along the spine of a quadruped can be created via A) 
unilateral resection of ribs and costovertebral joint, B) unilateral tethering between 
transverse processes of ipsilateral vertebrae, or C) unilateral tethering between ipsilateral 
pelvis and scapula. 
 
While others have expanded upon the early work of Langenskiold, there have been 
few fundamental advances with respect to the modelling of scoliosis in quadrupeds. 
Multiple studies have examined the effects of dorsal rhizotomy in rabbits on spinal 
deformity. [20-22] Dorsal rhizotomy (figure 1.10) involves the ablation of the dorsal 
nerve root which is responsible for the transmission of proprioceptive information. 
These studies tend to show that damage to the dorsal root ganglia produce a 
deformity with the convexity on the side of the injury. It has been proposed that 
individuals with idiopathic scoliosis have an abnormality of postural equilibrium which 
is likely mediated by proprioceptive loss on that side. The cause of the deformity in 
this instance was presumed to be related to unilateral muscle weakness secondary 
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to this deficit. Abnormal proprioception has been detected in adolescents with IS 
relative to age matched controls. [23-25] and post–mortem investigation of the 
spines of individuals with AIS showed abnormal dorsal root ganglia. [26] Alexander 
suggested that with respect to experiments that induce scoliosis via dorsal rhizotomy, 
it was not the proprioceptive loss from damage to the dorsal root that caused the 
weakness, but paralysis of the trunk muscles as a result of surgical damage to the 
anterior horn. [20] Similarly, the causal association made in observational studies of 
humans has been challenged, with suggestions that it is the curvature of scoliosis 
that results in proprioceptive imbalance rather than vice versa. [27]  
  
 
Figure 1. 10  Motor signals are carried from the spinal cord to muscle fibres via the ventral 
nerve root. Proprioceptive information, including information related to the relative position of 
muscles, is relayed via the dorsal nerve root from muscle to the spinal cord. 
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Following the success of Langenskiold experiments with the resection of lower ribs, 
which yielded a severe deformity in all subjects, this has become a popular 
technique for modelling scoliosis in animals. [28-36] All studies which have applied 
this technique have produced similar data with a high incidence of scoliosis 
produced. These experiments have typically done so using rabbit subjects, though it 
has also been performed on chickens. [37, 38] Common amongst this work is the 
conclusion that the curvature created by resection in dependent upon the continued 
non-union of the costovertebral joint. In animals where union developed, and 
presumably stability was restored, deformity was attenuated or reversed.  
 
Although Langenskiold achieved only moderate success with unilateral tethering, this 
has since become one of the preferred methods for inducing scoliosis in an animal 
model. It has certainly been applied to the broadest range of species including 
calves, [39, 40] goats, [28-30, 36, 41] pigs, [32, 33] dogs, [42] rabbits, [18, 31, 35, 43, 
44] and rats. [45, 46] In these models, a lateral curvature is created along a juvenile 
spine by fastening a series of adjacent vertebrae to each other or of the pelvis to the 
ipsilateral scapula. As the animal grows and the vertebral column elongates it is 
forced into a rotational lordosis which is resolved as a lateral curvature with the 
convexity facing the tether. In these experiments, all animals will develop an 
immediate post-operative scoliosis as curvature is ensured during the procedure. 
Persistence of the deformity is dependent upon the strength and durability of the 
fixation. Failure or intentional release of the tethering results in a reduction of the 
Cobb angle, occasionally with complete correction, followed by steady progression of 
the curve. [31, 47]  
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The models that have achieved the highest incidence of scoliosis have been those 
that induce a mechanical asymmetry, in particular the tethering models which have 
been discussed. Consequently, they are the most frequently used. As with the work 
of Langenskiold, these experiments provide a reliable and reproducible technique for 
producing a lateral curvature in a spine of an otherwise healthy mammal. Though the 
pathogenesis of the curvature in these animals may not mimic the human condition, 
the utility of these models is that they produce a consistent deformity upon which to 
investigate curvature reversal and straightening. By this measure they are very 
successful. Braun et al. created an experimental scoliosis in immature goats using a 
rib tether technique. They successfully attempted to correct the deformity using a 
shape memory alloy staple in the anterior thoracic vertebrae. [29, 48, 49] This 
experiment has been repeated several times with consistent success. [49, 50] The 
techniques designed to initiate a spinal deformity have also been proposed as 
treatments when applied to an established deformity in the opposite direction. [40] 
 
Genetic models 
Langenskiold observed bedridden patients and noted that scoliotic deformity could 
arise and progress in a spine orientated in a horizontal plane, and free from the 
dorsal shear forces of gravity. A central tenet of most scoliosis modelling is the 
concept that bipedalism is a requisite. Models that do not use an animal with erect 
posture, have either tried to induce such a posture, or mimic the deforming forces of 
gravity in the horizontal plane. Recent research involving observation of the 
curveback guppy [51] has demonstrated that spinal deformity closely mimicking AIS 
can develop in non-bipeds. The curveback guppy is a small live bearing fish whose 
young are born with fully ossified skeletons. Like humans, they develop a lateral 
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curvature of the spine at variable times after birth with predominance in females with 
distortion of the apical vertebra. Gorman suggests that although this deformity can 
arise in the absence of a bipedal gait, the biomechanical forces acting on the spine 
of the guppy may in fact be similar to those in the human. In humans the force acting 
on the spine in along the cranio-caudal axis as gravity acts vertically upon the head 
and upper body. The force on the guppy spine also acts along the cranio-caudal axis 
but is independent of gravity, instead originating from the power of the tail-beat 
motion pushing the animal through the dense medium of water. The result is a 
compressive force along this axis. As axial loading is not unique to humans as 
curveback guppies, it is likely that there is at least one secondary component acting 
in parallel with these forces to create spinal deformity. Humans and fish share many 
developmental pathways and many gene sequences isolated in the fish have 
analogues in humans. Several of these sequences, including those involved in 
osteoblast and chondrocyte differentiation, bone and muscle formation, pineal gland 
development, have been implicated in human scoliosis. 
Mice represent one of the least used animal species in scoliosis modelling. The 
example of the curveback guppy suggests that a genetic predisposition is likely to 
play a role in the development of AIS. The genome of the mouse has been 
sequenced and extensively studied. The ability to generate knock-out and transgenic 
mice provides the opportunity to study the function of various genes in vivo. We have 
only begun to apply this technology to the study of scoliosis. Giampetro et al 
performed a search of the Mouse Genome Database by phenotypic category 
yielding 100 mouse mutations. [52] Of the 66 of these whose genome had been 
mapped, 27 demonstrated a scoliotic phenotype. The loci of the mutations 
responsible for the deformities in these mice have analogues in humans, including 
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Pax1, Dll3, Wnt3a, Ky, Lmx1a, Fbn-2, and Sim2. The phenotypes associated with 
these mutations generally yield structural malformation of the vertebrae and ribs, 
consistent with congenital scoliosis rather than IS.  
NF1 (formerly von Recklinghausen’s disease) is a common genetic disease that is 
associated with a 20-25% rate of scoliosis in addition to a characteristic range of 
other clinical features. 4-43% of patients with NF1 will exhibit a degree of spinal 
deformity [53-57] with many of these requiring correction via external bracing or 
surgery depending upon the severity of the curvature.[58, 59] The pathogenesis of 
the deformities seen in NF1 are not easily classified into the scoliotic divisions 
presented earlier. Suggested causes include one or a combination of compressive or 
erosive effects of adjacent neurofibromas, osteomalacia, endocrine disruption and 
muscular imbalance. Aetiological classification is further complicated by the fact that 
there are now two recognized subtypes of scoliosis in NF1 as determined by clinical 
and radiographic data. Dystrophic and non-dystrophic types are differentiated by the 
presence or absence of dysplastic changes in the vertebrae, including scalloping or 
wedging of the vertebral bodies, spindling of the transverse processes and rib 
pencilling. [60] Non-dystrophic scoliosis in NF1 patients is clinically and radiologically 
similar to idiopathic scoliosis and may therefore share a common pathogenesis.  
Animal models have reproduced the orthopaedic manifestations of NF1 with varying 
success [61-65], with scoliosis only demonstrated in one. An Nf1-/- genotype was 
induced in osteochondroprogenitor cells using the Col2α1-cre promoter to yield a 
severe phenotype with radiographic parallels to the human orthopaedic 
manifestations of NF1 [66]. Mice showed reduced growth, tibial bowing and 
progressive scoliosis and kyphosis. These changes were associated with increased 
cortical porosity, increased osteoclastogenesis and decreased osteoblast number. 
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The scoliosis observed in this model closely mimicked the features of dystrophic 
scoliosis seen in patients with NF1 demonstrating primary structural defects of the 
vertebrae, including fusion of adjacent vertebrae, as well as of the intervertebral 
discs. Histology of day 16.5 embryos showed that ossification centres were not 
present in all vertebral bodies unlike wild type controls where their presence was 
ubiquitous. A similar model involving targeting of osteoblast precursor cells using 
2.3kb promoter of Col1 [36] produced a vertebral phenotype with shorter vertebrae 
with reduced cortical and trabecular bone mass. When strength tested, a reduced 
peak load and peak stress to failure was noted in L5 vertebrae. However, it was not 
able to create spinal deformity. This was proposed to be the result of the 
quadrupedal gait of the mouse which did not mimic the axial loading in humans. The 
cortices of the bone in these mice has been noted to have increased microporsity 
which may be due to increased lacunae size. [160] 
Nf1-/- is an embryonically lethal condition secondary to cardiac abnormalities. Nf1+/- 
mice are viable, fertile and demonstrate a mild phenotype with minimally impaired 
bone healing [62], impaired spatial learning [63] and predisposition to tumour 
development [64]. Consequently several models have been created which are 
capable of inducing an Nf1-/- genotype that is localized to either a specific tissue, or 
to a specific location within the body with correspondingly more severe phenotypes. 
Impairment in healing can be simulated by local transduction of Nf1flox/flox mice with 
cre-expressing adenovirus [65] which initiates heterozygosity for Nf1 deletion in cells 
of preosteoblast lineage.  
The modelling of scoliosis in other genetic diseases with known bone phenotypes 
has proved more challenging. Scoliosis is a recognized feature of OI (brittle bone 
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disease), and CypB knockout mouse developed as a model of OI showed decreased 
bone mineral density and body mass as well as prominent kyphosis. [67]  
Mutations in Filamin B (FLNB), a gene that encodes a cytoplasmic actin-binding 
protein, is responsible for several skeletal disorders which are characterized by a 
degree of scoliosis, including spondylocarpotarsal syndrome, Larsen syndrome, and 
atelosteogenesis phenotypes I and III. Zhow et al [68] created a mouse in which 
FLNB is disrupted. While a majority of these mice did not survive to term, the few 
that survived were very small and showed severe skeletal manifestations with 
evidence of kyphosis, scoliosis, lack of intervertebral discs (IVD) and fusion of 
vertebral bodies. The degree of kyphosis and scoliosis was not defined in this 
experiment. The deformity was likely to have arisen secondary to the fusion of the 
vertebral bodies and the absence of IVDs. The dystrophic bone phenotype of these 
mice was sufficiently severe that they had to be euthanized at 4 weeks of age. 
Duchenne Muscular Dystrophy (DMD), which is caused by a loss of functional 
dystrophin and is primarily known for its muscular manifestations, is associated with 
an incidence of scoliosis of 75-90%. [8, 69] A dystrophin-utrophin double knockout 
mouse was created as a model of DMD [70]. This mouse exhibited a range of 
musculoskeletal abnormalities, including premature degeneration of the 
intervertebral discs, but did not show any spinal deformity.  
The dystrophic changes in the spine produced by these models, with and without an 
associated spinal deformity, are reminiscent of those seen in congenital scoliosis. 
With the exception of NF1 model in which scoliosis was reproduced, the difficulty 
achieving deformity in other models supports the concept that scoliosis is a 
multifactorial process that is particularly challenging to model when investigating 
variables in isolation. It is conceivable that the primary deficiencies created using 
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these genetic models may have yielded to the axial forces of gravity and produced a 
scoliotic deformity in a bipedal model.  
Most models to this point have been dependent upon some form of surgical 
intervention. The use of mice has presented a technical challenge that can be readily 
overcome with the use of larger animals. Knock out and transgenic mice likely 
represent a future direction for scoliosis research. These mice permit the 
investigation of the activity of specific genes, directed by observational genomic 
mapping of affected individuals and mice. Additionally, the breeding and lifecycles 
can produce a large volume of data over a short period of time, making them a 
potent tool for the investigation of the aetiology of the many varieties of scoliosis 
affecting humans. The development of murine models of NF1 that demonstrate 
orthopaedic phenotypes is an excellent example of the modelling power of 
transgenic mice. By targeting a specific cell lineage and obtaining an accurate 
representation of the human histology and morphology, significant information is 
obtained regarding the aetiology of dystrophic scoliosis in NF1.  
In summary scoliosis research has been enhanced by the development of both 
mechanical and genetic models. Mechanical models \permit the study of primarily 
surgical interventions that are aimed at reducing established deformity. Genetic 
models present a unique opportunity to develop disease specific interventions to 
treat and/or prevent the development of spinal deformity.  
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1.5.3 Bipedal Models of Scoliosis 
Mechanical models 
Bipedal animals are subject to axial forces upon the spine, secondary to gravity, as 
humans. They are therefore an attractive option for the modelling of human spine 
deformity. Following the success of quadrupedal rib resection models, this technique 
has been applied to bipedal animals, specifically the chicken [37, 38] and non-human 
primates. [71, 72] Deguchi first applied this model to chickens in which he either 
resected or transacted the dorsal ribs. He found that at 20 weeks, animals with 
transected ribs showed healing of the bone and no scoliosis. In those animals that 
received resection, marked scoliosis was observed. The degree of scoliosis was 
increased with decreased age at surgery and with increasing number of ribs 
resected. Animals showing regeneration at the resection site were noted to have 
milder scoliosis. These results are consistent with similar experiments involving 
quadrupedal animals.  
Although the Langenskiold technique for inducing scoliosis via rib resection has been 
successfully applied to the bipedal chicken, translation to primates has proven more 
challenging. A study was conducted on 10 young baboons, aged 2-3 months in 
which the heads of 4-5 ribs were resected unilaterally. At one year post-op, no 
subjects developed any degree of scoliosis. [72] Another study, involving 30 
monkeys of unspecified type, divided the subjects into three treatments groups of 
n=10. These groups consisted of: removal of dorsal end of lower 6 ribs on the right 
side, removal of costo-transverse ligaments of lower 6 costo-vertebral joints on the 
right side, and removal of the dorsal end of the lower 6 ribs on the right side followed 
by the same procedure on the left side 6 weeks later. Subjects from the first two 
groups only developed a mild rotational deformity. However, at 6 weeks post 
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operatively, all subjects from the third group had developed a severe scoliosis with 
an average angle of 46º. [71] 
 
Neuroendocrine models 
The most common model of bipedal scoliosis involves inducing a state of melatonin 
deficiency in test animals, often by removal of the pineal gland. The progression to 
scoliosis following pinealectomy was first observed in chickens [73-79] by Thillard 
[79] in 1959. Animals were subjected to pinealectomy (figure 1.11) upon hatching 
and were observed to develop a high incidence of spinal deformity of between 52% 
and 100%. In animals such as the chicken and rodents, the pineal gland has a 
superficial location relative to its position in the human and is more readily surgically 
accessible. The scoliosis produced in these animals can be prevented by melatonin 
therapy or reimplantation of the pineal gland into a skeletal muscle pouch. Grossly, 
the curvatures evident in these animals appeared very similar to those seen in IS, 
characterized by similar distributions of single and double curves, location of curves, 
degree of rotation and degree of stability. [74, 76]  
 
 
Figure 1. 11 Compared to the deep location of the pineal gland within the human brain (A), 
its position in the chicken (B) and rodent (C) brain is significantly more superficial. This 
position facilitates surgical access for its excision in melatonin deficiency models of scoliosis. 
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Nevertheless, the dissimilarities in the morphology of the chicken and human models 
are worth noting. The source of the deformity in human IS is initially predominantly 
due to wedging of the intervertebral discs and later from a slow progressive vertebral 
body wedging. [80] Chickens, unlike humans, have very small discs and the 
histology of their intervertebral joint has been described as being more like a 
synovial joint than a fibrous joint as seen in humans. As a result, there is no 
abnormality noted in the discs of pinealectomized vs control chickens. The lateral 
curvatures in the spines of pinealectomized chickens arises completely from 
wedging deformity of the vertebrae which is associated with significant morphologic 
asymmetry of the other vertebral structures including pedicles and processes. [74]  
The utility of the pinealectomized chicken as a model for IS has been cast into doubt 
when the same technique has been applied to non-human primates. Following 
pinealectomy in 18 rhesus monkeys between 8 and 11 months of age, 10 were 
melatonin deficient for 29 months during which time none of them developed 
scoliosis. [81] These results suggest that data obtained from pinealectomized lower 
animals may not be extrapolated to humans. Observational studies involving humans 
with both scoliosis and underactive pineal glands support this. In a prospective study, 
48 Australian children with pineal lesions aged one to 18 were followed up for 80 
months (30 for non-survivors). Two of the surviving boys developed scoliosis, one of 
which corrected itself spontaneously over 2 years, and none of the deceased were 
shown to have developed scoliosis on their final X-Rays and MRI. [82]  
Several cross sectional studies have been performed comparing melatonin levels 
between adolescents with and without scoliosis. While some studies support the 
theory that low melatonin secretion is associated with the development of AIS [83, 
84], the majority show that there is no correlation. [85-89]  
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Though research into melatonin deficiency as a cause of scoliosis is inconclusive, it 
fulfils Langenskiold criteria for a good model of scoliosis in that it constitutes a 
reliable and reproducible method for creating scoliotic deformity upon which 
experimental interventions may be applied. Deguchi et al successfully performed 
experiments in which they induced a scoliotic deformity in the spines of chickens via 
rib resection [38] and pinealectomy [90]. Subsequently, in a cohort of 
pinealectomized chickens, they performed rib resection on the concave side of the 
curvature in animals that showed >20° at 4 weeks of age. Chickens treated with rib 
resection developed milder scoliosis (6-56°) vs controls (24-85°).  
Research into melatonin deficiency and scoliosis has supported the concept that 
bipedalism is a prerequisite for deformity. In a series of experiments conducted by 
Machida et al. [75, 83, 91], scoliosis was induced in rodent following pinealectomy. 
Animals that were allowed to ambulate on 4 limbs did not develop any incidence of 
deformity. However, deformity could be produced in animals that had been made 
bipedal by amputation of the forelimbs and tail. Following amputation, animals were 
drawn into a bipedal stance by the gradual raising of food and water. The same held 
true when quadruped hamsters were subjected to pinealectomy. [92] These findings 
have been recapitulated by Akel et al using melatonin deficient C57BL6/NCrl mice 
which were made bipedal by forelimb and tail amputation with gradual raising of food.  
The bipedal rodent model has also been applied to another neuroendocrine theory of 
scoliosis. It has been observed that Adolescent girls with IS have low circulating 
leptin. [93-95] Wu et al performed an experiment in which they injected the 
hypothalamus of 8 bipedal mice with lentivirus vectors expressing leptin. These mice 
were noted to have high circulating levels of serum leptin relative to controls (n=8) 
which were injected with lentivirus vectors expressing physiologically inactive GFP. 
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100% of leptin lentivirus injected mice were noted to develop scoliotic deformity, a 
result which is in contrast to the clinical evidence.  
 
1.5.4 Summary  
There have been, over the years, many attempts to develop animal models to 
investigate scoliosis in humans. The aetiology of this deformity has thus far remained 
largely elusive, particularly with regard to idiopathic scoliosis which develops in youth 
and may progress to a debilitating degree. Most early research into scoliosis 
modelling can be characterized by attempts to reproduce the curvature that is seen 
in human scoliosis but not necessarily its pathogenesis.  
Scoliosis, in particular idiopathic scoliosis, is a common but poorly understood 
condition and is a sign expressed by several different disease processes rather than 
a diagnosis in itself. Intrinsic and extrinsic forces acting upon the spine, genetic 
predisposition, neuroendocrine dysfunction have been implicated in scoliosis and 
have been modelled with varying degrees of success. As proposed by Schimandle et 
al [96], the utility of a model is dependent upon the intention of the experiment. If the 
intention is to investigate mechanical factors, a larger animal of benefit as it will 
approximate the size and anatomy of the human. Several models, including tethering 
and melatonin deficiency models have been very successful at producing reliable 
deformity which can then be used to test a variety of interventions targeted at curve 
reduction. Smaller, skeletally immature animals, such as mice, are better for 
investigating biological questions.  
It is likely that the aetiology of scoliosis in humans is a multifactorial process. The 
impact of mechanical factors upon the spine with respect to scoliosis has been 
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extensively studied. Correspondingly, the only treatments for scoliosis today involve 
mechanical correction of curvature. The investigation of the biological causes of 
scoliosis is in its infancy. The use of mice to investigate the genetic factors 
influencing spinal deformity has just begun to be exploited and represent a valuable 
tool for future investigation. 
 
1.6 Hypothesis and Aims 
Neurofibromatosis type 1 may produce a scoliotic deformity of the spine that is 
challenging to treat. [93] The most successful method for correcting the deformity 
and limiting its progression involves the surgical implantation of paraspinal rods that 
act as internal braces. In the short term, these rods immobilize the spine such that 
bony union of adjacent vertebrae may be achieved. Failure to unite, pseudarthrosis, 
represents a failure of fusion and over time the repeated stresses places on the 
hardware will result in its weakening and breaking. Such failures are a significant 
source of morbidity and cause for reoperation, often in the setting of a paediatric 
population. [161-163] 
The reason for failure of spine fusion in NF1 scoliosis is multifactorial. First, the 
dystrophic scoliosis seen in NF1 is associated with significant deformity and often is 
subject to asymmetrical muscular forces secondary to tumour infiltration of the 
paraspinal tissues. Deformities of this severity are challenging to treat even in a non-
NF1 population.  
Second, patients with NF1 show defects in bone metabolism, including impaired 
anabolism and augmented catabolism via reduced osteoblastogenesis and 
increased osteoclastogenesis respectively. [105] Clinically, patients receiving 
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revision surgery for failed spine fusion are found to have fibrous tissue in place of 
bone uniting adjacent vertebrae. This must be excised to prepare the vertebrae for a 
second attempt at fusion. This process is similar to that seen in the case of 
pseudarthrosis of the tibia in NF1. It has been proposed that the unopposed action of 
Ras in NF1 patients may be implicated in these orthopaedic manifestations of the 
disease. [164, 165] 
Third, the formation of a successful fusion mass is dependent upon recruitment of 
osteoprogenitor cells. The source of this population of cells is largely considered to 
be the periosteum and bone marrow. It has been suggested that other tissue may be 
a source of progenitor cells that are able to contribute to bone formation and repair, 
including skeletal muscle, smooth muscle and vascular endothelial cells. [166-170] 
The cell populations that contribute to the formation of a spine fusion mass has not 
been well characterized.  
In this thesis, we will investigate methods to improve spine fusion outcomes in 
patients with NF1. In Chapter 2, we will explore the history of animal models used to 
model spine fusion surgery. We will build upon this in Chapter 3 to develop our own 
murine model of spine fusion. This model will specifically be developed to model 
posterolateral lumbar spinal fusion.  
The role of NF1 in bone metabolism and healing is well documented, primarily in the 
context of tibial pseudarthrosis. The effect of NF1 in the setting of spine fusion is not 
well researched. In Chapter 3, we will employ the developed surgical model for spine 
fusion in a transgenic mouse line that is Nf1+/- systemically. We will investigate the 
phenotype of this mouse line with respect to spine fusion and attempt to address the 
anticipated catabolic imbalance with the bisphosphonate Zoledronic acid.  
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Tumours analysed from patients with NF1 have shown double inactivation of the Nf1 
gene (Nf1-/-) in keeping with the two- hit hypothesis in which one allele is 
constitutionally inactivated and the other the subject of mutation. In mouse models, 
double inactivation of the Nf1 gene is associated with development of a more severe 
phenotype. In Chapter 4, we will apply the spine fusion procedure to a transgenic 
mouse in which we will initiate double inactivation of the Nf1 gene in the tissues local 
to the lumbar spine. Neurofibromin is known to downregulate Ras pathways, 
inactivation of the Ras-MEK pathways may represent an opportunity to correct the 
orthopaedic phenotype of NF1 in the spine. Animals will be dosed with the MEK 
inhibitor PD0325901 and the bisphosphonate to attempt to correct the unopposed 
activity of Ras and the excessive catabolism witnessed in NF1.  
The mobilisation of extra-osseous populations of osteoprogenitor cells may 
represent a niche that may be exploited to enhance bone formation. In chapter 5 we 
will apply the spine fusion surgical model to Tie2-Cre:Ai9 and αSMA-
creERT2:Col2.3-GFP:Ai9 reporter mice and observe the distribution of lineage-
labelled cells. We hypothesize that Tie2 and αSMA cells will contribute to the 
osteoprogenitor cell population in the fusion masses of experimental mice.  
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Abstract  
 
Background: Spinal fusion is a common orthopaedic procedure that has been 
previously modeled using canine, lapine, and rodent subjects. Despite the increasing 
availability of genetically modified mouse strains, murine models have only been 
infrequently described.  
Purpose: To present an efficient and minimally traumatic procedure for achieving 
spinal fusion in a mouse model and determine the optimal rhBMP-2 dose to achieve 
sufficient fusion mass.  
Method: MicroCT reconstructions of the unfused mouse spine and human spine 
were compared to determine a surgical approach. In phase 1, posterolateral lumbar 
spine fusion in the mouse was evaluated using 18 animals allocated to three 
experimental groups. The spine was accessed via a midline excision with Group 1 
receiving decortication only (n=3), Group 2 receiving 10µg rhBMP-2 in a collagen 
sponge bilaterally (n=6), and Group 3 receiving 10µg rhBMP-2 + decortication (n=9). 
The surgical technique was assessed for intraoperative safety, efficacy, access and 
reproducibility. Spines were harvested for analysis at 3 weeks (Groups 1, 2) and 1, 2, 
and 3 weeks (Group 3). In phase 2, a dose response study was carried out in an 
additional 18 animals with C57BL6 mice receiving sponges containing 0, 0.5, 1, 2.5, 
5 µg of rhBMP-2 per sponge bilaterally.  
Results: Based on structural differences observed between the murine and human 
spines, exposure, decortications, and sponge insertion was placed upon the murine 
articular processes, found to be structurally more analogous to the human transverse 
processes and easily accessible via the midline. Decortication alone (Group 1) 
yielded no novel bone formation but introduction of rhBMP-2 (Groups 2 and 3) 
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yielded significant bone mass bridging the L4-L6 vertebrae by at week 3. For Group 
3 where longitudinal examination of bone formation was examined, no additional 
bone increase was seen between weeks 2 and 3. The dose response experiment 
revealed that all doses down to 0.5µg were sufficient to create a fusion mass. 
Conclusion: We describe a new approach for mouse lumbar spine fusion that is 
safe, efficient, and highly reproducible. The technique we employed is analogous to 
the human midline procedure and may be highly suitable for genetically modified 
mouse models. 
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Introduction 
 
Spinal fusion surgery has been performed since the pioneering work of Hibbs [171], 
Albee [88] and DeQuervain in the early 20th century. When successful the procedure 
has significantly reduced the morbidity associated with spinal deformity and, 
controversially, discomfort. Historically, the procedure has suffered from high rates of 
non-union. It has been estimated that 5-30% of spinal fusion procedures result in 
pseudarthrosis [108], the causes of which are certainly multifactorial.  
Animal surgical models have been utilized extensively to improve surgical technique 
and gain insight into the mechanisms of spinal fusion failure. Larger animals such as 
canine [110, 130, 132, 136, 172] and ovine subjects [131, 173] have traditionally been 
employed due to their close approximation of the size and anatomy of human patients. 
Rat and rabbit studies [30, 40, 134, 138, 174-180] typically represent the lower limit with 
respect to size that spine fusion procedures have been attempted. Mouse models have 
rarely been studied, likely owing to the technical difficulty associated with surgical 
access and technique demanded by their small size. Until recently, spinal fusion 
attempts in mice have been limited to percutaneous injection of BMP solution and 
mesenchymal stem cells into the paraspinal musculature [181, 182], thereby obviating 
the need to surgically expose and manipulate the vertebral structures.  
Advancements in transgenic mice have encouraged the use of surgical models that 
explore the impact of genetics on repair and regeneration. Rao et al ([183]) were the 
first to publish a consistent technique for performing posterolateral lumbar spinal fusion 
in mice, using a modified version of the paraspinal approach described by Wiltse [184]. 
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Fusion was induced via autogenous bone graft from donor mouse of same strain or 
rhBMP-2 delivered in a collagen sponge. Radiographic assessment demonstrated that a 
dense fusion mass was formed in 62% of fusion sites, although no specific breakdown 
was given for the bone graft and rhBMP-2 groups. This model also featured a prolonged 
operating time of 60 min.  
In this study we have utilized a surgical approach involving a single midline incision 
through the thoracolumbar fascia that more closely approximates the current human 
midline surgical technique. Such an approach aimed to minimize tissue trauma as well 
as increase visibility and access to the articular processes. One other aim of this 
modified procedure was to minimize the operative time and maximize the experimental 
reproducibility between subjects and the rate of spine fusion. 
 
Methods 
 
Anatomical Analysis by MicroCT 
The spines of 5 C57BL6 mice, aged between 8 and 10 weeks, were harvested and 
analyzed via microCT using a SkyScan 1174 compact microCT scanner (SkyScan, 
Kontich, 
Belgium). Samples were scanned in 70% ethanol at 21.3 um magnification, 0.5 mm 
aluminium filter, 50 kV X-ray tube voltage and 800 μA tube electric current. The images 
were reconstructed using NRecon, version 1.5.1.5 (SkyScan). A global threshold was 
used representing bone tissue. Representative three-dimensional fractures were 
reconstructed with sagittal slices using CTVol Realistic Visualisation software version 
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2.1.0.0 (SkyScan). The structure of the lumbar spine was documented and compared 
with the relevant human anatomy. Subsequently, 5 additional mice were culled and the 
lumbar spine was dissected. The relationships of the soft tissue to the bone were 
observed and documented with a view to establishing a clear and efficient surgical 
access to the lumbar vertebrae which would allow secure positioning of a collagen 
sponge for the delivery of osteoblast stimulating factors.  
 
Surgical Model 
18 C57BL6 mice (male and female aged 8-10 weeks) had posterolateral lumbar spine 
fusion surgery performed. Surgery was performed by a two surgeons in a single sitting 
with anesthetic support from an experienced animal technician.  
Mice were anaesthetized with ketamine (35mg/kg) / xylazine (5 mg/kg) solution 
administered intraperitoneally. Hair overlying the operative site was shaved with an 
electric razor once anaesthetized and the area prepped with iodine. Animals were 
positioned prone with folded gauze beneath the abdomen, increasing the excursion of 
the lumbar spine to facilitate access to and visibility of the surgical field. The head was 
covered with saline soaked gauze to protect the ears from overheating under operating 
lights. rhBMP-2 marketed under the brand name Infuse® (Medronic Australasia) was 
used in this study. Prior to surgery, the collagen sponge that was supplied with the vial 
of BMP for human use was cut into 2mm × 7mm sections. A solution of saline and BMP 
was made allowing the accurate pipetting of 10 mg of BMP onto each sponge 
intraoperatively.  
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With the intention of fusing the lumbar spine from L4-L6, surface anatomy was located 
to determine incision point. The iliac crest is approximately level with the L5-L6 
interspace [183]. This level as well as the midline was marked with surgical pen (Figure 
1A). The procedure was performed under an operating microscope or surgical loupes at 
2.5× magnification. A 15 mm incision was made in the skin made along the midline, 
centered over the line running between the iliac crests (Figure 2.1 B). The skin was 
opened and held in place with a self-retaining retractor (Figure 2.1 C). At this point, the 
midline was identified by the spinous processes. The iliac crest was directly visible. A 
second 15 mm incision, through the dorsolumbar fascia, was made in the midline, along 
the spinous processes. The spinous processes and lumbar paravertebral muscles have 
now been accessed. The paravertebral muscles overlying the articular processes of L4-
L6 were separated from the spinous processes in a single motion by scraping a # 10 
blade down the lateral border of the spinous process and pulling the muscles laterally 
(Figure 2.1 D). This motion shears the muscle at its junction to the bone minimizing 
trauma to the tissue. This was performed bilaterally exposing the articular processes 
and creating a potential space between muscle and bone. Muscle was retracted 
bilaterally with a purpose-built micro-retractor allowing controlled and gentle retraction 
while maintaining maximum visibility of all articular processes. A pneumatic 1 mm round 
tip diamond burr was used to decorticate the visible articular processes until punctuate 
bleeding was observed. Care was taken not to disturb surrounding muscle tissue.  
Two collagen sponges, impregnated with either saline or an rhBMP-2/saline solution 
(containing 10mg of BMP per sponge), were placed bilaterally in the potential space 
which has been created (Figure 2.1 E). The fascia was apposed and closed with a 
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single line of continuous sutures using 6.0 Vicryl, The skin was subsequently closed in 
the same fashion. Mice were placed on a heat pad following surgery and monitored for 
recovery. Antibiotics were administered in the drinking water for 24 hours 
postoperatively.  
 
Figure 2. 1 Following the administration of anesthetic the mouse was positioned prone. A 
marker was used to mark the location of the spinous processes, vertical line, and pelvic crest, 
horizontal line (A). A line drawn across the pelvic crests corresponds to the position of the L5-L6 
interspace. An incision was made through the skin which was the held by a self-retaining 
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retractor (B). A single incision was made through the thoracolumbar fascia over the spinous 
processes and the paravertebral musculature was dissected by scraping a blade down along 
the spinous processes and pulling laterally. The dissection of the local musculature forms a 
pocket on either side of the spine, bounded medially by the spinous processes and inferiorly by 
the articular processes (D). The articular processes are consequently exposed and visualized 
allowing decortication with a 1mm round diamond burr until punctate bleeding is observed. 
Following decortication of the visualized articular processes, a 7mm x 2mm collagen sponge 
impregnated with either saline or saline/rhBMP-2 solution is inserted into each of the pockets in 
contact with the posterior elements of the spine (E). The muscle and skin are then closed with 
continuous sutures using 5.0 Vicryl®. 
 
Study Design  
Once the safety and efficacy of the surgical model had been demonstrated, it was 
applied to a small study involving 18 C57BL6 mice to determine the optimal dose of 
rhBMP-2 required to establish fusion of the spine. Mice were divided into dose groups of 
0, 0.5, 1, 2.5, and 5 µg of rhBMP-2 per sponge bilaterally and culled at 3 weeks. Spines 
were harvested and fixed in 4% paraformaldehyde for 24 hours and then analyzed by X-
ray and microCT were used to visualize novel bone formation.  
 
Radiography 
Following harvesting and fixation in 4% paraformaldehyde, microCT data was obtained 
via SkyScan 1174 compact microCT scanner (SkyScan, Kontich, Belgium). Samples 
were scanned in 70% ethanol at 21.3 um magnification, 0.5 mm aluminum filter, 50 kV 
X-ray tube voltage and 800 μA tube electric current. The images were reconstructed 
using NRecon, version 1.5.1.5 (SkyScan). A global threshold was used representing 
bone tissue. Representative three-dimensional fractures were reconstructed with 
sagittal slices using CTVol Realistic Visualization software version 2.1.0.0 (SkyScan).  
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Histology 
Harvested vertebrae and surrounding musculature were fixed in 4% paraformaldehyde 
for 24 hours at 4°C on a shaker were and then stored in 70% ethanol until ready for 
decalcification. Samples were decalcified in 0.34M EDTA (pH 8.0) solution at 4°C on a 
shaker for 30 days with solution changes every 2-3 days. Samples were next embedded 
in paraffin and sectioned transversely through the center of the fusion mass at a 
thickness of 5 microns. Mounted sections were stained via Picro Sirius Red/Alcian Blue 
to differentiate bone and cartilage. 
 
Statistics 
The significance of the medians and distribution of bone volume data as a function of 
increasing dose was first analyzed via stringent non-parametric statistics (Kruskal-Wallis 
independent sample test; SPSS Statistics v18). Using an assumption of normally 
distributed data, an ANOVA with post-hoc Bonferroni test was then performed to 
compare individual groups. The limit for statistical significance was set at 0.05. 
 
Results 
 
Anatomical examination of the unfused mouse spine 
MicroCT images of the mouse lumbar spine were compared to human anatomical scans 
(Figure 2.2). Comparison of both species showed shared similar vertebral structures, 
although their position and orientation differed between species. Of particular note was 
the positioning of the transverse process (TP) in the mouse lumbar vertebrae. In the 
human, the TP is located posterolaterally, and is therefore the anchor point in 
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posterolateral spine fusion. In contrast, in the mouse it is the inferior articular processes, 
rather than the transverse processes that share this orientation. For the purposes of 
modeling a human surgery in a mouse, we concluded that a posterolateral interarticular 
process spine fusion would more closely approximate the posterolateral intertransverse 
procedure used in humans today.  
 
Figure 2. 2 Three-dimensional reconstructions of CT images demonstrating the anatomy of 
murine lumbar spine (left) vs human lumbar spine (right). (A) Anterior vertebral body. (B) 
Transverse process. (C) Inferior articular process. The position and orientation of the transverse 
process of the mouse spine differs significantly from the human spine. Both the murine inferior 
articular process and the human transverse process share a lateral orientation. 
 
 
Surgical timing and morbidity 
There was no intra- or post- operative morbidity or mortality in either the fusion outcome 
study or the rhBMP-2 dose response study. Animals were monitored for neurological 
impairment (particularly of the hind limbs), wound infection, weight loss and distressed 
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behavior. Operative time, in the hands of an experienced surgeon, was approximately 
15 minutes skin to skin. We believe that the brief operating, and hence anesthetic time 
as well as the minimized trauma contributed significantly to the observed safety of the 
procedure.  
 
 
Fusion outcomes 
Our results were consistent with previous studies [183], demonstrating little or no bone 
growth evident in decortication-only control animals on micro-CT reconstruction as well 
as in decortication/BMP animals culled at 1 week. By week 2, a significant volume of 
bone was observed in all animals which received BMP-2. The bone bridge typically 
united all vertebrae from L2/3-L6 with an AP dimension equal to or greater than that of 
the lumbar vertebrae to which it has fused (Figure 2.3). The bone mass was 
homogenously of lower density that the vertebral cortical bone. At week 3, areas of 
centralized resorption were noted in the bone mass. Decortication does not appear to 
have contributed significantly to new bone formation. MicroCT reconstructions were 
supported by histology (Figure 2.4). Paraffin sections stained with Picro Sirius 
Red/Alcian Blue stain demonstrated an abundance of collagen, stained blue, overlying 
the posterior elements of the spine. The observed collagen is likely a remnant of the 
collagen sponge used to deliver the rhBMP-2 and was associated with lateral 
displacement of the perispinal musculature, stained green. No new bone formation, 
stained red, was observed at 1 week time points in any group. Overwhelming bone 
formation was observed at the 2 week end point in all groups dosed with rhBMP-2. The 
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size of the fusion mass was unchanged at 3 weeks. However, consistent with microCT 
data, an area of centralized resorption was evident. This was visualized as a reduction 
of red staining structures in the center of the fusion mass relative to samples obtained at 
2 weeks.  
 
 
Figure 2. 3 Volume of the BMP induced fusion mass was assessed via microCT using a 
Skyscan 1174 scanner. A fusion mass was only produced in groups in which BMP was 
implanted. No new bone was observed at 1 week post op, while maximum fusion volume was 
achieved by week 2 and maintained at week 3. Decortication of the articular processes alone 
was insufficient to achieve novel bone formation. 
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Figure 2. 4 Histological samples retrieved from fused murine vertebrae. Samples have been 
stained with Pico Sirius red and Alcian blue stain to differentiate between bone and collagen. At 
1 week, a large collagen mass overlaying the posterior elements of the vertebrae forms with 
disruption of local musculature. By the second week postoperatively, a large bony mass that 
was continuous with the cortex of the vertebrae was present. This mass exhibited a resorptive 
marrow-like center by week 3. No novel collagen or bone was observed in the decortications 
only spine. 
 
 
rhBMP-2 dose response study 
A dose responsive relationship was observed between the rhBMP-2 dose and size of 
the fusion mass (Figure 2.5). When collagen sponges were added with 0µg of rhBMP-2, 
no fusion mass was observed. MicroCT data showed that a dose as low as 0.5µg was 
able to promote fusion and the amount of bone formed increased with increasing 
rhBMP-2 dose (Figure 2.6). The significance of the distribution of bone volume data as 
a function of increasing rhBMP-2 dose was found to be different by non-parametric 
independent sample analysis (P<0.01) and also by ANOVA (P<0.01). Post-hoc 
intergroup testing showed significant differences between the induced bone volumes 
between the 0 µg (no treatment) group and the 2.5 µg, 5 µg, and 10 µg rhBMP-2 groups 
(all P<0.01). Bonferroni post-hoc intergroup testing showed significant differences 
between the induced bone volumes between the 10 µg groups and the 0 µg (0.000), 0.5 
µg (0.005) and 1 µg (0.051) groups as well as between the 0 µg and the 2.5 µg (0.008) 
and 5 µg (0.005) groups. 
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Figure 2. 5 AP and lateral microCT images demonstrating the volume of new bone formed in 
response to rhBMP-2 dose. To the right of each set of microCT images was a cross sectional 
image of the spine taken at its widest point in the transverse plane. An increase in the size of 
the fusion mass was observed with increasing rhBMP-2 dose. It was noted that at a dose of 0.5 
µg sufficient bone was formed to bridge the L4-L6 vertebrae resulting in successful fusion. 
 
 
 
Figure 2. 6 Volume of spine fusion bone mass as a function of rhBMP-2 dose. A dose-response 
relationship was observed with consistent bone mass being formed with a dose as low as 0.5 µg 
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of rhBMP-2. Bone volume data for the 10 µg dose (n=6) is included from the first phase and was 
consistent with the dose-response trend. 
 
Discussion 
 
Historically, larger animals have been used to model spine fusion surgery due to their 
proximity in size and anatomy to humans. Recently, advancements in transgenic mice 
have generated an experimental niche for the use of murine surgical models. Knockout 
and transgenic mice offer a unique opportunity for insight into the genetic and cellular 
mechanisms underlying bone repair [185]. Idiopathic scoliosis (IS) is the most common 
cause of spinal deformity in children, but the etiology of the disease has remained 
elusive. Recent research has found a strong association between mutations of the 
CHD7 gene and the development of IS [186]. The potential exists to replicate CHD7-
mutation dependent IS in transgenic mice and to investigate intervention therapies in an 
accurate murine model. Similar advantages are offered to the modeling of scoliosis in 
neurofribromatosis type 1 (NF1) patients. NF1 Is the most common single gene disorder 
and at least 10% of patients diagnosed with NF1 will show signs of scoliosis in 
childhood [187]. A transgenic mouse model for human NF1 is currently available [188]. 
Additionally, there are several collateral advantages that may be gained by using mice 
for surgical modeling. As evidenced by this study, the small size of the mouse, though 
technically challenging, allows for a relatively quick operations which results in 
decreased intraoperative morbidity and mortality. Furthermore, this factor, when 
combined with the short generation time and the inexpensive housing costs of the 
mouse allows for a large volume of data to be obtained over a short period of time at 
little cost.  
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primary major drawback to using the mouse to replicate human surgery lies in the 
anatomical differences between the two species. With respect to the lumbar spine, our 
investigation into the murine anatomy yielded several distinct morphological differences 
between the mouse and the human lumbar vertebrae which have been previously 
overlooked, particularly the position and orientation of the transverse processes. 
However, the structural similarities of the mouse articular processes and the human 
transverse processes may be exploited to yield a procedure that is functionally 
analogous to that which is performed in humans.  
Previous mouse and rat models of posterolateral spine fusion have adopted a 
modification of the Wiltse technique which utilizes a paraspinal approach to the 
transverse processes [178, 183, 184]. Given the anatomical differences between 
rodents and humans we don’t believe that this is an optimal approach. Furthermore, the 
Wiltse technique uses twice as many incisions as a midline approach and is not 
currently in popular practice. The result is a procedure that does not mimic 
contemporary technique or relevant anatomy and leads to longer operating times with a 
consequent risk of increased morbidity and mortality. The surgical approach used in this 
study minimizes the number of incisions, tissue trauma and ultimately the total operative 
time. 
In mice who only received articular process decortication as intervention, no bone 
formation was observed. Additionally, little difference was noted in the size of the fusion 
mass between the BMP-only group and the BMP + decortications group. This may 
suggest a limited contribution to the fusion mass by the periosteum. Local muscle and 
vasculature have been proposed as potential contributors of osteogenic cells to the 
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bone repair process [12, 18, 21, 45, 53, 55, 166-168, 185, 189-193] and may play a 
significant role in the context of spine fusion.  
The initial study used an rhBMP-2 dose of 10µg per sponge. This dose was chosen by 
scaling down the dose currently used by our lab to achieve an rhBMP-2 mediated bone 
mass in rats. This yielded a very large amount of bone formation which is equal to or 
greater in volume than the spine itself. Such a large mass of bone suggests that the 
mouse spine is particularly sensitive to the osteogenic effects of rhBMP-2 and that a 
functional and stabilizing fusion mass could be achieved with a lower dose. We propose 
that the overwhelming response to the 10µg dose may be obscuring the influence of 
additional variables, such as decortications of the articular processes. A follow-up study 
was performed to determine minimum dose of BMP-2 required to obtain fusion. At 3 
weeks a significant dose response relationship between rhBMP-2 and the volume of the 
fusion mass was observed. It was found that a dose of 0.5µg, equivalent to 5% of the 
original dose, was sufficient to achieve successful fusion. The resulting fusion mass was 
significantly smaller than that achieved using 5µg or 10µg rhBMP-2. This smaller fusion 
mass may be more sensitive to the effects of intervention. In our analysis we included 
bone volume data for a 10 µg rhBMP-2 dose. This data was obtained from our initial 
pilot experiment which used identical mice and methods to the dosing study. In figure 5, 
the 10 µg data is represented with hollow circles to identify these mice as having being 
operated on at a different point. The bone volumes for the fusion mass obtained from an 
rhBMP-2 dose of 10 µg is consistent with the dose-response relationship exhibited by 
the 0-5 µg groups.  
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 We have demonstrated that a midline approach to posterolateral interarticular process 
spine fusion in a mouse model is safe, efficient, and yields consistent and reproducible 
results. A BMP-2 dose of 0.5µg per sponge is sufficient to achieve fusion of adjacent 
vertebrae. By exploiting anatomical similarities between the species, the technique 
closely mirrors that which is used in humans. The development of a surgical protocol in 
mice that is functionally analogous to the procedure in human patients is advantageous. 
This model permits the rapid observation of a large number of subjects over a relatively 
short period of time and allows valid extrapolation of reproducible data and results, 
thereby fulfilling the criteria for the ideal animal model as proposed by Schimandle and 
Boden [179].  
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Abstract 
Spinal pseudarthrosis is a well described complication of spine fusion surgery in NF1 
patients. Reduced bone formation and excessive resorption have been described in 
NF1 and anti-resorptive agents may be advantageous in these individuals. In this study, 
16 wild type and 16 Nf1+/- mice were subjected to posterolateral fusion using collagen 
sponges containing 5µg rhBMP-2 introduced bilaterally. Mice were dosed twice weekly 
with 0.02mg/kg zoledronic acid (ZA) or sterile saline. The fusion mass was assessed for 
bone volume (BV) and bone mineral density (BMD) by microCT. Co-treatment using 
rhBMP-2 and ZA produced a significant increase (p<0.01) in BV of the fusion mass 
compared to rhBMP-2 alone in both wild type mice (+229%) and Nf1+/- mice (+174%). 
Co-treatment also produced a significantly higher total BMD of the fusion mass 
compared to rhBMP-2 alone in both groups (p<0.01). Despite these gains with anti-
resorptive treatment, Nf1+/- deficient mice still generated less bone than wild type 
controls. TRAP staining on histological sections indicated an increased osteoclast 
surface/bone surface (Oc.S/BS) in Nf1+/- mice relative to wild type mice, and this was 
reduced with ZA treatment.  
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Introduction 
 
Neurofibromatosis type 1 (NF1) is a genetic disease with an incidence of 1 in 3000 that 
results from mutations in the NF1 gene. [194] NF1 is expressed in many tissues and its 
deficiency is associated with a range of characteristic features that present with variable 
penetrance. Orthopedic manifestations are one of the standard diagnostic criteria for 
NF1. As many as 25% of individuals will go on to develop some degree of scoliosis. 
[195, 196]Spine fusion surgery to correct the curvature and prevent future deformity is 
not uncommon, however with NF1 this can have an increased complication rate. [197] 
Pseudarthrosis at the fusion site may develop in as many as 25% of NF1 cases; in 
these incidents the adjacent vertebrae are united by fibrous tissue rather than with a 
solid bone bridge. [163] Solid fusion is seen in as few as 7% of cases. [93] 
These poor surgical outcomes are likely due to primary defects in NF1 bone 
metabolism. Up to 30% of adolescents and adults with NF1 show reduced bone mineral 
density (BMD), [198, 199] likely related to reduced bone formation and increased bone 
resorption. [50] Moreover, poor bone healing is observed in murine models of NF1-
deficient and NF1-null fracture repair, and these feature delayed union and 
pseudarthrosis respectively. [159, 200] Orthopedic models have likewise shown a bone 
anabolic deficiency as well as excess resorption from abundant osteoclasts.[49] 
Consequently, combination therapies using recombinant human bone morphogenetic 
proteins (rhBMPs) together with bisphosphonates have been proposed for the treatment 
of tibial pseudarthrosis. This strategy is supported by both genetic mouse models of 
NF1 [201, 202] and a published case series of NF1 tibial pseudarthrosis patients. [203] 
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Currently therapeutic development for NF1 spine fusion is hampered by a lack of an 
appropriate pre-clinical model to test interventions. Such a system requires both a 
genetic model of NF1 deficiency as well as an established protocol for spine fusion 
surgery. We have previously described a novel protocol for spine fusion in mice which 
we have shown to be safe, reliable and reproducible. [204] This model utilizes rhBMP-2 
delivered by surgically implanted collagen sponges to induce a posterolateral fusion. In 
this study we describe the application of this surgical model to Nf1 deficient mice (Nf1+/-) 
with and without systemic bisphosphonate treatment. It was hypothesized that 
bisphosphonate treatment would maximize the retention of rhBMP-2 induced bone 
yielding a superior fusion outcome as determined by bone volume and density.  
 
Materials and Methods 
 
Nf1 Gene Knockout Mice  
Nf1 knockout mice were a gift from L. Parada (UT Southwestern, Dallas, TX). [205] This 
mouse line possesses no tissue specificity in its Nf1 deficiency. The mouse line was 
maintained on a C57BL/6J background and genotyping was performed using a PCR-
based method. Nf1+/- heterozygous knockout mice aged 8-10 weeks were compared 
with wild-type (Nf1+/+) littermate controls. Female mice were used for all experiments. All 
animal experiments were approved by the local institutional ethics committee. 
 
 
Study Design  
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16 wild type mice and 16 Nf1+/- mice were used for the experiment. All mice underwent 
surgery for posterolateral fusion using bilateral paravertebral acellular collagen sponges 
(ACS, Medronic), each loaded with 5µg rhBMP-2. This dose was specifically chosen to 
represent the lower limit of the dose used in pediatric surgery (4.2mg in a 40 kg 
individual). For each genotype, n=8 were dosed twice weekly with saline and n=8 with 
five doses of the bisphosphonate zoledronic acid (ZA, Novartis AG). ZA was given at 
0.02 mg/kg (total dose 0.1 mg/kg) by biweekly subcutaneous injection commencing 3 
days postoperatively. Mice were culled at 3 weeks and spines harvested for 
radiographic and histological analyses.  
 
Surgery 
The surgical technique was performed with the intention of fusing the lumbar spine from 
L4-L6 using a published technique[204] modified from prior approaches in rodents. [183, 
184] Surgery was performed on mice aged between 8-10 weeks old by two surgeons in 
a single sitting with the aid of a trained animal technician. Anesthesia, preoperative prep 
and postoperative observation were performed by the animal technician. The procedure 
was performed under an operating microscope at 2.5× magnification. A 15 mm incision 
was made in the skin along the midline, centered over a line running between the iliac 
crests. The skin was retracted and held with a self-retaining retractor. The paravertebral 
muscles overlying the articular processes of L4-L6 were separated from the spinal 
column by scraping a 10 mm blade down the lateral border of the spinous process and 
pulling the muscles laterally. A pneumatic 1 mm round tip diamond burr was used to 
decorticate the visible articular processes until punctate bleeding was observed. Two 
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collagen sponges, impregnated with either saline or a BMP/saline solution were placed 
bilaterally adjacent to the decorticated bone. The fascia was closed with a single line of 
continuous sutures using 6.0 Vicryl, and the skin was subsequently closed in the same 
fashion. Mice were placed on a heat pad following surgery and monitored for recovery. 
Antibiotics were administered in the drinking water for the duration of the experiment. 
 
Radiography 
Bone volume (BV; mm³) and total bone mineral content (TMD; mg/mm³) of the fusion 
mass were measured by microCT using software that encompassed the fusion mass 
within a uniform region of interest (ROI). MicroCT data was acquired using a SkyScan 
1174 compact microCT scanner (SkyScan, Kontich, Belgium). Samples were scanned 
in 70% ethanol at 21.3 um magnification, 0.5 mm aluminum filter, 50 kV X-ray tube 
voltage and 800 μA tube electric current. The images were reconstructed using 
NRecon, version 1.5.1.5 (SkyScan). The bone of the fusion mass was isolated from 
native bone by means of manually drawn regions of interest (ROI) and thresholded 
using CTAn software version 1.10.03. A global threshold of 0.3g/mm3 was set for bone 
tissue. Representative 3-dimensional fractures were reconstructed with sagittal slices 
using CTVol Realistic Visualization software version 2.1.0.0 (SkyScan).  
 
Histology 
Harvested vertebrae and surrounding musculature were fixed in 4% paraformaldehyde 
for 24 hours at 4°C on a shaker and were then stored in 70% ethanol until 
decalcification. Samples were decalcified in 0.34M EDTA (pH 8.0) solution at 4°C on a 
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shaker for 30 days with solution changes every 2-3 days. Spines were cut axially and 
the central 5mm of the fusion mass were isolated and embedded in paraffin. Axial 
sections were taken through the center of the fusion mass at a thickness of 5μm. 
Mounted sections were stained via Picro Sirius Red/Alcian Blue to differentiate bone 
and cartilage. Adjacent sections were stained for tartrate-resistant acid phosphatase 
(TRAP) expression to highlight osteoclasts, and counterstained with light green. Bone 
volume/trabecular volume (BV/TV) for the heterotopic bone and osteoclast number 
(OcN) and surface area (OcS) was calculated relative to bone surface (BS) in mm using 
Bioquant software.  
 
Statistical Analyses 
The volume and density of bone present at 3 weeks was compared between Nf1+/- and 
wild type groups and between groups receiving ZA and saline. Statistical analysis and 
graphing were performed using Graphpad Prism. The influences of genotype and 
bisphosphonate treatment were examined by non-parametric Kruskal Wallis/Mann 
Whitney U tests between the relevant groups with a significance cutoff of 0.05. Error 
bars on graphs represent the 95% confidence intervals.  
 
 
 
 
Results 
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Nf1+/- mice and wild type mice develop a robust fusion mass in response to 
rhBMP-2 
Posterolateral inter-transverse spine fusion surgery was performed on 32 mice and, 
consistent with prior applications of the model, [204] there were no cases of morbidity or 
mortality. Two surgeons working in tandem were able to complete an operation in ~20 
minutes. Animals showed no post-surgical complications or adverse reactions to 
bisphosphonate treatment. On examination at 3 weeks, a large, bony fusion mass was 
palpable, and occasionally visible overlying the lumbar vertebrae. Mice did not display 
any discomfort or neurological impairment as a result of the overwhelming bone 
formation, as can occur in human patients. [206]  
MicroCT images of harvested mouse vertebrae obtained at 3 weeks were reconstructed 
from all spines recovered from both wild type and Nf1+/- mice (Figure 3.1). Analysis of 
the total bone volume of the fusion masses showed a -11% decrease in the bone 
volume and density of fusion masses of Nf1+/- mice relative to wild type controls 
(p=0.08). While this did not reach significance, post-hoc power analysis indicated 
β=0.34 suggestive of significance with a larger sample size. Notably, the effect size for 
Nf1 genotype influencing spine fusion mass was less than that previously reported for 
rhBMP-2 induced ectopic bone nodules. [202] 
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Figure 3. 1 MicroCT reconstructions of harvested spines. ZA treatment led to an increase in the 
opacity of the rhBMP-2 induced fusion mass relative to controls. Spine fusion was achieved in 
all samples. 
 
Evaluation of the effects of ZA co-administration in wild type and Nf1+/- mice 
Co-treatment with rhBMP-2 and systemic ZA was examined in the spines of wild type 
and Nf1+/- mice. Radiography (XR and microCT) obtained at 3 weeks postoperatively 
showed that co-treatment with ZA led to a more radio-dense fusion mass. The size of 
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the fusion mass, however, remained unchanged. Both the wild type and Nf1+/- mice 
showed significant improvements in fusion with ZA treatment. 
Quantification of bone volume by microCT showed a +226% increase (wild type) and 
+174% increase (Nf1+/-) (p<0.01, Figure 3.2 A). In addition, ZA treatment resulted in a 
consistent 1% increase in BMD that was statistically significant (p<0.01 for WT and 
Nf1+/- groups, Figure 2B). Despite the substantive increases in net bone with ZA 
treatment, Nf1+/- animals showed a -20% reduction in bone compared to wild type 
controls (p=0.02). 
 
Figure 3. 2 MicroCT assessment of bone volume (A) and bone mineral density (B). BV was 
significantly increased with ZA treatment (a, p<0.01) and in the ZA treated groups significantly 
less bone was associated with the Nf1+/- genotype (b, p=0.02). Likewise, BMD was significantly 
increased with ZA treatment (a, p<0.01) relative to untreated controls of the same genotype. 
 
ZA treatment reduces the resorption of rhBMP-2 induced bone in the fusion mass 
of Nf1+/- and wild type mice 
Transverse sections were taken from the widest level of the fusion mass and used for 
osteoclast quantitation (Figure 3). Osteoclast surface area (OcS) and bone surface area 
(BS) were calculated via Bioquant software. Analysis revealed an increase in the 
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osteoclast surface area to bone surface area ratio (OcS/BS) in Nf1+/- samples relative to 
wild type controls (p=0.05).  
Co-treatment with rhBMP-2 and ZA treatment led to a significant reduction in OcS/BS in 
both wild type mice (p <0.01) and Nf1+/- mice (p <0.01) with respect to animals treated 
exclusively with rhBMP-2 (Figure 4). The decreases in osteoclast surface with ZA 
treatment were consistent with the increases in net bone identified by radiography. With 
ZA treatment there was no difference between wild type and Nf1+/- mice with respect to 
OcS/BS (p=0.28). 
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Figure 3. 3 Transverse sections of fusion masses with a TRAP stain, counterstained with fast 
green. 
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Figure 3. 4 Osteoclast surface relative to bone surface was quantified from tissue sections. 
Without ZA treatment, Nf1+/- mice showed an increase in OcS/BS relative to wild type controls 
(a, p=0.05). Treatment with ZA led to significant decreases in OcS/BS for both genotypes (b, 
p<0.01). 
 
Discussion 
 
The bone phenotype of NF1 is characterized by excessive resorption and decreased 
osteoblast activity. [165, 207] This poses a significant challenge in the context of spine 
fusion surgery, which is commonly used to correct the scoliosis that is associated with 
the disease. Although an Nf1+/- mouse model has been previously studied in the context 
of tibial fracture repair, [200] investigation of spine fusion therapies has been limited by 
the unavailability of a suitable model of posterolateral spine fusion. We have previously 
described a novel approach for mouse lumbar spine fusion that is safe, efficient, highly 
reproducible, and analogous to contemporary human surgery. [204] By applying this 
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model to Nf1 deficient mice we have demonstrated that dual treatment with rhBMP-2 
and ZA is superior to treatment with rhBMP-2 alone. The combination of rhBMP and 
bisphosphonate treatment has been previously applied in the context of NF1 
pseudarthrosis, [201, 203] but this approach has also been shown to be generally 
effective in other orthopedic models. [208, 209] 
This study confirms that at a dose of 5µg bilaterally, rhBMP-2 is able to reliably and 
reproducibly promote the formation of a large multilevel fusion mass in the lumbar spine 
in both wild type and Nf1+/- mice. Thus this model does not recapitulate the poor 
response to rhBMP and complications associated with spine fusion associated with 
NF1. While the differences in BV between Nf1+/- mice and wild type controls approached 
significance, the effect size was less than predicted based on prior studies [202] and did 
not reach significance with the sample size employed.  
We propose two possible factors that may have contributed to this lack of difference. 
First, this could reflect species-dependent effects between humans and mice and may 
indicate an intrinsic limitation of this model system. Deletion of a single Nf1 allele has 
been reported to be less impactful in mice than in individuals with NF1. The Nf1+/- mice 
do not show reduced bone density or develop spontaneous delayed or non-unions 
comparable to a clinical NF1 congenital pseudarthrosis. [200, 209] We have recently 
utilized a model of localized double inactivation of Nf1 in the tibia to model tibial 
pseudarthrosis [159] and it is possible that such a localized genetic approach could be 
developed for the spine.  
Second, it is possible that employing lower doses of rhBMP-2 could lead to more 
profound differences in the fusion rate of wild type and Nf1+/- mice. The selected dose of 
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5µg per side was comparable to other murine ectopic bone formation studies that model 
the clinical application of rhBMPs, [210-212] and human patients, particularly those with 
NF1, typically receive large doses of rhBMPs in order to stimulate a maximal response. 
[47]Comparable doses were used in ectopic bone studies that showed a difference 
between wild type and Nf1+/- mice, [202]but use of rhBMPs at a bony location can 
stimulate a greater response than in an ectopic/intramuscular location. 
The addition of the bisphosphonate ZA, a known modulator of bone remodeling, 
effectively shifted the equilibrium of bone homeostasis in favor of bone formation by 
inhibiting resorption. The net effect was a measurable and significant increase in fusion 
mass bone volume and density when compared to controls receiving rhBMP-2 alone. 
Notably, a significant difference in fusion mass BV was observed between wild type and 
Nf1+/- mice treated with ZA. This implies that Nf1 deficiency is associated with a bona 
fide anabolic deficiency in this mouse model. Nevertheless, inhibition of resorption led to 
considerable (+174%) increases in bone.  
Translation of this concept could yield increased fusion success rates in the treatment of 
scoliosis in NF1 patients, reducing the incidence of pseudarthrosis which is a source of 
great morbidity in this population. Additionally, the robust fusion masses seen in wild 
type mice dosed with ZA suggest that uncomplicated cases of spine fusion may also 
benefit from bisphosphonate therapy. As an approved anti-resorptive drug, ZA is a 
candidate for translational application.  
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ABSTRACT 
 
Spine fusion is a common procedure for the treatment of severe scoliosis, a frequent 
and challenging deformity associated with Neurofibromatosis type 1. Moreover, 
deficiencies in NF1-Ras-MEK signaling have intrinsic effects on bone formation and 
resorption that impact on spine fusion outcomes. In this study we describe a new model 
for AdCre virus induction of Nf1 deficiency locally in the mouse spine in a fusion 
procedure. This model produces abundant fibrous tissue (Nf1null +393%, P<0.001) and 
decreased marrow space (Nf1null -67%, P<0.001). This was associated with a lesser 
histological quality anticipated to impact on union quality in humans, despite no 
significant impact on bone volume of the fusion mass (Nf1null -14%, P=0.999 n.s.). 
Similar to prior reports of multinucleated TRAP+ cells in NF1 fibrous tissue distal from 
the bone, we observed such cells in the fibrous tissues seen in Nf1null spines. Systemic 
adjunctive treatment with the MEK inhibitor PD0325901 and the bisphosphonate 
zoledronic acid were trialed in this model. MEK inhibitor increase bone volume (+194, 
P<0.001) whereas ZA increased bone density (+10%, P<0.002). Both MEKi and ZA 
decreased TRAP+ cells in the fibrous tissue (MEKi -62%, P<0.01; ZA -43%, P=0.054). 
In Nf1null spines, no adverse effects were seen with either treatment, however in wild 
type spines MEKi led to a 23-fold increase in residual cartilage in the fusion mass 
(P<0.01). In summary, the AdCre-virus induced knockout spine model has utility for 
modeling spine fusion, and allow screening of alternative adjunctive therapies for 
improving NF1 spine fusion.  
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INTRODUCTION 
 
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder with 
an estimated incidence of 1 in 2500 live births [213]. The NF1 gene is expressed in 
numerous tissues and can thus affect a wide range of clinical features, each with 
variable penetrance. Individuals with NF1 are prone to tumor development, including 
cutaneous and subcutaneous neurofibromas, plexiform neurofibromas, optic gliomas, 
and peripheral malignant nerve sheath tumors [214, 215]. A subset of NF1 individuals 
are born with or develop osseous manifestations, with scoliosis and tibial pseudarthrosis 
being the most clinically challenging to treat [213].  
The reported incidence of scoliosis in NF1 varies, but has been reported to be between 
11% [216] and 64% [217], and may be classified into non-dystrophic or dystrophic types. 
Non-dystrophic scoliosis is similar in presentation to idiopathic scoliosis while dystrophic 
scoliosis is associated with dystrophic changes to the vertebrae. Dystrophic scoliosis is 
associated with short, acute curves, due to the vertebral wedging and segmentation 
abnormalities which are seen in the disease. [218]. The dystrophic curves present 
earlier and with more severe deformity,[219] however despite the severe angulation of 
these curves, neurological compromise is not always present. 
Intervention for scoliosis can be further complicated by intraspinal and paraspinal 
neurofibromas, that can be present in up to 50% of individuals with NF1-associated 
dystrophic scoliosis. Paraspinal neurofibromas are often found to the concavity of the 
curve and may present as massive soft tissue tumors which may invade the muscle and 
compress surrounding structures. [220, 221] [222-224] Similarly, intraspinal tumors may 
represent a source of significant morbidity as they compress neurological structures. 
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Dural ectasia is a widening of the thecal sack which may erode bony and soft paraspinal 
tissues. This is seen as vertebral scalloping on plain radiographs. In the presence of 
severe angulation, it may serve a protective function by limiting cord compression. [148, 
221].  
Surgery remains the primary means of correcting and preventing further deformity for 
NF1 individuals with worsening scoliotic curves. Positive surgical outcomes are primarily 
dependent upon establishing robust fusion between adjacent vertebrae [197]. As is 
seen in the case of tibial pseudarthrosis, patients with NF1 demonstrate impaired bone 
repair at the spine. Pseudarthrosis in the postoperative spine is seen in as many as 
25% of cases [163], with as few as 7% of cases developing a clinically robust fusion [93]. 
To overcome the poor bone formation seen in NF1, combinations of anabolic bone 
agents (e.g. Bone Morphogenetic Proteins; BMPs) and anti-resorptive drugs (e.g. 
bisphosphonates) have been promoted as potent adjunctive agents. In animal models 
of tibial non-union, this has led to improved healing in Nf1 knockout fractures [225]. 
Comparable positive outcomes were reported in a clinical tibial pseudarthrosis case 
series employing off-label BMPs and bisphosphonates [203]. Limited reports have 
attempted to model BMP and bisphosphonate use in the spine, with one report showing 
a significant increase in bone volume and mineral density of the fusion mass in Nf1+/- 
and wild type mouse fused spines [226]. However, this model featured heterozygosity 
for NF1, whereas recent clinical reports show double inactivation of NF1 in tibial 
pseudarthrosis [227] and preclinical models affect Nf1null tissues in tibial fracture healing 
[159], [228]. 
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Moreover, adjunctive treatments such as BMPs and bisphosphonates fail to target the 
specific cellular pathways associated with NF1 deficiency. The NF1 gene encodes for 
the protein neurofibromin, a negative regulator of the Ras oncogene. Impairments in 
osteoblast function have been linked to elevated Ras signaling [229], and the Ras-ERK 
cascade has been implicated in the uncontrolled cell proliferation and fibrosis [230, 231]. 
In pseudarthrosis surgery, invading fibrotic/mesenchymal tissue is recommended to be 
aggressively surgically resected [232] [203]. Fibrosis is also a complication of localized 
Nf1null fracture mouse models [159].  
Ras canonically acts via a phosphorylation cascade through Raf, MEK (mitogen-
activated protein kinase kinase), and ERK (mitogen-activated kinase). Thus it was 
speculated that downstream inhibition of the NF1-Ras-MEK axis using a MEK inhibitor 
(MEKi) could reduce fibrosis and enhance bone formation. The MEKi PD0325901 has 
been shown to reduce tumor growth in preclinical xenograft models [233, 234] and has 
subsequently been shown to be tolerated in human trials with a measureable effect on 
decreasing melanoma tumor size.[235]  
In this study we further describe a new murine model that recapitulates the challenging 
clinical nature of NF1 spine fusion. NF1 is inactivated in the spine of Nf1flox/flox mice by 
employing cre-expressing adenovirus (AdCre) system, similar to prior tibial non-union 
studies [159]. This fusion model shows a lack of bony union and extensive fibrosis. Next, 
interventions combining rhBMP-2 with the MEK inhibitor PD0325901 or the 
bisphosphonate Zoledronic Acid were tested. Outcome measures were radiographic 
and histological. We submit that this model can be used not only for therapeutic testing, 
but as an archetypical approach to gene deletion in the context of spine fusion.  
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METHODS 
 
Animal Colony 
We sourced Nf1flox/flox mice, as originally generated by Prof Luis Parada, from the 
National Cancer Institute (NCI) mouse repository (Bethesda, MD, USA). The Nf1+/- 
strain was supplied directly by Prof Parada. Both colonies were maintained on a 
C57/Bl6 background. All animal experiments were approved by the Westmead Hospital 
Animal Ethics Committee.  
 
Adenovirus production and purification 
Human embryonic kidney cells, HEK293, were grown in T175 culture flasks to 80% 
confluence and transduced with AdCre (gift from Dr Thomas Gajewski) [236]. 72 hrs 
after transduction, cells were harvested as it was observed that cells were beginning to 
detach. Harvested cells were pelleted and subjected to cell lysis and DNase treatment. 
The resulting supernatant was ultracentrifuged for 1 hr. Viral fractions were then pooled 
and re-spun for 20 hrs. Centrifugation was performed at 35,000 rpm in a standard CsCl 
gradient in a Beckman SW-41Ti rotor. Purified virus was dialyzed in a Slide-A-Lyzer 
Dialysis Cassette, 10 kDa cutoff (Thermo Scientific, USA) for up to three days in a 
10mM Tris (pH 8.0) solution. Following dialysis, virus was titered using the Adeno-X 
titration kit (Clontech, USA) and used or frozen at -80°C in 10% glycerol. 
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Surgical model 
Female C57BL6 mice aged 8-10 weeks were subjected to a surgical spine fusion 
procedure using a published model.[237] Surgery was performed by a single surgeon 
over two sessions with support from an experienced animal technician. 15 mm midline 
longitudinal incision was made centered at the level of the iliac crests. Mice were 
anaesthetized with an intraperitoneal injection of ketamine (35mg/kg) and xylazine 
(5mg/kg) with a 27G needle. Anesthesia was maintained with inhaled isofluorane as 
required. Paraspinal muscles at the level of L4-L6 were swept laterally to expose the 
bony anatomy which was decorticated with a diamond tipped burr. A collagen sponge 
loaded with either saline, saline/rhBMP-2 or AdCre virus solution/rhBMP-2 was inserted 
into this paraspinal pocket (Figure 4.1). The rhMBP-2 was delivered at a dose of 10 μg 
in each sponge. Animals were culled at day 21 by CO2 asphyxiation and spines from L1 
to lower sacrum, were harvested for radiographic and histological analysis.  
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Figure 4. 1 Animals were divided as per the table into groups (A) and subjected to a 
posterolateral intertransverse spine fusion surgery in which rhBMP-2 and AdCre virus are 
delivered to the lumbar spine via implantation of paired collagen sponges (B) as per previous 
publication. Dosing with ZA and the MEK inhibitor PD0325901 began 2 days prior to the date of 
surgery. 
   
Drug Treatments 
Oral drug delivery with PD0325901 was performed as described by Sullivan et al. [238]. 
Prior to the experiment, mice were single housed to ensure that consistency in oral 
dosing of drug/vehicle. Strawberry jelly was used as a vehicle for drug delivery. Animals 
were trained to eat the jelly prior to the experiment and dosing began at day -2. Jelly 
was made with 0.8% DMSO (Sigma-Aldrich, St. Louis, MO, USA), 16% Splenda 
(Splenda® Low Calorie Sweetener, Johnson-Johnson Pacific Pty, NSW, Australia), 
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9.6% gelatine (Davis Gelatin, GELITA Australia Pty, NSW, Australia) and 7.9% flavoring 
(QUEEN Flavoring Essence Imitation Strawberry, Queen Fine Foods Pty, QLD, 
Australia). Jelly was loaded with PD0325901 dissolved in DMSO to be delivered as a 
daily dose per animal of 10mg/kg. Dosing began on day 1 post op and continued until 
cull at day 21.  
Subjects in the bisphosphonate treatment group received a five doses of 0.02mg/kg ZA 
(total dose 0.1mg/kg) (Novartis AG) by biweekly subcutaneous injection commencing 3 
days postoperatively, as previously published [202]. 
 
MicroCT analysis 
MicroCT analysis was performed as described in our previously published study of NF1 
spine fusion. [226] Spines and surrounding soft tissue were harvested at day 21 and 
fixed in a 4% paraformaldehyde solution for 24 hours at 4°C and then stored in 70% 
ethanol. Samples were scanned using a SkyScan 1174 compact microCT scanner 
(SkyScan, Kontich, Belgium). Samples were scanned in 70% ethanol at 21.3 um 
magnification, 0.5 mm aluminium filter, 50 kV X-ray tube voltage and 800 μA tube 
electric current. The dicom images were reconstructed using NRecon software, version 
1.5.1.5 (SkyScan). The fusion mass was isolated from native bone by manually drawing 
regions of interest (ROI) and thresholded using CTAn software version 1.10.03. A global 
threshold of 0.3g/mm3 was set for bone tissue. Representative 3-dimensional fractures 
were reconstructed with sagittal slices using CTVol Realistic Visualization software 
version 2.1.0.0 (SkyScan). 
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Tissue histology  
Following microCT scanning, samples were decalcified in 0.34M EDTA (pH 8.0) solution 
at 4°C on an agitation tray for 30 days with solution changes every 2-3 days. Spines 
were cut axially at the level of the largest portion of the fusion mass. This typically 
coincided with a vertebral level of L5-6. Samples were embedded in paraffin and 
sectioned in the axial plane at a thickness of 5μm and were stained via Picro Sirius 
Red/Alcian Blue [159] to differentiate bone and cartilage. Adjacent sections were 
stained for tartrate-resistant acid phosphatase (TRAP) expression to highlight 
osteoclasts, and counterstained with light green. Histology was quantified using 
BioQuant Osteo software 2016 v16.1.60 (BioQuant Nashville, TN, USA). 
Representative regions of interest (ROI) were selected for each sample and volumes of 
target tissue were measured and expressed proportionately against the ROI. Outcomes 
included bone volume (BV/ROI), fibrous tissue volume (FV/ROI), cartilage volume 
(CV/ROI), marrow volume (MV/ROI) and Osteoclast number (OcN/ROI).  
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 7 (GraphPad, La Jolla, USA) 
using one-way ANOVA with multiple comparisons. Statistical significant was calculated 
using a cut-off of α<0.05. 
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RESULTS 
 
Fibrosis following spine fusion surgery is considerably increased in Nf1null spines  
Spine fusion surgery was performed involving the implantation of collagen sponges 
containing rhBMP-2 to promote bone formation. All mice were of the Nf1flox/flox genotype, 
with groups featuring Nf1null tissue having AdCre virus co-administered during surgery 
via the implanted sponges. No morbidity or mortality was noted in any of the test 
animals up until the cull date of 21 days. At the experimental endpoint, all of the animals 
possessed a palpable fusion mass (Figure 4.2).  
 
Figure 4. 2 Spines were harvested from all animals 21 days post operatively. Representative 
reconstructions of the bony anatomy using uCT data demonstrates that AdCre treatment at the 
time of surgery results in a visually smaller and less robust fusion mass. Axial cross sections are 
taken from the midpoint of the fusion mass where it was the most substantial. 
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Fibrous tissue showed a significant increase in Nf1null spines compared to untreated 
controls, as quantified on histological sections (Nf1null +393%, P<0.001) (Figure 3B). 
Furthermore, fibrous tissue accounted for 48% of the fusion mass area in Nf1null spines, 
where it was only 10% of the fusion mass area in control spines. Nf1null spines showed 
a significant decrease in marrow space compared to controls (Nf1null -67%, 
P<0.001)(Figure-4.3C).    
 
 
127 
 
 
Figure 4. 3 Significant findings in uCT analysis of fusion mass volume were not reproduced by 
hstological analysis (A).  
Histology confirmed that a significant increase of fibrous tissue was found in the fusion masses 
of all AdCre treated mice (B) relative to mice that did not receive AdCre virus. This trend is 
mirrored by the relative proportion of marrow space measured in the fusion masses (C). All 
groups that receive treatment with AdCre virus showed significantly less marrow space than 
control groups suggesting that the volume of fibrous tissue seen in the AdCre groups is 
infiltrating the free marrow space of the fusion mass.  
A significant increase in the relative proportion of cartilage in the fusion mass was noted only in 
the BMP-2 + MEKi group (D).  This increase was dramatic (2304%) and was not reproduced in 
the AdCre + BMP-2 + MEKi group.  
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Qualitatively, Nf1null spines exhibited fibrous tissue invading the remnants of the 
collagen sponge. This was rarely observed in control spines, where this space was 
largely replaced by trabecular bone and marrow. Within the fibrous tissue of Nf1null 
spines, abundant multi-nucleated TRAP+ cells were seen (Figure 4.5), comparable to 
prior models of pseudarthrosis [159] and clinical biopsies [239]. 
 
Figure 4. 4 Bone volume of the fusion masses, as determined with uCT (A), demonstrated that in 
saline/BMP-2 co-dosed animals, treatment with the MEK inhibitor PD0325901 significantly 
increases the volume of bone formed in the fusion mass relative to controls (301%). A similar 
increase in the volume of the fusion mass was noted when mice cotreated at the time of surgery 
treatment with AdCre/BMP-2 were dosed with PD0325901 (194%). uCT analysis demonstrated 
that co-treatment with AdCre/BMP-2 yielded a fusion mass that was 14% smaller than saline 
treated mice , though this difference was not found to be significant. Treatment with the 
bisphosphonate Zoledronic Acid yielded a significant increase (10%) in the bone mineral density 
of the fusion mass (B) in mice treated with AdCre virus and BMP-2 at the time of surgery. 
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Bone volume and mineral density were increased by MEKi and bisphosphonate in 
Nf1null spines 
Bone volume, as quantified by microCT, showed no significant decrease in Nf1null 
spines relative to controls (Nf1null -14%, P=0.999 n.s.) (Figure 4.5A). This contrasts with 
prior findings in the Nf1+/- spine fusion [226] and in Nf1null pseudarthrosis [159]. 
However, both adjunctive pharmacotherapeutic interventions impacted on the fusion 
mass, as quantitatively assessed by microCT (Figure 4.2, Figure 4.4). In Nf1null spines, 
MEKi dosing increased bone volume. Bone volume was increased by +194% (P<0.001) 
compared to saline controls. Similarly, ZA treatment increase bone density in Nf1null 
spines by +10% (P<0.002) relative to saline treated controls (Figure 4.5 B). 
In wild type spines, MEKi dosing was also found increase bone volume independent of 
the Nf1null genotype (+301%, P<0.001). Bone mineral density was also increased (+13%, 
P<0.05) (Figure 4.5 B).  
The number of TRAP+ cells in the tissue surrounding the collagen sponge remnant was 
assessed for both treatments. MEKi significantly reduced the number of TRAP+ cells 
found within the fibrous tissue adjacent to the collagen sponge remnant in wild type 
mice (-62%, P<0.03), with an identical decrease noted in Nf1null spines (-62%, P=0.001)  
(Figure 6). Similarly, ZA reduced the number of TRAP+ cells surrounding the collagen 
sponge remnant (-43%, P=0.054) (Figure 4.6). 
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Figure 4. 5 Histological sections were stained with a Picro Sirius Red and Alcian Blue protocol 
which stains bone (red) and cartilage (blue) and TRAP stain with Light Green counterstain. The 
bony fusion mass is seen to be more robust in animals that received saline/BMP-2 co-dosing at 
the time of surgery. These spines demonstrate a large bony fusion mass with uninterrupted 
cellular marrow space. In contrast, animals that received AdCre-BMP-2 co-dosing at the time of 
surgery have fusion masses that are less robust and show a varying degrees of marrow 
infiltration with a fibrous material (F). In mice which received AdCre treatment, a rim of TRAP 
positive cells (O) is seen between the remnant of the collagen sponge (S) and the fibrous tissue. 
Treatment with MEK inhibitor in the saline/BMP-2 group shows a large volume of cartilaginous 
tissue (C) in the fusion mass. This finding was not found to be significant nor was it reliably 
reproduced in the AdCre-BMP-2 group treated with MEK inhibitor.  
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Figure 4. 46  Quantification of the number of osteoclasts located at the perimeter of collagen 
sponge revealed that the MEK inhibitor PD0325901 and the bisphosphonate ZA led to an 81% 
and 43% reduction respectively. Animal groups which did not receive AdCre delivery did not 
generate a fusion mass with infiltration of marrow space by fibrous tissue and did not exhibit a 
significant volume of collagen sponge remaining at the 21 day cull. There was, therefore, no 
population of osteoclasts located remote from bone to be quantified.  
 
 
 
MEKi and bisphosphonate treatments did not reduce fibrosis in Nf1null spines 
Neither MEKi nor bisphosphonate treatment had any significant effect on the amount of 
fibrous tissue (n.s.) (Figure 4.3 B).  
In wild type spines, a considerable increase was seen in the relative proportion of 
cartilage in the fusion mass (23-fold) (Figure 4.3 D). This is consistent with prior reports 
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of retained cartilage with PD0325901 in mouse tibial fracture healing [240] . Notably, no 
change was seen in cartilage in the Nf1null spines. 
 
DISCUSSION 
 
A variety of approaches have used to model the manifestations of NF1, and in this 
paper we describe a combination of genetic manipulation and surgery. Historically, 
conditional knockout mice have been used for several purposes: to model features of 
the NF1 heterozygous state that are not recapitulated in mice, and to model clinical 
manifestations associated with NF1 double inactivation. In the case of bone, the 
traditional Nf1+/- mouse [241] was found to have normal systemic bone density [242], 
which contrasted with clinical findings of low bone mineral density in adults and children 
with NF1 [11,12]. However, there is no evidence that NF1 osteopenia is associated with 
double inactivation of the NF1 gene. In contrast, tibial pseudarthrosis has been linked to 
localized double inactivation of NF1 [227]. This led to murine genetic models of bone-
targeted conditional Nf1 deletion, including osteocytes [243] and mesenchymal stem 
cells and osteoblasts [228, 229, 244, 245]. Notably, the first of these studies [244] 
produced mice with a scoliotic deformity, albeit not as severe as seen clinically. The 
differences in the models may be due to either genetics or differing biomechanical 
forces in quadrupeds [246]. 
While there have been unpublished accounts of NF1-/- tissue in dystrophic scoliosis 
(David A Stevenson, personal communications) there is no consensus data on the 
prevalence of double inactivation of the NF1 allele in dystrophic scoliosis. Nevertheless, 
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other groups have employed tissue specific double knockout models in order to 
recapitulate spinal deformity. [227] In this study, we used a cre-expressing adenovirus 
to drive deletion of Nf1-flox alleles in the spine. This is analogous to the technique we 
used to delete Nf1 in fracture healing to model a clinical pseudarthrosis [240]. It has 
been previously validated by PCR and by fluorescent reporter that AdCre drives 
recombination in local tissues. Moreover, this method produced reduced bone healing, 
increased fibrous tissue at the fracture site, and aberrant multinucleated TRAP+ cells 
within the fibrous tissues. Notably, increased fibrous tissue and associated TRAP+ cells 
were recapitulated in this spine model. In particular, the fibrous tissue proliferation was 
a major complication in the spine model, with 47% of the mean fusion mass identified as 
mesenchymal or fibrous. 
Treatment with AdCre virus yielded an insignificant difference in bone volume when 
compared to non-virus groups. Similar results were previously reported with this surgical 
approach in the Nf1+/- heterozygous line [226]. Unlike Nf1+/- and Nf1null fracture models 
[240], the spine fusion procedure employs a substantive dose of rhBMP-2 that 
stimulates considerable bone formation. We hypothesize that this dose of rhBMP-2 is 
sufficient to overcome the limited bone anabolism associated with NF1. However, in a 
clinical setting, rhBMP-2 doses may be insufficient to yield a robust bony fusion mass, 
and the high degree of fibrosis seen in this model may similarly impede successful 
union. Consequent to the strength of rhBMP-2, this model does not reliably produce 
failure of fusion, which is an intrinsic limitation of the system.  
Considering the role of the Ras-MEK-ERK cascade in bone homeostasis, interruption of 
this pathway was expected to shift the equilibrium in favor of bone formation. In tibial 
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fracture models, MEK inhibitor PD0325901 increased the volume of mineralized bone in 
a fracture callus in wild type and Nf1null fractures [240]. In the spine, PD0325901 
increased the bone volume in both wild type and Nf1null fusion masses, and by a similar 
amount. Due to the robust response to rhBMP-2 alone this increased bone with MEKi 
treatment did not impact on fusion rate, which was complete in all groups. In the case of 
wild type fractures, PD0325901 led to cartilage retention at the fracture site, possibly 
due to suppression of matrix metalloproteinase activity [159] . In the context of spine 
fusion, this was hypothesized to be of lesser importance, as the rhBMP-2 induced 
fusion mass was speculated to form with minimal cartilage. However, some increased 
cartilage retention was nonetheless seen in wild type spine fusions, indicating the 
rhBMP-2 stimulates both cartilage and bone formation at the spine. This was not a 
complication seen in the Nf1null fusion setting.  
PD0325901 was found to decrease the number of osteoclasts (TRAP+) cells in the 
fusion mass of all mice. Prior reports have shown that Nf1 deficiency can produce 
upregulations in osteopontin, Rankl, and Tgfβ, [235]  which may be exploited by dosing 
with PD0325901. However, MEK inhibition yielded a global reduction in osteoclast 
number which was independent of Nf1 activity which suggest it has anti-resorptive 
effects The bisphosphonate ZA was used as a positive control in this system as it has 
reliably increased rhBMP-2 bone masses in Nf1-deficient fracture [15, 225] and spine 
fusion [226] models. The effect of ZA was chiefly to increase bone mineral density, 
rather than bone volume; this was the inverse of that seen with PD0325901 treatment. 
This suggests that the bisphosphonate produces more highly mineralized bone rather 
than augmenting the zone of effective rhBMP-2 action.  
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In terms of clinical translation, both PD0325901 and ZA both have potential utility in 
augmenting rhBMP-2 induced spine fusion. ZA is an established and well tolerated 
therapy for improving bone mineral density that has been used off-label for improving 
BMP-induced NF1 pseudarthrosis repair [203]. PD0325901 is currently undergoing 
clinical trials for treating NF1 tumors, however has not been applied in an orthopedic 
scenario. The use of MEK inhibitors in humans is reasonably new, but has been shown 
to be well tolerated in a cancer setting [247]. However, their side effect profile is 
significant with many patients exhibiting hematological dyscrasias (leucopenia, 
thrombocytopenia, and anemia) and symptoms such as rash, fatigue, diarrhea, 
epistaxis, and blurred vision.  
 
 
CONCLUSIONS 
 
In this paper we describe a new model for spine fusion in individuals with NF1. While 
this model has a number of significant limitations, such as a lack of an initial scoliosis 
and an inability to produce a failure of fusion, key features such as extensive fibrotic and 
osteoclastic infiltration were recapitulated. Treatment with both ZA and the MEK 
inhibitor PD0325901 produced positive effects on the model, indicating that 
symptomatic and pathway-focused approaches both have potential as therapeutic 
modalities.  
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Abstract  
To better understand the relative contributions of mesenchymal and endothelial 
progenitor cells to rhBMP-2 induced bone formation, we examined the distribution of 
lineage-labelled cells in Tie2-Cre:Ai9 and αSMA-creERT2:Col2.3-GFP:Ai9 reporter mice. 
Established orthopedic models of ectopic bone formation in the hind limb and spine 
fusion were employed. Tie2-lineage cells were found extensively in the ectopic bone 
and spine fusion masses, but co-staining was only seen with tartrate-resistant acid 
phosphatase (TRAP) activity (osteoclasts) and CD31 immunohistochemistry (vascular 
endothelial cells), and not alkaline phosphatase (AP) activity (osteoblasts). To further 
confirm the lack of a functional contribution of Tie2-lineage cells to BMP-induced bone, 
we developed conditional knockout mice where Tie2-lineage cells are rendered null for 
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key bone transcription factor osterix (Tie2-cre:Osxfx/fx mice). Conditional knockout mice 
showed no difference in BMP-induced bone formation compared to littermate controls. 
Pulse labelling of mesenchymal cells with Tamoxifen in mice undergoing spine fusion 
revealed that αSMA-lineage cells contributed to the osteoblastic lineage (Col2.3-GFP), 
but not to endothelial cells or osteoclast populations. These data indicate that the 
αSMA+ and Tie2+ progenitor lineages make distinct cellular contributions to bone 
formation, angiogenesis, and resorption/remodeling.  
 
Research Highlights 
 Tie2-lineage cells were tracked in BMP-2 induced bone using fluorescent report 
mice 
 Tie2-lineage cells contributed to vessels and osteoclasts but not osteoblasts 
 αSMA-lineage (mesenchymal) cells contributed to osteoblasts 
 Conditional deletion of Osx in Tie2-lineage cells did not affect BMP-2 induced 
bone
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Introduction 
 
Bone is a tissue that developmentally arises from the mesoderm. This is regulated by a 
variety of signals, however expression of the bone morphogenetic proteins (BMPs) are 
key factors that modulate this process [248]. Recombinant human BMPs (rhBMPs) are 
utilized in orthopedic medicine as potent inducers of new bone formation and are 
approved for the treatment of open fractures and non-unions [249]. When used clinically, 
cells are exposed to super-physiological concentrations of these factors, which has the 
potential to transform cells beyond those of the mesenchymal lineages.  
In 2009 a study by Lounev et al. examined the contribution of different cell lineages to 
bone in a model of rhBMP-2 induced ectopic bone formation and in the Nse-BMP4 
transgenic mouse [250]. A variety of transgenic mouse strains employing the Rosa26R 
(R26R) reporter were used to assess the relative input of MyoD-lineage, Tie2-lineage, 
and SMMHC-lineage cells. These were intended to reflect the contributions of myogenic, 
endothelial and mesenchymal progenitors respectively. Ectopic bone formed readily in 
muscle, a tissue that is often adjacent to bone and has been speculated to contain 
numerous types of cellular progenitors that could contribute to bone formation and 
repair [185, 251]  
Lounev et al. reported that MyoD-lineage cells made a negligible contribution to rhBMP-
2 induced ectopic bone formation [248]. This was later contrasted by studies showing 
greater MyoD-lineage contribution in a variant of the ectopic bone formation model 
featuring rhBMP-7 as well as increased tissue trauma [252]. Intriguingly, Lounev et al. 
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found that up to 50% of cells in the ectopic bone were of the Tie2-lineage. In a 
subsequent study, the group described a mechanism by which Tie2-lineage cells could 
undergo an endothelial-mesenchymal transition (EMT) to form osteoblasts [253]. While 
this study focused on describing the genetic disease fibrodysplasia ossificans 
progressiva, it was unclear whether EMT could also occur when endothelial cells were 
exposed to high concentrations of rhBMPs. 
The potential of endothelial Tie2-lineage cells to contribute to bone repair has been 
further implied by a range of cell transplantation studies. Purified endothelial progenitor 
cells (EPCs) have been repeatedly demonstrated to enhance orthopedic repair [254-
258], although the precise mechanism for this is unclear. EPCs have been shown to 
enhance angiogenesis, potentially by secretion of pro-angiogenic growth factors [259], 
or by direct contribution to new vessels. Transplanted EPCs have also been shown to 
enhance tissue mineralization [253], raising the possibility of a direct contribution of 
these cells to bone repair. 
In 2012 Wosczyna et al. published a report indicating that the Tie2-lineage cells 
included multiple sub-populations of cells, some capable and some incapable of 
contributing to rhBMP-2 induced cartilage and bone formation [260]. The populations 
that formed cartilage and bone were not of endothelial origin, suggesting that EMT was 
not the underlying mechanism in this model. Both the Lounev and Wosczyna studies 
utilized a Tie2-cre line that demarks endothelial and hematopoietic, progenitors as well 
as a subset of mesenchymal-like progenitors [261].  
In this study we report the contribution of endothelial cells to rhBMP-2 induced ectopic 
bone formation and spine fusion using an alternative Tie2-cre mouse, which shows 
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greater specificity for the endothelial lineages [262, 263]. These cell tracking studies 
employ a Cre-dependent fluorescent tdTomato reporter that allows for co-labeling with 
chondrocyte, osteoblastic, osteoclastic, and vascular markers [264]. Conditional 
knockout mouse models were also employed where Tie2-lineage cells selectively 
inactivated the key osteogenic transcription factor osterix. This approach allowed for the 
functional assessment of the contribution of cells of the Tie2-lineage to new bone 
formation. To complement these experiments we examined the contribution of 
mesenchymal progenitors using mice with an inducible αSMA-creERT2 transgene. Prior 
studies have shown that this cell lineage directly contributes to bone formation and 
repair [169, 265-267].  
 
Materials & Methods 
 
Mouse lines and Genotyping 
The Ai9 reporter line (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) was purchased 
from Jackson Laboratories[262]. The Tie2-cre line (B6.Cg-Tg(Tek-cre)12Flv/J) was 
sourced from the Garvan Institute for Medical Research with permission from the 
original laboratory [268]. The Osxfx/fx line was sourced from Benoit de Crombrugghe 
(MD Anderson Cancer Center, Houston, TX, USA) [258]. The Tie2-cre × Ai9 line was 
generated in-house by cross breeding and showed no adverse phenotype; the line 
specifically labels Tie2-lineage with a fluorescent tdTomato reporter. The Tie2-cre × 
Osxfx/fx line was generated by crossing for two generations to create homozygous 
conditional double knockout mice; in this line there is targeted disruption of the key 
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osteoblastic gene osterix (Osx) in all cells of the Tie2-lineage. Mice were genotyped 
from ear biopsies using real time PCR with specific probes designed for each gene 
(Transnetyx, Cordova, TN, USA). Experiments using the Tie2-cre cross strains were 
approved by the CHW/CMRI Animal Ethics Committee (Protocol K248, K303). All 
strains were on the C57BL6/J background, and hemizygous strains were maintained on 
wild type mice purchased from the Animal Resources Centre (ARC, Perth, Australia).  
αSMA-creERT2 (smooth muscle α-actin promoter) × Ai9 mice, which enable labeling of 
mesenchymal progenitors [169, 265] that also incorporated a GFP transgene under the 
control of the upstream 2.3kb region of the Col1a1 promoter (Col2.3-GFP transgene) to 
label osteoblasts [269] were sourced from in-house colonies at the University of 
Connecticut (Farmington, CT, USA). Experiments using these mice were approved by 
the UConn animal ethics committees. 
 
Surgical models 
Implants were manufactured by adding 20 µl sterile saline containing 5µg recombinant 
human BMP-2 (Medronic Australasia, North Ryde, Australia) onto collagen-
hydroxyapatite sponge prior to surgery. For the ectopic bone formation model, uniform 
discs manufactured using a surgical tissue punch were surgically implanted into the 
hind limbs of mice using published methods [202]. For the spine fusion model, twin 
porous collagen sponges (Medronic Australasia) were inserted parallel to the vertebrae 
as previously described [204]. All mice were aged 8-12 weeks. Anesthesia was induced 
with inhaled isofluorane (hind limb model) or using Ketamine/Xylazine (35mg/kg; 
5mg/kg) (spine fusion model). Buprenorphine (0.05–0.1 mg/kg) was administered 
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subcutaneously (s.c.) preoperatively and every 12 hours as required for pain 
management. Post-surgery saline was given s.c. to prevent dehydration. Mice of the 
αSMA-creERT2 × Ai9 cross received tamoxifen at a dose of 75 mg/kg on the day of 
surgery to induce lineage labelling. Mice were euthanized at 7, 14, or 21 days (ectopic 
bone) or 2, 10, or 17 days (spine fusion) for radiological and/or histological analyses. 
 
Radiological imaging  
The formation of rhBMP-2 induced bone was confirmed and visualized by digital X-ray 
(25 kV, 2× magnification; Faxitron X-ray Corp, Illinois, USA). For studies where ectopic 
bone was quantified, samples were scanned by micro-computed tomography (microCT) 
using a SkyScan 1174 compact microCT scanner (Kontich, Belgium) at a pixel 
resolution of 14.8 µm. All samples were scanned in 70% ethanol, using a 0.5 mm 
aluminum filter, 50 kV X-ray tube voltage, and 800 µA tube electric current. A global 
threshold to define bone tissue in pellets was set at a mineral density of 0.3 g/cm3. 
Images were reconstructed using NRecon, version 1.6.1.7 (SkyScan), and analyzed 
using CTAnalyser software, version 1.11.8.0 (SkyScan). 
 
Immunofluorescence and Microscopy 
The endogenous fluorescent signal from the tdTomato reporter strain was captured 
using either an epi-fluorescent microscope or a Leica TCS SP5 confocal laser scanning 
microscope. The sections were cover-slipped and the intrinsic fluorescent signal imaged 
directly. ELF97 Phosphatase Substrate (Molecular Probes) was used to detect alkaline 
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phosphatase (AP) and tartrate-resistant acidic phosphatase (TRAP). AP assay was 
done according to the manufactures instructions. For TRAP: The classical TRAP buffer 
(110 mM acetate buffer, pH 5.2, 1.1 mM sodium nitrite, 7.4 mM tartrate) was used 
followed by 200μM concentration of ELF97 incubation for 5-min. Slides were washed 
with an EDTA containing wash buffer. The fluorescence was visualized with a 
DAPI/Hoechst longpass filter set. 
For examining co-labelling between endogenous tdTomato signal and 
immunofluorescent staining for lineage markers, the following methods were used. 
Slides were rehydrated in PBS for 20 min and treated with 0.5% Triton X-100 for 20 min. 
The sections were blocked in 10% goat serum PBS for 1 h at room temperature prior to 
incubation with a primary antibody (SOX9, Millipore AB5535; CD31, BD Pharmigen 
MEC13.3) in blocking buffer overnight at 4°C. After washing the sections were 
incubated with Alexa-Fluor-647 conjugated secondary antibody (Molecular Probes 
diluted in PBS. Tissue was counter stained with 200 ng/ml 4',6-diamidino-2-pheylindole 
(DAPI, molecular probes) for 1 min and washed in PBS and mounted in Aqueous 
Mounting Medium (DAKO). Images were captured using an epi-fluorescent microscope 
with appropriate filters or using the Leica TCS SP5 confocal laser scanning microscope 
 
Statistical analyses 
Statistical analysis of microCT data was conducted with non-parametric testing as 
amount of bone formed by these assays has not been determined to follow a normal 
distribution. Significance differences in bone volume were determined using a Mann 
Whitney U test with a cutoff of α<0.05 (Graphpad Prism, La Jolla, CA, USA).  
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Results 
 
Tie2-lineage cells localize to rhBMP-2 induced bone 
To assess the contribution of Tie2-lineage cells to newly formed bone we performed a 
model of rhBMP-2 induced ectopic bone formation in Tie2-cre:Ai9 reporter mice. Ectopic 
bone was present at 2 weeks by X-ray and specimens were analyzed by fluorescent 
imaging. The muscle adjacent to the ectopic bone had labelling with the appearance of 
microvessels, and labelling was absent from the muscle fibers (Figure 5.1 A). The 
ectopic bone showed abundant staining suggestive of a significant involvement of Tie2-
lineage cells in the bone formation process. Closer examination revealed an abundance 
of Tie2-lineage cells on the bone surfaces (Figure 5.1 B). 
Examination of native long bones revealed negligible staining in the cortical bone, 
although again vessel-like staining was seen in the bone marrow space (Figure 5.1 C).  
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Figure 5. 1 Confocal fluorescent images of Tie2-lineage cells (tdTomato, red) in rhBMP-2 
induced muscle, native bone, bone marrow, and rhBMP-2 induced ectopic bone. Images are 
shown at the muscle/ectopic bone interface (A) within an ectopic bone nodule (B), and within 
the native bone of the femur (C). Text labels, m = muscle, eb = ectopic bone, bm = bone 
marrow, cb = cortical bone. Scale bar = 50 µm. 
 
Tie2-lineage cells contribute to the vasculature and to resorbing osteoclasts in 
native and rhBMP-2 induced bone 
Specimens from d7 were analyzed to look at the contribution of Tie2-lineage cells to 
early progenitors. Co-staining for endothelial cell marker CD31 revealed that all new 
vessels were derived from Tie2-lineage cells (Figure 5.2A). Some cells that were of the 
Tie2-lineage that did not co-express CD31 were present, often near or adjacent to 
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vessels. Co-staining for cartilage marker Sox9 showed no overlap between or co-
staining between chondrocytes and Tie2-lineage cells (Figure 5.2 B).  
 
Figure 5. 2  Fluorescent images of ectopic bone showing Tie2-lineage cells (tdTomato) overlaid 
with vascular marker CD31 (A) or chondrocyte marker SOX9 (B). Tie2-lineage cells were found 
to demark the new blood vessels in the ectopic bone but not cartilage islands. Scale bar = 50 
µm 
 
Fluorescent histochemical staining was performed on d14 sections for the osteoclast 
marker TRAP and the osteoblast marker AP. TRAP+ cells co-labelled with tdTomato, 
indicating they originated from the Tie2-lineage (Figure 5.3 A-B). In contrast, there was 
no overlap between tdTomato and AP (Figure 5.3 C-D). 
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Figure 5. 3 Fluorescent images of ectopic bone showing Tie2-lineage cells (tdTomato) overlaid 
with tartrate-resistant acid phosphatase/TRAP activity stain (ELF97, green) to label osteoclasts 
(A, zoom in B). No overlap was seen between Tie2-lineage cells with an alkaline 
phosphatase/AP activity stain (ELF97) to label osteoblasts (C, zoom in D). Scale bar = 50 µm. 
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Targeted deletion of osterix in Tie2-lineage cells does not affect rhBMP-2 induced 
bone formation 
To further examine the functional importance of Tie2-lineage cells in this model, 
experiments were performed in Tie2-cre:Osxfx/fx mice. Osx has been previously shown 
to be essential for the osteogenic differentiation of osteochondral progenitors [270] and 
thus this line could be used to assess whether Tie2-lineage cells make a significant 
contribution to osteoblastic bone formation. Tie2-cre:Osxfx/fx mice underwent 12 weeks 
of assessment for health and welfare and no adverse phenotype was found. This 
included no defects in skeletogenesis or skeletal health (data not shown), implying that 
the contribution Tie2-lineage cells to osteoblasts is not developmentally important.  
Next, rhBMP-2 induced bone nodules at 21d were imaged by X-ray (Figure 5.4A-B) and 
microCT reconstruction (Figure 5.4C-D) from control littermates lacking the Tie2-cre 
transgene (Tie2-cre-/-; Osxfx/fx, Osxfx/+). Ectopic nodules had a standard appearance by 
tissue histology, with a cortical-like shell and an interior marrow-like space with 
trabecular-like bony elements (Figure 5.4E). Quantification by microCT confirmed that 
there was no significant difference in bone formation between the genotypes (Figure 
5.4F).  
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Figure 5. 4 rhBMP-2 induced ectopic bone formation in Tie2-cre-Osxfx/fx mice and littermate 
controls. Representative XRs (A, B) and microCT reconstructions (C, D) are shown for the 
specimens corresponding to the median bone volume for each group (A, C = littermate controls, 
B, D = Tie2-cre-Osxfx/fx mice). The bone formed in all cases showed a cortical shell with some 
trabecular-like elements visualized using Picro Sirius Red/Alcian Blue staining (E). MicroCT 
quantification revealed no significant difference in bone volume of ectopic rhBMP-2 induced 
bone with deletion of the Osx gene in Tie2-lineage cells (F). 
 
Contribution of Tie2-lineage cells and αSMA-lineage cells in an rhBMP-2 induced 
spine fusion model 
As an alternative model of rhBMP-2 induced bone formation, fusion was induced in the 
mouse spine as a location that would have a capacity for contribution by soft tissue 
progenitors and endogenous osteoprogenitors. Fusion occurred rapidly after the 
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surgical procedure, with new bone bridging the vertebral processes apparent within 10 
days (Figure 5.5).  
 
Figure 5. 5 X-ray (XR) images showing the progression of rhBMP-2 induced spine fusion. After 
implantation of collagen sponges loaded with rhBMP-2, no mineralized bone was seen at D2, 
but a fusion mass was apparent in all specimens by D10 and D17. Anterior-posterior and lateral 
views are shown for all time points. 
 
In the Tie2-cre:Ai9 reporter mice, comparable results were seen to the hind limb rhBMP-
2 implantation model. Samples obtained from mice culled at day 2 post-operatively had 
not yet formed any new bone overlying the vertebrae and no significant tdTomato 
staining was noted in these areas. However, specimens from this time point showed a 
pattern of co-localization of tdTomato and TRAP+ cells in the original cortical bone of 
the lumbar spinous process (Supp Figure 5.1). Abundant staining tdTomato was noted 
in the vertebral fusion masses of Tie2-cre:Ai9 mice by day 10. Co-staining with TRAP 
revealed that all TRAP+ cells co-labelled with endogenous tdTomato (Supp Figure 5.1). 
Additionally, it was noted that the majority of cells that expressed tdTomato were co-
labelled with TRAP+ cells, suggesting that the majority of cells in the fusion of a Tie-2-
152 
 
lineage contribute to the cellular milieu by way of osteoclastogenesis. CD31 staining 
was also found to significantly overlap with tdTomato expression (Supp Figure 5.2).  
The spine fusion model was also performed in the αSMA-creERT2:Col2.3-GFP:Ai9 
mouse line to allowed for the tracking of mesenchymal progenitors after tamoxifen 
induction (tdTomato) while co-labeling osteoblasts (GFP). Tamoxifen injection was 
administered at the time of surgery and the contribution of αSMA-lineage progenitors 
was assessed at day 2, 10 and 17 (Figure 5.6). As with the Tie2-cre:Ai9 reporter mice, 
at the 2 day time point, no contribution by tdTomato cells was seen. However by day 10 
and day 17, a robust fluorescent signal was present throughout the fusion mass. All 
osteoblastic cells expressing Col2.3-GFP were found to be tdTomato+ and thus 
originate from the αSMA-lineage. A greater proportion of the tdTomato+ expressed the 
Col2.3-GFP marker over time, and by day 17 a significant proportion of the αSMA cells 
labelled at surgery expressed the osteoblastic marker (Figure 5.6). In contrast, αSMA-
lineage cells were found to not co-localize with the TRAP activity stain. Control animals 
not receiving tamoxifen showed no leakiness of the tdTomato reporter at any time point 
(example at d17, Supp Fig 3). 
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Figure 5. 6 Fluorescent images of spine fusion bone masses with co-labeling for αSMA-lineage 
cells expressing tdTomato (red), Col2.3-GFP (green), and a TRAP activity stain (blue). Based 
on the image overlays, Col2.3-GFP+ cells are demonstrated to originate from αSMA-lineage 
progenitors. In contrast, no overlap was seen with TRAP+ cells previously shown to originate 
from the Tie2-lineage. Scale bar = 50 µm. 
  
 
 
Discussion 
 
In orthopedic medicine, the cell populations that give rise to osteoblasts that generate 
new bone remain poorly defined. It is generally accepted that cells from the periosteum 
can play a major role in fracture repair, particularly in closed fractures where the 
periosteum is largely intact [271]. Conversely, in animal models and clinical practice 
periosteal stripping is associated with impairment of bone repair [272]. Mesenchymal 
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cells from the marrow compartment have been shown to readily differentiate into an 
osteogenic lineage in vitro, but the importance of these cells in bone repair is less well 
defined [204, 273, 274]. However, even in fractures with intramedullary nailing, poor 
marrow availability and significant periosteal stripping, healing can still eventuate. This 
indirectly evidences a potential contribution by progenitors from non-osseous tissues to 
new bone formation.  
In this study we have aimed to address the potential transdifferentiation of vascular 
endothelial progenitors under conditions featuring high concentrations of exogenously 
supplied rhBMP-2. Endothelial to mesenchymal transitions have emerged as a 
occurring in range of tissue processes, particularly in development and in tissue fibrosis 
[275]. It has also been linked to genetic disease, specifically the abnormal ossification 
seen in fibrodysplasia ossificans progressiva and mutations in the BMP-receptor 
ACVR1 [253]. This led us to speculate that even if Tie2-lineage cells did not make a 
significant contribution to normal bone formation or repair, excessive BMP signaling 
could lead to transition of endothelial progenitors into osteoblasts.  
Nevertheless, these data comprehensively demonstrate that Tie2-lineage cells 
contribute to the developing vascular network and not osteoblasts. Prior studies 
showing extensive Tie2-lineage reporter staining in the bone are likely to be confounded 
by two issues. Firstly, Tie2 is expressed by hematopoietic lineages as well as 
endothelial cells, which give rise to osteoclasts. The co-staining of the osteoclastic 
marker TRAP with tdTomato+ cells reinforces the concept that the cells seen within the 
bone in prior studies may have been osteoclasts. Prior studies using histochemical 
markers such as LacZ did not allow for co-staining with other lineage markers [191]. 
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Secondly, other studies demarking cells of the Tie2-lineage in bone utilized an 
alternative transgenic mouse line that showed a wider pattern of distribution including 
mesenchymal cells [261]. In contrast, our Tie2-cre:Ai9 mouse line demonstrates a more 
restrictive pattern of expression [262, 263], which may explain the lack of contribution to 
mesenchymal elements. This highlights a challenge associated with lineage tracking 
studies, which can be the non-specificity and/or leakiness of Cre mouse models [276]. 
Thus caution must be made with the interpretation of all tracking studies. 
The findings of a lack of contribution of Tie2-lineage cells to osteoblasts was found in 
both the hind limb rhBMP-2 induced ectopic bone formation model and in the rhBMP-2 
induced spine fusion model. In the latter model, all osteoblasts (marked with the Col2.3-
GFP transgene) were observed to originate from αSMA-lineage lineage progenitors. 
This mouse, which enables the inducible labelling of progenitors just prior to intervention, 
has proven a valuable tool for identifying physiological processes where the primary 
cellular contribution is mesenchymal [169, 265, 267]. 
Finally, confirmation of the lack of a functional importance for Tie2-lineage cells in the 
direct formation of bone was seen using the novel Tie2-cre:Osxfx/fx mouse line. Loss of 
the osterix gene in cells of the chondrogenic lineage has been previously reported to 
disrupt global bone formation [259]. In contrast the Tie2-cre:Osxfx/fx were viable with no 
adverse phenotype, suggesting no significant contribution of Tie2-lineage cells to bone 
formation. Moreover, in parallel with the findings of the Tie2-cre:Ai9 mouse line showing 
no reporter expression in osteoblasts, the Tie2-cre:Osxfx/fx line showed no deficit in 
rhBMP-2 induced ectopic bone formation. 
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In summary, this study uses rigorous methodology to demonstrate that Tie2-lineage and 
αSMA-lineage cells make distinct contributions to rhBMP-2 induced bone formation. 
Moreover, despite evidence that BMPs and in particular high doses of rhBMPs may be 
able to induce endothelial to mesenchymal transitions, we have found no evidence for 
this in our in vivo bone formation models. We conclude that while this process may be 
problematic in certain disease states, it does not feature under normal physiological 
conditions. These data further suggest that the advantages of endothelial progenitor 
transplantation in orthopedics and bone tissue engineering are likely due to increases in 
angiogenesis rather than by these cells contributing directly to the local osteoblastic 
populations. 
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Supplemental Figures 
 
 
Supplementary Figure 5. 1 Fluorescent images of Tie2-lineage cells (tdTomato) with TRAP 
activity (ELF97) in spine fusion masses showing recapitulates the findings seen in ectopic bone 
nodules (Figure 3). Osteoclasts were observed in the fusion mass from D10 onwards. Scale bar 
= 50 µm 
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Supplementary Figure 5. 2 Fluorescent images of Tie2-lineage cells (tdTomato) with CD31 
immunohistochemistry in spine fusion masses showing recapitulates the findings seen in 
ectopic bone nodules (Figure 2A). Scale bar = 50 µm 
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Supplementary Figure 5. 3 Control fluorescent images of rhBMP-2 induced spine fusion 
masses in Tamoxifen untreated αSMA-CreERT2Col2.3-GFP:Ai9 mice at d17. (A) DAPI staining 
(blue) of nuclei, (B) tdTomato (red) is not seen without Tamoxifen treatment, (C) Col2.3-GFP+ 
expression (green) is seen in the new bone, and (D) an overlay with light microscopy to 
visualize the bone. Scale bar = 50 
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(v) DISCUSSION 
 
 
Animal Models of NF1 and Clinical Translation 
Despite the apparent limitations of animal (particularly mouse) models, they can be an 
invaluable tool for bridging the gap between in vitro research and clinical trials. 
Appropriate planning and selection of an animal model is critical for translating to 
human clinical applications. [277] Our research relied upon a capacity to reproduce an 
NF1 phenotype in a physiologically complex system enabled by an in vivo model. 
Appropriate outcomes measures and study design were employed to increase 
translational power. The development of our model was informed by prior research 
which employed similar models to achieve translational results. In particular, genetic 
models of NF1 have been successful is reproducing the cellular picture observed in the 
bone healing deficiencies in humans [159, 278]. Successful pharmacological 
intervention in these models, such as with BMPs and bisphosphonates, has informed 
current clinical standard of care for treating these complications. [232]  
Murine models of NF1 have proven to be of great utility for screening pharmacological 
treatments for the learning deficits, cognitive impairment, and neurobehavioral deficits 
reported in children with NF1. Nf1+/- mice have been shown to display features that 
mimic the cognitive phenotype of humans with NF1. [279, 280] The observed learning 
difficulties likely result from increased GABA release, which is normally regulated by 
Ras activity. Lovastatin, a drug that targets Ras phosphorylation, is able to reverse 
GABA release as well as the learning impairments in mice. When lovastatin was given 
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to children with NF1, it was observed to improve verbal and nonverbal memory. [280, 
281].  
A genetically modified mouse that featuring double inactivation of NF1 in GFAP 
expressing glial cells (Nf1 OPG mouse) has been generated that develops optic gliomas. 
Optic gliomas are lesions that present in 15% of children with NF1. [282]. The Nf1 OPG 
mouse exhibits deficits in selective and non-selective attention [128] and are noted to 
have decreased levels of dopamine. Treatment with an agent that increases dopamine 
signalling, Methylphedinate (MPH), normalizes the attention system abnormality in 
these mice. [128, 283]. When Methylphedinate is given to children with NF1, a similar 
effect is noted. [284] It can therefore be appreciated that genetic modelling of NF1 in 
mice has significant relevance to treatment options in humans.  
Since the publication of our research, there have been contributions to the field that may 
represent novel directions to guide future research. With respect to NF1 pseudarthrosis, 
Ghadakzadeh et al, employed the AdCre virus transduction to generate a model of tibial 
pseudarthrosis [285]. This group demonstrated significant amounts of fibrous tissue in 
the fracture site, supporting both our research with this mouse when applied to tibial 
pseudarthrosis  [159] and spine fusion. Elevated levels of β-catenin were found in the 
pseudarthrotic tissue. By crossing Catnbtm2Kem mice with Nf1 conditional knockout 
(KO) mice, they were able to conditionally express a null β-catenin protein. By inhibiting 
β-catenin, they were able to rescue the pseudarthrotic phenotype. This result was 
reproduced when mice were injected with an adevovirus that expressed Dkk-1, a 
negative regulator of the canonical Wnt pathway, which is implicated in β-catenin 
signalling . Baht et al [278] were able to improve healing and reduce fibrous tissue in the 
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same model by treating the mice with Nefopam, a non-narcotic analgesic known to 
reduce β-catenin signalling.  
The AdCre-virus induced knockout model of NF1 has proven to be reproducible and 
reliable by our team and others. It has been shown to be able to reproduce the poor 
healing and fibroproliferation seen in humans. However, the effectiveness of this 
technique is limited to the tissue population that is exposed to the virus. Recent mouse 
models have been developed which conditionally result in double inactivation of the Nf1 
gene in osteocytes [243], mesenchymal stem cells and osteoblasts [228, 229, 244, 245]. 
Conditional deletion of Nf1 in osteoblasts produced a scoliotic deformity with similarities 
to human dystrophic scoliosis. A tibial fracture model in this mouse [244] demonstrated 
impaired healing. We predict that this mouse would also exhibit an impaired response to 
spine fusion surgery. Wang et al found that treatment with lovastatin improved fracture 
healing. Notably, this model did not show an abundance of fibrous tissue in the fracture 
site. This suggests that the cell lineages contributing to the healing deficiencies in Nf1 
are multiple and not limited to the mesenchymal/osteoblast line.  
To date, there is no consensus on which approach to modelling NF1 deficiency in mice 
is ideal. Each model has benefits and weaknesses that must be considered when 
constructing a study. Systemic Nf1+/- mice perhaps most accurately model the genetics 
of the human deficiency, but this produces variable and often weaker phenotypes than 
humans. Despite this they have proven very useful in NF1 cognitive research. [128] In 
the context of bone, lineage specific homozygous knock-out models mimic the 
morphology of the NF1 skeletal dysplasia, but lack some important cellular features with 
great clinical relevance, such as the presence of fibrous tissue in fracture non-unions 
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and paraspinal tumours [229]. Homozygous deletion of the Nf1 gene with an AdCre 
virus provides the most accurate picture of pseudarthrosis in the tibia [159], but does 
not recapitulate the dystrophic developmental abnormalities of the NF1 skeleton, such 
as tibial bowing, scoliosis and dural ectasia. Considered together, these techniques 
represent a piecemeal approach to modelling the human phenotype of NF1.  
 
Models of NF1 Spine Fusion 
In order to effectively investigate spine fusion in NF1 and the effect of interventions, we 
undertook the creation of a reproducible and reliable preclinical model. Prior to our 
research, there is a body of literature involving animal models of scoliotic deformity that 
we were able to draw upon. The majority were considered to be mechanical models and 
typically relied upon larger animals so that vertebrae and ribs could be manipulated to 
induce scoliosis. [246] [173]. Such models are useful for investigating corrective 
techniques. However, in the context of NF1 – specifically dystrophic type curves – the 
deformity is often driven by an identifiable anatomic abnormality such as vertebral 
dystrophy or parivertebral soft tissue masses. [286]. In these patients, the primary 
problem is not one of intraoperative correction, but one of postoperative failure of fusion 
[93]. For this reason, we sought to create a model of spine fusion that would allow us to 
study the factors that limited the success of these procedures in NF1. Building upon this 
model, we aimed to examine interventions which may be able to rescue the non-healing 
phenotype of NF1.  
We designed a surgical approach with the intention of applying it to a model of NF1. At 
the time of our formulation, mice were the only animal available in which an Nf1 
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deficient state could be established. Additionally, the small size of the mouse, low cost 
of housing, and large breeding litters were advantageous for the purpose of study [237]. 
The anatomy of the mouse spine differs from that of the human with respect to 
orientation, vertebral number and morphology. The horizontal orientation of the spine 
has been cited as a limitation of quadrupedal models in reproducing the mechanical 
conditions present in human scoliosis. This represents a significant limitation in the 
context of reproducing deformity. Considering our intention was to reproduce the 
cellular picture of NF1 rather than the biomechanical environment surrounding scoliosis, 
we did not suspect this would overly limit our results. In the rodent lumbar spine, the 
transverse processes, one of the osseous targets for a posterolateral intertransverse 
fusion, is orientated more anteriorly than in the human in which it projects directly 
laterally. The result of this is that in our model, in which we reproduced the surgical 
approach used in humans, the transverse processes are excluded from the fusion and 
the articular processes provide the bony bed for the fusion. Our model involved the 
decortication of the fusion bed with consequent stripping of the overlying periosteum. 
The removal of the periosteum was performed to reproduce the surgical approach 
utilized in humans, rather than to isolate the fusion process from periosteal contribution.  
 
In wild type mice, our model was able to reproducibly and reliably produce a robust 
fusion of the lumbar spine when a dose of 10 µg of rhBMP-2 was delivered bilaterally 
via implanted collagen sponge. 10 µg was chosen as this was a proportionate dose to 
that delivered in rabbit models and is the dose that our lab has utilized reliably in murine 
fracture models. [287] This yielded a very large fusion mass in all animals, larger than 
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what is seen in humans at recommended doses. This is a predictable finding as rodent 
fracture models have repeatedly shown that they heal more readily than their human 
counterparts. So called ‘critical defect’ models in rodents have been shown to heal 
without intervention at a rate than exceeds humans. [288] This is particularly relevant to 
mice, whose size and ability to heal does not reflect the clinical outcomes in human 
patients. For this reason we did not rely upon fusion rate as an outcome measure in our 
work. Instead, we looked at the cellular response at the site of fusion and compared the 
osteogenic response between animals and intervention groups. In the future, it may be 
possible to apply our model to larger rodents as genetic models become available. The 
recent presentation of a rat NF1 knockout model may represent a viable subject for this 
research. 
When we applied the spine fusion to a mouse strain that was systemically Nf1+/-, we 
noted a decrease in bone volume and density, reflecting a decreased osteogenic 
activity and excessive resorption. This finding reflects the results seen in fracture and 
ectopic bone models in this genotype.[50, 200] Although this model of NF1 apparently 
reproduces the genotype seen in individuals with the disease, it fails to recapitulate the 
severity of the human phenotype. When subjected to a midshaft tibial fracture, which 
often results in non-unions in humans with NF1, Nf1+/- mice were not shown to have 
any deficiency of healing compared to wild type mice. Additionally, in the human patient, 
the non-united fractures are infiltrated with fibrous tissue. This was only replicated to a 
small degree in mice receiving fractures of the distal tibia and did not sufficiently mirror 
the non-unions seen in humans. The reason for this discrepancy may be genetic. There 
is evidence that NF1 tumorigenesis is associated with a double inactivation of the NF1 
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gene, in which one allele is constitutionally inactivated and the other is lost to somatic 
mutation. Such a process is referred to as the ‘two-hit’ hypothesis. [289] Garcia et al 
found that 25% of dermal neurofibromas showed loss of heterozygosity (LOH) for the 
Nf1 gene [290], while Upadhyaya et al found LOH in 36% of excised spinal 
neurofibromas. [291]. Samples of fibrotic tissue retrieved from tibial pseudarthrosis at 
the time of surgery showed double inactivation of the NF1 gene, suggesting that the 
second hit occurred in the mesenchymal progenitors from the periosteum. [292] LOH, 
therefore, may contribute to the severity of the human phenotype.  
In order to recreate the conditions found in NF1 LOH, fracture studies have utilised a 
location specific condition knockout model of NF1. In this model, injection of a cre 
expressing adenovirus induces local double inactivation of the Nf1 gene in Nf1flox/flox 
mice. When injected at the site of tibial fractures, these mice showed an increased non-
union rate relative to controls with significant amounts of fibrous tissue in the fracture 
site. [159] Encouraged by the apparent similarity to the clinical results seen in humans, 
we applied our spine fusion model to this mouse model of NF1. As was seen in the 
Nf1+/- mouse, all spines fused and thus intervertebral union rate was not an acceptable 
outcome measure. The aggressive osteogenic response to BMPs by mice was noted 
earlier and seemingly overwhelms the Nf1-/- phenotype. Mice receiving paraspinal 
delivery of the AdCre virus demonstrated significant volumes of fibrous tissue and 
increased number of TRAP+ cells surrounding the delivery sponge. This provided a 
more suitable model for investigating the conditions associated with spine fusion failure 
in NF1 than the previous model which used Nf1+/- mice. With the AdCre virus 
167 
 
generated Nf1-/- tissue in the spine, we produced a model of spine fusion in NF1. This 
exhibited more abundant fibrosis than seen in the Nf1+/- model.  
Animal models of human disease have been burdened at times by poor translatability. 
This is particularly true of mouse models. It has been suggested that the efficacy of 
novel therapies has been overestimated by as much as 30% due to poor translation 
from animal models. [293]. Despite their advantages in size and cost, a trend of moving 
away from mouse models is developing as they may not accurate model human 
disease processes. Seok et al demonstrated that mice do not mimic their human 
counterparts with respect to inflammatory diseases [294] and that this is due to different 
genomic responses to inflammatory stresses. Due to the significant role of inflammation 
in the process of bone healing, mice are a problematic subject. This has been explored 
earlier with respect to the augmented healing abilities of mice relative to humans and 
the exaggerated response to BMPs.  
 
Pharmaceutical interventions to rescue poor NF1 spine fusion 
We hypothesized that by addressing the osteogenic deficiency and increased resorption 
seen in NF1 with targeted interventions, we would improve the fusion outcomes. Loss of 
activity of neurofibromin results in the unopposed activity of Ras. The MEK inhibitor 
PD0325901 was chosen to interfere with the Ras-MEK-ERK pathway. This agent had 
been shown to be effective in reducing NF1 tumour growth [295, 296]. Zoledronic acid, 
a bisphosphonate, is well tolerated and is an effective anti-resorptive agent which has 
shown efficacy in preserving bone in patients with Nf1. [203] We found that dosing with 
PD0325901 resulted in increased volume of bone in both wild type and Nf1-/- spines 
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and to decrease the number of local TRAP+ cells observed in the fibrous tissue of Nf1-/- 
spines. It did not, however, reduce the volume of fibrous tissue in the fusion masses. 
The similar osteogenic activity of PD0325901 in both wild type and Nf1-/- spines 
suggests that its primary activity in bone is anabolic, but it may have a small anti-
resorptive capacity in light of its effect on TRAP+ cells.  
 
BMPS 
BMPs are strongly osteogenic, and have long been used to augment bone anabolism 
clinically. RhBMP-2 and rhBMP-7 are both approved for use in lumbar spine fusion and 
recalcitrant long bone unions. [297] Various doses of rhBMP-2 were investigated during 
the development of our murine spine fusion model. [237] We found that the 
development of a reliable fusion mass depended upon treatment with rhBMP-2. Those 
mice that received saline delivered locally via collagen sponge instead of rhBMP-2 did 
not yield any evidence of fusion. With respect to clinical translation, this may represent a 
limitation. The use of BMPs for augmenting lumbar fusion has been a source of 
controversy. The osteogenic and pro-inflammatory properties of BMPs may result in 
compression of nearby anatomy via the formation of ectopic bone and inflamed soft 
tissues respectively. [298-300] This has predominantly been a problem when used off-
label for cervical fusion. Additionally, published clinical guidelines for treatment of NF1 
pseudarthrosis [232] suggest that the use of growth factors in the context of NF1 is 
poorly understood. There is anecdotal evidence that in addition to increasing bone 
anabolism in these patients BMPs may also increase the risk of malignancy [301] or 
worsen the patients existing tumour burden. [302] Current recommended practice for 
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promoting fusion in humans is to use autogenous bone graft harvested from the iliac 
crest. Bone graft is osteogenic, osteoinductive and osteoconductive and may behave 
more predictably in patients with NF1. Future research may modify the established 
surgical model to investigate the use of bone graft, rather than BMPs, to induce a 
reliable fusion.  
 
Bisphosphonates are a recognized class which exert their anti-resorptive activity by 
inhibiting osteoclast activity. They are well tolerated in the elderly population where they 
are used to maintain bone mineral density. They are less frequently used in the 
paediatric population, but have been used with success in treating children with 
hypercalcaemia [303] [304], osteopathy [305] and calcinosis [306, 307]. A systematic 
review of the literature [308] has found that oral and intravenous use of 
bisphosphonates in a paediatric Osteogenesis Imperfecta population increases bone 
mineral density and reduces fracture incidence. Adverse effects are uncommon and 
when present include gastrointestinal upset, fever and muscle soreness. As mentioned 
previously, it has proven to be advantageous in treatment of NF1 related pseudarthrosis 
of the tibia. [203, 232] For this reason, it is likely to be a safe and effective candidate for 
adjuvant treatment of spine fusion in NF1. Consistent with this theoretic basis, 
zoledronic acid increased bone mineral density of fusion masses. Moreover, in the 
context of bone repair, long term bisphosphonates could maintain any new bone formed 
by pre-treatment or co-treatment with a pro-anabolic agent. 
MEK inhibitors are a newer class of drug that have found popularity in several trials 
attempting to target and slow cancer growth. MEK inhibition represents an attractive 
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approach as the Ras-MEK-ERK pathway is implicated in the mitogenic signalling 
activated by known oncogenes. [309] Although the drug has been shown to well 
tolerated at active doses in cancer trials, it is associated with a number of side effects 
including rash, diarrhoea, nausea, fatigue and blurred vision. [310]. It has also been 
associated with increased incidence of blood dyscrasias (anaemia, thrombocytopaenia, 
leucopaenia) [247]. Clinically, the MEK inhibitor AZD644 has been trialled as a therapy 
for refractory low-grade gliomas in a paediatric cohort [311]. The side effect profile was 
similar to that observed in adults. MEK inhibition in mice with Trametinib has been 
shown to improve strength and size of callus in Nf1-defficient mice. [312]  Our research 
suggests that while they may show non-specific anabolic activity in bone which 
augments BMP mediated fusion, they do not reduce the amount of fibrous tissue in the 
fusion mass (or fracture callus) and as such do not represent a sufficiently targeted 
approach to treating the orthopaedic dysplasia of NF1. While the use of MEK inhibitors 
is associated with unpleasant side effects, these are limited to the duration of treatment 
and resolve one therapy is ceased.  
We have shown that the anabolic deficiency and increased resorption in NF1 can be 
targeted and improved with a combination therapy of osteogenic agents such as BMPs 
and antiresorptive agents such as bisphosphonates. These have been used to great 
effect in humans and well as mice. Our recent research suggests that the osteogenic 
activity of BMPs can be further augmented with adjuvant therapies, such as a MEK 
inhibitor.  Despite this, we have not been able to reduce the volume of fibrous tissue in 
the fusion mass of the lumbar spine. We expect that clinically, this will continue to be a 
challenge that limits the success of corrective procedures. We are interested in 
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investigating novel adjuvant therapies which may rescue the fibrous proliferative 
phenotype. By targeting β-catenin expression, Nefopam has been shown to reduce the 
presence of fibrous tissue in tibial pseudarthrosis. [278]. This may prove beneficial in 
improving outcomes in spine fusion. Like MEK inhibitors, Lovastatin targets the 
unopposed activity of Ras that occurs secondary to neurofibromin deficiency. This drug 
is effective at reversing the cognitive phenotype in Nf1+/- mice and humans, and 
improves tibial fracture healing in osteoblast double-knockout models. The later model 
did not show evidence of fibrous tissue at the fracture site, and thus lovastatin was not 
tested against a fibroproliferative non-union. Future research may utilise our established 
AdCre virus model, which reliably produces a fibrous tibial non-union and lumbar fusion 
mass, and treat with lovastatin in order to investigate its ability to rescue this process.  
We were unable to demonstrate reduction of fibrous proliferation by antagonism of the 
Ras-MEK-ERK cascade with the MEK inhibitor PD0325901. An alternative method for 
interfering with this process is via inhibition of the c-Jun NH2-terminal kinase (JNK) 
pathway. JNK signalling is required for the Ras to exert its oncogenic activity. [313] 
Increased JNK activity in bone marrow stromal cells (BMSCs) has been observed in 
vitro, and inhibition of this signalling resulted in increased osteoblastogenesis. [238] Our 
lab, in a currently unpublished study, has investigated the effect of JNK inhibition on 
open tibial fracture healing using the drug CC-930 in the AdCre virus model of NF1. 
Treatment with CC-930 significantly reduced the amount of fibrous tissue within the 
fracture site. This agent may demonstrate utility in reducing the fibrous proliferation we 
observed in BMP induced spine fusion surgery in our murine model of NF1. It would be 
expected that the short-term use of this drug during the post-operative healing phase, in 
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conjunction with bisphosphonates would yield a robust fusion mass with less fibrous 
tissue. The anabolic activity of our intervention may be further strengthened with the 
addition of PD0325901. The translational power of this agent is unclear at this moment 
as it is a novel drug. CC-930 has recently undergone phase 1 clinical trial and has 
shown to be generally well tolerated with limited adverse effects. [314] 
 
Cellular contributors to the bony fusion mass 
It has been a long held assumption [315] that vascular endothelial cells contributed to 
bone healing as osteoblastic progenitors. Early investigations used bright-field and 
electron microscopy without using lineage tracking techniques. Sequential histological 
sections from time points throughout the fracture healing period seemed to suggest that 
endothelial cells migrated from vascular lumens and differentiated into osteoblast 
progenitors. This early research was rudimentary and modern lineage tracking 
techniques have improved the resolution of this field of study. The limitations of early, 
non-genetic, cell labelling studies has been previously discussed. An optimal lineage 
tracing technique selectively and permanently labels a cell type permitting the 
observation of its contribution to differentiated cell populations. Transgenic subject that 
have been bred to express fluorescence under a cell specific promoter following Cre 
recombination are frequently used for this research. When the promotor is stable, 
labelling is specific and permanent.  These are classified as ‘knock-in’ models, and 
allow the observation of cellular mechanisms without interfering with their function. 
When these techniques are used to delete a gene, they are ‘knock-out’ models. By 
altering cell physiology and deleting genes responsible for promoting differentiation, 
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knock-out models are also able to provide valuable information about cellular 
contribution to various processes. Targeted interventions can be developed and tested 
if the cellular contributors to a physiological or pathological process are known.  
In an attempt to identify the cellular contributors to spine fusion, Tie-2 and α-smooth 
muscle actinin (α-SMA) expressing cells were labelled and their contributions observed. 
In contrast to our hypothesis, Tie-2 expressing cells did not contribute to the osteoblast 
population within the fusion mass. These cells were noted to co-label with CD31 
expressing cells and TRAP+ cells, suggesting a contribution to angiogenesis and to the 
osteoclast population respectively. Tie-2 is used as a marker of vascular endothelial 
cells but is also expressed by haematopoietic stem cells, which give rise to osteoclasts. 
Although we cannot demonstrate contribution of endothelial cells to osteoblastogenesis, 
evidence suggest that increasing availability of endothelial cells to a fracture site 
improves healing. Critical defect models involving sheep tibia [316] and rat femora [317] 
demonstrated improved union rates after transplantation of blood derived endothelial 
progenitor cells (EPCs). This is likely a primary consequence of increased angiogenesis 
and neovascularization. Seebach et al  propose that that while transplanted EPCs 
contribute to early vascularization, they exert their effect primarily by recruiting host 
EPCs via the cytokine VEGF [318]. Considering our results, it is unlikely that endothelial 
cells contribute directly to the process of osteogenesis.  
Tie-2 expressing cells were found not to contribute to the osteoblast population of the 
fusion mass, nevertheless all osteoblastic cells expressing Col2.3-GFP were found to 
co-label with tdTomato+ cells, indicating that they derive from the α-SMA lineage. 
Mobilisation of α-SMA expressing mesenchymal stem cells (MSC) may present a 
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clinical benefit where healing or bone formation is impaired. AMD3100 is an antagonist 
of CXCR4, which regulates release of MSC from the bone marrow. Kumar et al found 
that treatment with AMD3100 and the growth factor IGF1 increased the proportion of 
circulating MSC and improved healing in a murine tibial defect model. [319] In a study 
investigating kidney fibrosis, treatment with AMD3100 increased expression of α-SMA in 
kidney biopsies. [320] Similar results were found in the liver of mice receiving AMD3100 
[321] Under the trade name Plerixafor, AMD3100 has been demonstrated to be well 
tolerated and effective at mobilising haematopoietic cells in human patients. [322, 323]. 
MSCs contributed to osteogenesis in our model, however the relationship between 
MSCs and fibrosis may limit its effectiveness as a target for therapy in NF1.  
Cho et al [324] found that fibrous tissue retrieved from tibial pseudarthrosis from 
patients with NF1 showed evidence that the hamartoma cells were arrested at a certain 
stage of osteoblastic differentiation. This was supported by the work of Lee et al, which 
demonstrated that human fibrous hamartoma showed signs of failed osteoblastic 
differentiation [242]. Our recent work with JNK inhibitors in the AdCre model of NF1 
showed that when a tdTomato fluorescent transgene was included, the fibrous cells 
were labelled as being Nf1-/-. Together, this suggests that the cells implicated in fibrous 
proliferation are a subset of otherwise normal osteogenic cells (likely of mesenchymal 
origin) that fail to differentiate fully secondary to the aberrant signalling observed in NF1.  
Ghadakzadeh et al reported that antagonism of β-catenin expression with Dickopf-
related protein 1 (DKK1) rescued the fibroproliferative phenotype in Nf1-/- tibial 
pseudarthrosis. Similarly, conditional knockout of β-catenin expression using a 
Nf1flox/flox;Catnbtm2Kem mouse showed improved healing with decreased fibrous 
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tissue at 21 days post fracture. [284]. Future research might investigate the effect of 
deletion of β-catenin alleles on cellular contribution to a fusion mass in Nf1-/- spines.  
Inclusion of a fluorescent transgene would permit the tracing of cells contributing to the 
fusion mass that were transduced by the virus, though this would certainly compound 
the time and cost required to generate the transgenic mouse line.   
Lineage tracing using an α-SMA promoter yielded valuable insights into mesenchymal 
stem cell contribution to the fusion mass in wild type mice.  
Though labour intensive and costly, this transgenic mouse could be crossed with an 
Nf1flox/flox mouse to generate a mouse that is Nf1-/- in cells expressing α-SMA. These 
cells would be traceable due to labelling by the TdTomato transgene. This model could, 
by itself, generate quantitative data regarding the contribution of α-SMA expressing cells 
to the spine fusion process in NF1. Moreover, it would provide a compelling foundation 
upon which to investigate signalling modulation, as with β-catenin blockade, and 
mesenchymal cell mobilisation, as with AMD3100.  
Future in vitro research may investigate the altered gene expression witnessed in MSCs 
in Nf1 deficient states. The loci of aberrant expression could be used as targets for 
future investigation and therapeutic intervention.  To achieve this, MSCs would be 
harvested from the marrow of Nf1+/- and  Nf1flox/flox  and exposed to Cre-expressing 
adenovirus. RNA sequencing (RNA-seq) would be performed to profile the gene 
expression in these cells and identify differences between the groups.  
 
Future approaches to NF1 modelling and treatment 
Advanced Genetic Models of NF1 deficiency 
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Conditional mutagenesis via the Cre-LoxP system has proven to be a powerful tool for 
generating new models of gene modified mice. This system permits the lineage-specific 
genetic recombination with high specificity. Changes to a parent cell are maintained in 
its progeny, allowing the descendent cells to be tracked after division or 
transdifferentiation. Moreover, tissue-specific cre-expressing strains can be crossed 
with a variety of reporter or conditional knockout strains allowing substantive versatility 
in new model generation. 
Despite its wide adoption and utility for generating new genetic models of disease, Cre-
loxP mice possesses significant limitations. Traditionally, this technique has been 
limited to use in mice due in part to early mapping of the mouse genome and generation 
of reliable lines of mouse clones. However, recent advancements in the mapping of the 
rat genome and development of rat clones has enabled the use of Cre-LoxP systems in 
rats. [325]. In addition, the generation of a transgenic line requires multiple generations 
of breeding and cross-breeding. [326] This process is lengthy and costly, even in 
animals such as mice which are small and have a relatively short gestation period. 
Should the technology be applicable to larger animals, the issues of cost are 
proportional to animal size and gestation time, rendering it increasingly prohibitive as 
animal size increases. This process must be repeated for every gene that is 
investigated. Finally, any leakiness of Cre-recombinase leads to decreased specificity of 
recombination and mosaicism.  
The CRISPR/Cas9 system has been established as a simple tool for genome editing in 
plants and animals.  [327] It has been used successfully to generate double allelic 
knockouts of targeted genes in one step in a single generation by injecting of sgRNA 
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and CAS9 mRNA into the pronuclear stage zygotes. This method yields systemic 
knockout of the targeted gene. [328, 329] For the purposes of the modelling of genetic 
disease, this technique may prove to be a more convenient alternative to the Cre-LoxP 
system as it avoids the processes of gene floxing and selective breeding. In the face of 
CRISPR/Cas9 technology, one of the strengths of Cre/LoxP system has been that it 
permits tissue specific recombination. Carroll et al [330] have described a technique for 
generating a cardiac-specific Cas9 transgenic mouse by targeting cardiomyocytes of 
post-natal mice with an Adeno-Assiciated Virus 9 (AAV9). They targeted the Myh6 locus, 
which would be embryonically lethal if edited at the zygote stage. Bi-allelic deletion of 
Nf1 is similarly embryonically lethal. The AAV9 delivery system may represent a 
promising technique for inducing tissue specific knockout of the Nf1 gene.   
Yang et al [331] have proposed a technique for conditional gene editing that bridges the 
CRISPR/Cas9 and Cre/LoxP systems. The demonstrated that it was possible to flox 
targeted alleles by injecting Cas9 mRNA, sgRNAs and single-stranded DNA oligos into 
mouse zygotes. This was a one-step process and successful editing was confirmed by 
PCR. Subsequent gene editing could then be initiated by Cre-driven recombination. 
This technique was limited by low efficiency and off-target insertion. As this technology 
improves, it may provide an alternative to the labour-intensive generation of transgenic 
mice.  
Far from being a silver bullet, the technology is in its infancy and must overcome some 
limitations including issues of specificity and delivery. CRISPR/Cas9 achieves its effect 
by inducing cleavage of the genome at a targeted location. Lack of specificity of the 
system would result in cleavage at off target sites, which may result in either an 
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impaired effect or an unpredicted phenotype. Fu et al found that in human genome 
editing, off-target cleavage may occur between 5.6% and 125% as often as on-target. 
These off-target cleavages may be up to 5 nucleotides away from the target location. 
[332] Recent work suggests that the error in Cas9 targeting can be anticipated and 
minimized with careful design. [333, 334] The efficiency of the CRISPR/Cas9 system is 
also complicated by issues of delivery. In order to effect alterations to the genome, the 
system must enter the nucleus of the target cell. In vitro, this may be achieved by 
physical intracellular implantation. In vivo delivery of the system, to date, remains a 
challenge. Viral and non-viral delivery systems have been explored for use in mammals. 
[335] Viral delivery, while the most common, is associated with limited packing size and 
longer exposure of the Cas9 system with consequent increases in off-target cleavage 
and acquired immunogenicity. These limitations may be overcome with non-viral 
delivery systems, in particular nanoparticle delivery. [336] 
 
It is unlikely that the CRISPR/Cas9 technology will represent a therapy or cure for 
patient with NF1 in the near future. It is more likely that its prime utility will be to create 
genetic models of the disease in animals to investigate interventions. The orthopaedic 
manifestations of NF1 present with deformity and pathology that must be addressed 
surgically, often in tandem with pharmacological therapy.  Generation of NF1 models 
using larger animals would provide a useful foundation upon which to investigate 
surgical intervention, as larger animals experience biomechanical forces more similar to 
humans.  CRISPR/Cas9 has been proven to be effective at initiating gene deletion in 
larger animals such as rabbits [337], goats [338], sheep [339] and chickens [340] 
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amongst others. Recently, 3 groups have produced swine models of NF1 using this 
technology, though the results have not yet been published. 
 
Non-Pharmaceutical Therapeutic Approaches 
For orthopaedic NF1 patients, surgery has remained the mainstay of treatment for 
correcting spinal deformity and non-union despite the potential benefits of adjuvant 
pharmacological therapies. In the context of spine fusion, the primary complication 
facing NF1 spines is the development of non-union. However, this is only a failure with 
respect to the intentions of early work in the field, which depended upon intervertebral 
fusion to maintain correction. This fusion came at the cost of high incidences of revision 
and growth arrest in the spines of patients. A modification to the expected outcomes of 
surgery, namely to initiate correction without establishing fusion, may decrease the rate 
of morbidity observed with the procedures.  
Intervertebral spinal fusion alone can have a high utility in maintaining correction of a 
scoliotic deformity of the spine. Early experience in the field advocated early and 
aggressive fusion [93, 148]. These patients were often younger than 12 years old with 
up to a quarter of them requiting reoperation for failed fusion. The difficulty in achieving 
successful fusion in patients with NF1 has prompted investigation into correction of 
deformity without fusion. Growing rods are a type of spinal instrumentation that are used 
to correct deformity without fusion, thereby permitting continued growth of the immature 
spine. A recent retrospective analysis of 14 patients suggests that this is a safe and 
effective option for correcting early onset scoliosis (EOS) in patients with NF1. 
Complications were primarily that of implant failure. [341]  
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Currently, the literature regarding growing rods without fusion, as an alternative to early 
fusion, is limited. This is a fertile topic for exploration with preclinical models in which 
deformity may be induced. The conditional osteoblast murine model described by Wang 
et al [229] would be ideally suited to such modelling were it not for the small size of the 
animal which prohibits instrumentation. Induction of deformity in the spines of larger 
animals, either CRISPR/cas9 deletion of the Nf1 gene in cells of osteoblast lineage or 
by means of mechanical tethering are options for investigating outcomes between 
treatment modalities.  
 
Conclusion 
The unifying aim of this research has been to contribute to the understanding of NF1 
bone phenotype and the challenges it imposes upon spine fusion for the correction of 
scoliosis. In order to achieve this, we initially created a rodent model for posterolateral 
lumbar spine fusion. This built a foundation upon which would could test investigate 
cellular contributions to spine fusion as well as interventions in the context of NF1. This 
surgical model has since been used by other teams [342-344], and is testament to its 
reproducibility and reliability. We consider this to be a significant contribution to the field.  
 
Using this surgical approach we were able to incorporate genetic models of NF1 
affecting the spine, comparing both heterozygosity and loss of heterozygosity for the 
Nf1 gene. These models recapitulated the bone healing phenotype seen in humans with 
varying degrees of severity. We were able to use this model to investigate anabolic 
(BMP) and anti-catabolic (bisphosphonate) pharmacological interventions, as well as 
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targeted therapies that are specific to the NF1 disease process (MEK inhibitor). This 
research has yielded significant data which suggests a possible utility for these agents 
in humans.  
The spine fusion model also allowed us to perform in vivo lineage cell tracing 
experiments. This research has provided insightful data that counters prior assumptions 
about the contribution of Tie-2 expressing cells to the process of bone repair. We have 
shown that these cells co-label with osteoclasts, and hence may play a resorptive role in 
bone homeostasis. Additionally, we were able to show that α-SMA expressing cells, 
which represent a population of cells of mesenchymal origin, strongly co-label with 
osteoblasts and may therefore be exploited to improve bony union.  
Treatment of scoliosis in NF1 remains a challenge as the success of fusion is impeded 
by deficiencies of anabolism, excessive resorption, and fibroproliferation. The molecular 
and cellular pathways responsible are likely multifactorial and therefore will require a 
multimodal approach to therapy consisting of surgical techniques and adjuvant 
pharmacological interventions. Genome editing via the CRISPR/Cas9 system may 
present with therapeutic options in the future, but in the short term this technique will 
provide the most utility in expanding the pre-clinical models of NF1 at the disposal of 
researchers. Such models have been and will continue to be valuable in the screening 
of novel pharmacological and surgical interventions that are targeted at the deficiencies 
specific to the NF1 disease process.  
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